0000912061-19-000029.txt : 20190426 0000912061-19-000029.hdr.sgml : 20190426 20190426171514 ACCESSION NUMBER: 0000912061-19-000029 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 68 CONFORMED PERIOD OF REPORT: 20181231 FILED AS OF DATE: 20190426 DATE AS OF CHANGE: 20190426 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATURAL HEALTH TRENDS CORP CENTRAL INDEX KEY: 0000912061 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MISCELLANEOUS NONDURABLE GOODS [5190] IRS NUMBER: 592705336 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36849 FILM NUMBER: 19772821 BUSINESS ADDRESS: STREET 1: UNITS 1205-07, 12F, MIRA PLACE TOWER A STREET 2: 132 NATHAN ROAD, TSIMSHATSUI, KOWLOON CITY: HONG KONG STATE: K3 ZIP: 00000 BUSINESS PHONE: 852-3107-0800 MAIL ADDRESS: STREET 1: UNITS 1205-07, 12F, MIRA PLACE TOWER A STREET 2: 132 NATHAN ROAD, TSIMSHATSUI, KOWLOON CITY: HONG KONG STATE: K3 ZIP: 00000 10-K 1 nhtc2018123110k.htm 10-K Document
false--12-31FY20180000912061YesfalseAccelerated FilerfalsetrueNoNoP5DP2D0.0835350.50.5P1M21P1Y0.020.160.0015000000012979414129794140.1022246000000.00150000000000P7YP5YP5YP3YP3YP3YP3Y163752416033220 0000912061 2018-01-01 2018-12-31 0000912061 2018-06-30 0000912061 2019-04-22 0000912061 2018-12-31 0000912061 2017-12-31 0000912061 2017-01-01 2017-12-31 0000912061 us-gaap:RetainedEarningsMember 2016-12-31 0000912061 us-gaap:TreasuryStockMember 2017-12-31 0000912061 us-gaap:RetainedEarningsMember 2017-12-31 0000912061 us-gaap:TreasuryStockMember 2016-12-31 0000912061 us-gaap:PreferredStockMember 2017-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000912061 us-gaap:CommonStockMember 2016-12-31 0000912061 us-gaap:CommonStockMember 2018-12-31 0000912061 us-gaap:RetainedEarningsMember 2018-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000912061 us-gaap:TreasuryStockMember 2018-12-31 0000912061 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000912061 us-gaap:PreferredStockMember 2018-12-31 0000912061 us-gaap:CommonStockMember 2017-12-31 0000912061 us-gaap:PreferredStockMember 2016-12-31 0000912061 us-gaap:TreasuryStockMember 2017-01-01 2017-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000912061 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000912061 us-gaap:TreasuryStockMember 2018-01-01 2018-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000912061 2016-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000912061 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0000912061 us-gaap:AccountingStandardsUpdate201602Member us-gaap:ScenarioForecastMember us-gaap:SubsequentEventMember 2019-01-01 0000912061 nhtc:NoncurrentLiabilitiesMember 2018-12-31 0000912061 country:KR 2018-12-31 0000912061 country:CN 2015-06-30 0000912061 country:CN 2017-12-31 0000912061 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0000912061 nhtc:PremiumNoniJuiceMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2018-01-01 2018-12-31 0000912061 country:CN 2018-12-31 0000912061 nhtc:OtherAccruedExpensesMember 2018-12-31 0000912061 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2018-01-01 2018-12-31 0000912061 srt:MinimumMember 2018-01-01 2018-12-31 0000912061 srt:MaximumMember 2018-01-01 2018-12-31 0000912061 nhtc:LongTermIncentivePlanPaymentCommencingInFebruary2021AndEndingInDecember2023Member 2018-12-31 0000912061 nhtc:EnhancedEssentialProbioticsMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2018-01-01 2018-12-31 0000912061 nhtc:LongTermIncentivePlanPaymentCommencingInFebruary2021AndEndingInDecember2023Member 2017-12-31 0000912061 nhtc:LongTermIncentivePlanPaymentCommencingInFebruaryOfTheCalendarYearImmediatelyFollowingTheConclusionOfThePerformancePeriodMember 2018-12-31 0000912061 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-01-01 2018-12-31 0000912061 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2018-01-01 2018-12-31 0000912061 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-01-01 2018-12-31 0000912061 nhtc:AutoShipAdvancesMember 2018-12-31 0000912061 nhtc:UnshippedProductMember 2018-12-31 0000912061 nhtc:OtherRevenueMember 2017-12-31 0000912061 nhtc:UnshippedProductMember 2017-12-31 0000912061 us-gaap:CashMember 2018-12-31 0000912061 us-gaap:CashMember 2017-12-31 0000912061 nhtc:AutoShipAdvancesMember 2017-12-31 0000912061 nhtc:OtherRevenueMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember 2017-12-31 0000912061 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000912061 us-gaap:FairValueInputsLevel12And3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel12And3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000912061 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000912061 us-gaap:FairValueInputsLevel12And3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel12And3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000912061 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000912061 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember nhtc:FinancialInstitutionInstrumentsMember 2017-12-31 0000912061 us-gaap:CashEquivalentsMember nhtc:MunicipalBondsAndNotesMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember nhtc:MunicipalBondsAndNotesMember 2017-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember nhtc:FinancialInstitutionInstrumentsMember 2018-12-31 0000912061 2013-05-31 0000912061 nhtc:SecuritiesClassActionMember 2018-04-02 2018-04-02 0000912061 nhtc:ShareholderDerivativeClaimMember 2018-07-16 2018-07-16 0000912061 2013-05-01 2013-05-31 0000912061 nhtc:SecuritiesClassActionMember us-gaap:SubsequentEventMember us-gaap:ExecutiveOfficerMember 2019-01-08 2019-01-08 0000912061 nhtc:SecuritiesClassActionMember 2016-03-29 2016-03-29 0000912061 nhtc:SecuritiesClassActionMember 2016-01-01 2016-01-31 0000912061 nhtc:EmploymentAgreementsMember 2018-01-01 2018-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2018-01-01 2018-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2018-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-01-01 2017-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2016-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2018-02-01 2018-02-01 0000912061 2016-01-12 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:CommonStockMember 2018-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-01-24 2017-01-24 0000912061 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0000912061 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:CommonStockMember 2016-04-07 0000912061 2015-07-28 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-12-31 0000912061 2018-11-23 2018-11-23 0000912061 2018-08-24 2018-08-24 0000912061 2018-05-25 2018-05-25 0000912061 2018-03-09 2018-03-09 0000912061 nhtc:OtherRestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-12-31 0000912061 nhtc:OtherRestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-01-01 2017-12-31 0000912061 nhtc:OtherRestrictedStockMember nhtc:EquityIncentive2016PlanMember 2016-12-31 0000912061 2017-08-31 2017-08-31 0000912061 2017-05-19 2017-05-19 0000912061 2017-11-24 2017-11-24 0000912061 2017-03-03 2017-03-03 0000912061 2017-01-01 2017-06-30 0000912061 us-gaap:DomesticCountryMember 2018-12-31 0000912061 us-gaap:InlandRevenueHongKongMember 2018-01-01 2018-12-31 0000912061 us-gaap:CaymanIslandsTaxInformationAuthorityMember 2018-01-01 2018-12-31 0000912061 us-gaap:StateAdministrationOfTaxationChinaMember 2018-01-01 2018-12-31 0000912061 us-gaap:StateAdministrationOfTaxationChinaMember 2017-01-01 2017-12-31 0000912061 us-gaap:InlandRevenueHongKongMember 2017-01-01 2017-12-31 0000912061 us-gaap:CaymanIslandsTaxInformationAuthorityMember 2017-01-01 2017-12-31 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2018-01-01 2018-12-31 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember 2018-01-01 2018-12-31 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2018-12-31 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:SharngHoldingsMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2018-12-31 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2017-01-01 2017-12-31 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember 2015-04-29 2015-04-29 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember us-gaap:DirectorMember 2013-02-28 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember 2017-01-01 2017-12-31 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember nhtc:PresidentandHisWifeMember 2018-12-31 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2017-12-31 0000912061 country:US 2018-01-01 2018-12-31 0000912061 country:HK 2017-01-01 2017-12-31 0000912061 srt:EuropeMember 2017-01-01 2017-12-31 0000912061 country:PE 2017-01-01 2017-12-31 0000912061 country:CA 2017-01-01 2017-12-31 0000912061 country:TW 2018-01-01 2018-12-31 0000912061 country:CN 2018-01-01 2018-12-31 0000912061 nhtc:RussiaandKazakhstanDomain 2018-01-01 2018-12-31 0000912061 country:CA 2018-01-01 2018-12-31 0000912061 srt:EuropeMember 2018-01-01 2018-12-31 0000912061 nhtc:RussiaandKazakhstanDomain 2017-01-01 2017-12-31 0000912061 country:KR 2018-01-01 2018-12-31 0000912061 country:KR 2017-01-01 2017-12-31 0000912061 country:US 2017-01-01 2017-12-31 0000912061 country:PE 2018-01-01 2018-12-31 0000912061 country:TW 2017-01-01 2017-12-31 0000912061 nhtc:OtherForeignCountriesMember 2017-01-01 2017-12-31 0000912061 country:CN 2017-01-01 2017-12-31 0000912061 nhtc:OtherForeignCountriesMember 2018-01-01 2018-12-31 0000912061 country:HK 2018-01-01 2018-12-31 0000912061 nhtc:OtherForeignCountriesMember 2018-12-31 0000912061 country:US 2017-12-31 0000912061 nhtc:OtherForeignCountriesMember 2017-12-31 0000912061 country:HK 2018-12-31 0000912061 country:US 2018-12-31 0000912061 country:HK 2017-12-31 0000912061 us-gaap:ShippingAndHandlingMember 2017-01-01 2017-12-31 0000912061 us-gaap:ProductMember 2017-01-01 2017-12-31 0000912061 us-gaap:ProductMember 2018-01-01 2018-12-31 0000912061 us-gaap:ShippingAndHandlingMember 2018-01-01 2018-12-31 0000912061 us-gaap:SubsequentEventMember 2019-01-27 2019-01-27 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember us-gaap:SubsequentEventMember 2019-02-01 2019-02-01 0000912061 us-gaap:SubsequentEventMember 2019-03-15 2019-03-15 xbrli:pure nhtc:defendant nhtc:plaintiff nhtc:order utreg:Rate nhtc:class xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:CNY nhtc:installment nhtc:claim

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
 
FORM 10-K
 
(Mark One) 
þ
 
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the fiscal year ended December 31, 2018
 
or
 
¨
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from       to      
 
Commission file number: 001-36849
 
NATURAL HEALTH TRENDS CORP.
(Exact name of registrant as specified in its charter) 
 
Delaware
59-2705336
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)
Identification No.)
 
Units 1205-07, 12F
Mira Place Tower A
132 Nathan Road, Tsimshatsui
Kowloon, Hong Kong
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: +852-3107-0800
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Name of each exchange on which registered
Common Stock, par value $0.001 per share
 
The NASDAQ Stock Market LLC
 
Securities registered pursuant to Section 12(g) of the Act:
None
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No þ
 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No þ
 
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ¨
 
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. þ
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer ¨
Accelerated filer þ
Non-accelerated filer ¨
Smaller reporting company þ
 
Emerging growth company ¨
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No þ
 
The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the closing price of such common equity on June 30, 2018: $182,584,301
 
At April 22, 2019, the number of shares outstanding of the registrant’s common stock was 11,398,695 shares.
 
DOCUMENTS INCORPORATED BY REFERENCE
 
Portions of the registrant’s definitive proxy statement to be filed with the United States Securities and Exchange Commission no later than 120 days after the end of the registrant’s fiscal year end to which this report relates are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.
 




NATURAL HEALTH TRENDS CORP.
Annual Report on Form 10-K
December 31, 2018
 
TABLE OF CONTENTS
 
 
 
Page
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 




FORWARD-LOOKING STATEMENTS
 
This Annual Report on Form 10-K, in particular “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Item 1. Business,” include “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). When used in this report, the words or phrases “will likely result,” “expect,” “intend,” “will continue,” “anticipate,” “estimate,” “project,” “believe” and similar expressions are intended to identify “forward-looking statements” within the meaning of the Exchange Act. These statements represent our expectations or beliefs concerning, among other things, future revenue, earnings, growth strategies, new products and initiatives, future operations and operating results, and future business and market opportunities.
 
Forward-looking statements in this report speak only as of the date hereof, and forward-looking statements in documents incorporated by reference speak only as of the date of those documents. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. We caution and advise readers that these statements are based on certain assumptions that may not be realized and involve risks and uncertainties that could cause actual results to differ materially from the expectations and beliefs contained herein.
 
For a summary of certain risks related to our business, see “Item 1A. Risk Factors” in this report. Additional factors that could cause actual results to differ materially from our forward-looking statements are set forth in this report, including under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in our financial statements and the related notes.
 
Unless otherwise noted, the terms “we,” “our,” “us,” and “Company,” refer to Natural Health Trends Corp. and its subsidiaries. References to “dollars” and “$” are to United States dollars.




Part I
 
Item 1. BUSINESS

Overview of Business
 
Natural Health Trends Corp. is an international direct-selling and e-commerce company. Subsidiaries controlled by us sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. Our wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. We also operate in Russia and Kazakhstan through our engagement with a local service provider.

Most of our order volume, particularly in our Hong Kong subsidiary, is for personal consumption through existing members’ referrals. Our objectives are to enrich the lives of the users of our products and enable our members to benefit financially from the sale of our products.
 
We were originally incorporated as a Florida corporation in 1988. We re-incorporated in Delaware effective June 29, 2005. In January 2019, the Company relocated its corporate headquarters from Rolling Hills Estates, California to Hong Kong.
 
Our common stock is currently traded on the NASDAQ Capital Market under the symbol “NHTC.”
 
Available Information
 
Our website is located at www.naturalhealthtrendscorp.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to such reports are available, free of charge, on our website as soon as reasonably practicable after we file electronically such material with, or furnish it to, the United States Securities and Exchange Commission, or SEC. The information provided on our website should not be considered part of this report. The SEC maintains an internet website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.
 
Our Principal Products
 
We offer a line of “NHT Global” branded products in seven distinct categories: wellness, herbal, beauty, lifestyle, home, baby, and active. These product categories, along with the business opportunity we offer in most of our markets, provide our members a platform to further their goal of achieving and maintaining healthy, quality lifestyles complete with product supplementation and the opportunity for financial rewards.


1


The following table summarizes our product offering by category:
Product Category
 
Description
 
Products
 
 
 
 
 
Wellness
Products formulated and designed to meet specific wellness goals of our customers. Includes targeted nutrition for joint health, antioxidant support, digestive health, heart health, vision health, immune support and cellular health.
 
Liquid, encapsulated, tableted and powder dietary and nutritional supplements, vitamins, minerals
 
Premium Noni Juice, Triotein®, Cluster X2®, Children’s Chewable MultiVitamin, ReStor Silver®, ReStor Vital®, HerBalance®, Trifusion Max, Glucosamine 2200, FibeRich®, Energin, Enhanced Essential Probiotics®, Omega 3 Essential Fatty Acids, Memory Burst®, StemRenu®, OcuFocus, FE Enzyme Toothpaste, RespFactor®, CurcuMore®, AdaptoGin®
 
 
 
 
 
Herbal
Products formulated incorporating ingredients commonly found in traditional Chinese medicine.
 
Herbal supplements
 
LivaPro®, Cordyceps Mycelia CS-4, Purus, CogniMax®
 
 
 
 
 
Beauty
Products to help improve skin health and bring an appearance of youthful vibrancy. This product line includes anti-aging and hydrating cleansers, creams, lotions, serums and toners to moisturize, protect and improve the appearance of skin.
 
Facial skin care and hand and body care
 
Skindulgence® 30-Minute Non-Surgical Facelift System, Time Restore Eye Cream and Essence, BioCell SC Mask, 24K Renaissance Rejuvenation Serum, Valesce®, Floraeda Hydrating Series, NHT Homme®, Botanical Hand Protector, Airelle® Exfoliating Cleanser, Airelle® Age-Defying Facial Serum, Airelle® Intense Hydrating Repair Complex, Airelle® Age-Defying Eye & Lip Treatment, Airelle® Hydrating Manuka Mask
 
 
 
 
 
Lifestyle
Products uniquely formulated to improve overall quality of life and to support active, physical and healthy lifestyles including weight management, intimacy support and energy enhancing supplements.
 
Supplements and topical gels for improved vitality
 
Alura® Lux by NHT Global, Valura Lux, LaVie Vibrant Energy drink, Twin Slim Diet Jelly®, NaturalGlo 
 
 
 
 
 
Home
Products designed to create a clean and natural living environment for the home.
 
Home and car appliances
 
PurAir Air Purifier, AquaPur Water Purifier
 
 
 
 
 
Baby
Products uniquely formulated with gentle ingredients from nature for infants and babies.
 
Infant and toddler bath and body care
 
Moisturizing Lotion and Foaming Cleanser
Active
Products uniquely formulated to support those with active, healthy lifestyles. Products include dietary supplements to enhance daily nutrition for lasting energy and offer pre- and post- workout support.
 
Dietary supplement drink mixes for nutritional support, mental and physical performance enhancement and refuel and recovery support
 
Phyto Daily Active, Charge NOX, Optimal Recovery

We continuously source unique, proprietary and immediate impact products to offer to our members and customers. Our product development is an ongoing process that is fueled by marketplace trends, new technologies and scientific findings, members’ input, research and vendor proposals.

2


 
Working closely with raw material manufacturers and contract manufacturers, our mission is to co-develop and bring to market the highest quality products. Our manufacturers are primarily located in the United States, as well as a few in South Korea, Hong Kong and China. Our raw materials are sourced from reputable suppliers around the world. All current and new products introduced into the market are tested to ensure country and state regulatory compliance requirements are met where the products are sold. This includes proper handling, shipping, and shelf-life recommendations for our products. In addition, raw material Certificates of Analysis are reviewed to ensure that appropriate testing has been performed and are within required ingredient specifications.
 
Operations of the Business
 
Operating Strategy
 
Our objective is to help our members succeed in achieving their life objectives; be it personal health, beauty, happiness or financial rewards. Our employees focus on assisting our members in attaining their goals.

We believe we have a competitive business model applicable to the markets in which we operate based on six key competencies:
 
Our field leaders are experienced and culturally coherent. They work effectively with our management, implementing our strategies and providing continuous feedback to improve our services.

A discipline and capability has been established to continue launching high-quality consumer products that are designed to facilitate the accomplishment of our corporate objectives.

We have developed and rolled out a comprehensive training system that provides a complete career path appropriate for our members. Our training material covers the needs of our members, be they prospects, new recruits, product evangelists, sales leaders or dream builders.

We have developed a year-round, multi-faceted promotional plan that targets different segments of our membership and has proven effective in the last few years.

We have implemented a commission structure that makes it as easy as possible to join our business, while giving existing members a chance to start earning money as quickly as possible in multiple ways.

The continuously improving mentality and methodology in our customer services have not only distinguished us as an organization, but have also given us a constant flow of information as to how we can do better to service our members.

Sourcing of Products
 
Our staff works with research and development personnel of our manufacturers and other prospective vendors to create product concepts and develop the product ideas into actual products. We then may enter into supply agreements with the vendors pursuant to which we obtain rights to sell the products under private labels (or trademarks) that are owned by us. In addition, some of our local markets introduce their own products from time to time and these products are sometimes adopted by our other markets.
 
We generally purchase finished goods from manufacturers and sell them to our members for retail and personal consumption. We believe that in the event we are unable to source products from our current or alternate suppliers, our revenue, income and cash flow could be adversely and materially impacted. We have some contracts with our suppliers with automatic renewal rights.
 
Marketing and Distribution
 
We distribute our products internationally primarily through a network marketing system, which is a form of person-to-person direct selling.  Under this system, members primarily refer our products to prospective consumers or they may buy at wholesale prices for personal consumption or for resale to consumers.  The concept of network marketing is based on the strength of personal recommendations that frequently come from friends, neighbors, relatives, and close acquaintances.  We believe that network marketing is an effective way to distribute our products because it allows person-to-person product education and testimonials as well as higher levels of customer service, all of which are not as readily available through other

3


distribution channels. In this document, we generically use the term “member” to refer to members who purchase for their own consumption or for resale, or both, as well as to members who only sign up to consume our products.
 
Each of our products is designated a specified number of bonus volume points. Commissions are paid to members based on total personal and group bonus volume points per weekly sales period. Bonus volume points are essentially a percentage of a product’s wholesale price.

Virtually all of our members are independent full-time or part-time contractors who purchase products directly from our subsidiaries via the internet for their own personal consumption or for resale to retail consumers. Purchasers of our products in some of our smaller markets and purchasers of our products from our China subsidiary may purchase only for their own personal consumption and not for resale.
 
The following table sets forth the number of active members by market as of the dates indicated. We consider a member “active” if they have placed at least one product order with us during the preceding year. Members may not necessarily reside in the market for which they sign up as a member.
 
December 31,
 
2018
 
2017
Americas1
6,880

 
5,540

Hong Kong (including those members residing in China)2
84,690

 
82,150

Taiwan
2,970

 
4,460

South Korea
180

 
200

Japan
170

 
130

Singapore
70

 
80

Malaysia
150

 

Russia and Kazakhstan
790

 
790

Europe
1,940

 
2,320

Total
97,840

 
95,670

_____________________________ 
1 United States, Canada, Mexico and Peru
2 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.

Members must agree to the terms and conditions of our member agreement posted on our website. The member agreement sets forth our policies and procedures, and we may elect to terminate a member for non-compliance.
 
We pay commissions to eligible members based on product purchases by such members’ down-line customers and members during a given commission period. To be eligible to receive commissions, members in some countries may be required to make nominal monthly or other periodic purchases of products. See “Working with Members.
 
Members generally place orders through the internet and pay by credit card prior to shipment. Accordingly, we carry minimal accounts receivable and credit losses are historically negligible.
 
We sponsor promotional meetings, product education, motivational and personal development training events for current and potential members. These events are designed to inform prospective and existing members about both existing and new product lines, our latest marketing and promotional plans, and new services improvements. These events also serve as a venue for recognition of member accomplishments. Members typically share their experiences in using our products and developing their business at these events. We are continually developing and updating our marketing strategies and programs to motivate our members.
 
Management Information Systems
 
Our business uses a proprietary web-based system to process orders and to communicate bonus volume activity and commissions to members. We have automated a substantial amount of our financial reporting processes through implementation of Oracle’s E-Business Suite, and have integrated other critical business processes such as inventory management, purchasing and costing in our most significant markets.

4


 
Employees
 
At December 31, 2018, we employed 153 total full-time employees worldwide, of which 102 were located in Greater China (Hong Kong, China, and Taiwan), 34 in the Americas (United States, Canada, Cayman Islands, and Peru), three in Russia, three in Malaysia, three in South Korea, three in Europe, two in Japan, one in Singapore, one in Thailand, and one in Vietnam.
 
Seasonality
 
From quarter to quarter, we are somewhat impacted by seasonal factors and trends such as major cultural events and vacation patterns. For example, most Asian markets celebrate their respective local New Year in the first quarter. This generally has a significant impact on the services of our third-party providers, and can negatively impact our net sales. We believe that net sales can also be negatively impacted during the third quarter, when many of our members traditionally take time off for vacations. In addition, the national holidays in Hong Kong, China and Taiwan in early October tend to have an adverse effect on sales in those markets.
     
Our spending, as well as to some extent revenue, is affected by the major events planned at different times of the year. A major promotional event could significantly increase the reported expenses during the quarter in which the event actually takes place, while the revenue that might be generated by the event may not occur in the same reporting period.

Intellectual Property
 
Most of our products are packaged under a “private label” arrangement. We have obtained or applied for trademark registration for certain names, logos and various product names in several countries in which we are doing business or considering expanding. We also rely on common law trademark rights to protect our unregistered trademarks. These common law trademark rights do not provide us with the same level of protection as afforded by a United States federal trademark. Common law trademark rights are limited to the geographic area in which the trademark is actually utilized, while a United States federal registration of a trademark enables the registrant to discontinue the unauthorized use of the trademark by a third party anywhere in the United States even if the registrant has never used the trademark in the geographic area where the trademark is being used; provided, however, that the unauthorized third party user has not, prior to the registration date, perfected its common law rights in the trademark within that geographic area.
 
We have U.S. and foreign holding and operating company structures for our businesses, which involve the division of our United States and non-United States operations. Under this structure, the foreign holding company retains the economic ownership of the intangible property outside of the United States, including trademarks, trade secrets and other proprietary information.

Working with Members
 
Sponsorship
 
Enrolling new members creates multiple levels in our direct selling structure. The persons that a member enrolls within the network are referred to as “sponsored” members, who may purchase product solely for their own personal consumption, for resale, or both. Persons newly enrolled are assigned into network positions that can be “under” other members, and thus they can be called “down-line” members. If down-line members also enroll new members, they create additional levels within the structure, but their down-line members remain in the same down-line network as the original member that introduced them to our business.
 
While we provide informational brochures and other sales materials, members are primarily responsible for enrolling and educating their new members with respect to products, the compensation plan and how to build a successful membership network.
 
Members are not required to enroll other members as their down-line, and we do not pay any commissions for enrolling new members. However, because of the financial incentives provided to those who succeed in building a member network that consumes and resells products, we believe that many of our members attempt, with varying degrees of effort and success, to enroll additional members. Because they are seeking new opportunities for income, people are often attracted to become members after using our products or after attending introductory seminars. Once a person becomes a member, he or she is able

5


to purchase products directly from us at wholesale prices via the internet. The member is also entitled to enroll other members in order to build a network of members and product users.

Compensation Plans
 
We employ what is commonly referred to as a binary compensation plan, enhanced with certain unilevel features. Under our compensation plan, members are paid weekly commissions by our subsidiary in which they are enrolled for product purchases by their down-line member network across all geographic markets. Our China subsidiary maintains an e-commerce retail platform and does not pay commissions, although our Chinese members may participate in our compensation plan through our other subsidiaries. This “seamless” compensation plan enables a member located in one country to sponsor other members located in other countries. Currently, there are basically two ways in which members can earn income:

Through commissions paid on the accumulated bonus volume from product purchases made by their down-line members and customers; and

Through retail profits on sales of products purchased by members at discount and wholesale prices and resold at retail prices (for purchasers in some of our smaller markets and purchasers from our China subsidiary, sales are for personal consumption only and income may not be earned through retail profits).
 
Each of our products is designated a specified number of bonus volume points. Commissions are based on total personal and group bonus volume points per sales period. Bonus volume points are essentially a percentage of a product’s wholesale price. As the member’s business expands, the member receives higher commissions from purchases made by an expanding down-line network. To be eligible to receive commissions, a member may be required to make nominal monthly or other periodic purchases of our products. Certain of our subsidiaries do not require these nominal purchases for a member to be eligible to receive commissions. In determining commissions, the number of levels of down-line members included within the member’s commissionable group increases as the number of memberships directly below the member increases. Under our current compensation plan, some of our commission payout may be limited to a hard cap dollar amount per week or a specific percentage of the total product sales. In some markets, commissions may be further limited.
 
In some markets, we also pay certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Members can also earn income, trips and other prizes in specific time-limited promotions and contests we hold from time to time.
 
Occasionally, we make modifications and enhancements to our compensation plan to help motivate members, which can have an impact on member commissions. We may also enter into agreements for business or market development, which could result in additional compensation to specific members.
 
Member Support
 
We are committed to providing a high level of support services tailored to the needs of our members in each market we are serving. We attempt to meet the needs and build the loyalty of members by providing personalized member services and by maintaining a generous product return policy (see “Product Warranties and Returns”). We believe that maximizing a member’s efforts by providing effective member support has been, and could continue to be, important to our success.

Through product training meetings, regular conventions, web-based messages, member focus groups, regular telephone conference calls and other personal contacts with members, we seek to understand and satisfy the needs of our members. Via our websites, we may provide product fulfillment and tracking services that result in user-friendly and timely product distribution.
 
To help maintain communication with our members, we offer the following support programs:

Teleconferences – we hold teleconferences with associate field leadership on various subjects such as technical product discussions, member organization building and management techniques.

Internet – we maintain a website at www.nhtglobal.com. On this website, the user can read company news, learn more about various products, sign up to be a member, place orders, and track the fulfillment and delivery of their orders.
 
Product Tools – we offer a variety of marketing tools to members, including product catalogs, videos, informational brochures, pamphlets and posters for individual products, which are both printed and available online.

6


 
Broadcast E-mail and Text Messages – we send announcements via e-mail and/or text messages to members who opt in to receive this form of communication.

Social Media Tools – in some countries we maintain country-specific social media sites to foster a community environment around our product offering and business opportunity.

Technology and Internet Initiatives
 
We believe that the internet is important to our business as more consumers communicate online and purchase products over the internet as opposed to traditional retail and direct sales channels. As a result, we have committed significant resources to our e-commerce capabilities and the abilities of our members to take advantage of the internet. Substantially all of our sales take place via the internet. We offer a global web page that allows a member to have a personalized replicating website through which he or she can sell products in all of the countries in which we do business. Links to these websites can be found at our main website for members at www.nhtglobal.com. The information provided on these websites should not be considered part of this report.
 
Rules Affecting Members
 
Our member policies and procedures establish the rules that members must follow in each market. We also monitor member activity in an attempt to provide our members with a “level playing field” so that one member may not be disadvantaged by the activities of another. We require our members to present products and business opportunities in an ethical and professional manner. Members further agree that their presentations to customers must be consistent with, and limited to, the product claims and representations made in our literature.
 
Our policies and procedures require that we produce or pre-approve all sales aids used by members such as presentations, videos, audio recordings, brochures and promotional clothing. Further, members may not use any form of media advertising to promote products unless it is pre-approved by us. Members are not entitled to use our trademarks or other intellectual property without our prior consent. If we are made aware of unapproved materials being used, we notify and direct the relevant members to cease using such materials. In addition to regularly communicating to our members what is and is not appropriate to say about product or income claims, we have engaged a third-party service provider to assist us in monitoring the internet and various social media to identify potential misconduct or violations of our policies and procedures.
 
Our compliance and member services department reviews reports of alleged member misbehavior. If we determine that a member has violated our member policies or procedures, we may terminate the member’s rights completely. Alternatively, we may impose sanctions, such as warnings, probation, withdrawal or denial of an award, suspension of privileges of the membership, fines, withholding commissions, until specified conditions are satisfied or other appropriate injunctive relief. Virtually all of our members are independent contractors, not employees, and may act independently of us. Further, our members may resign or terminate their membership at any time without notice. See “Item 1A. Risk Factors.”

Government Regulations
 
Direct Selling Activities
 
Direct selling, or multi-level marketing, activities are regulated by various federal, state and local governmental agencies in the United States and other countries. These laws and regulations are generally intended to prevent fraudulent or deceptive schemes. The laws and regulations in our current markets often:
 
impose cancellation/product return, inventory buy-backs and cooling-off rights for consumers and members;

require us or our members to obtain a license from, or register with, governmental agencies;

impose reporting requirements; and

impose upon us requirements, such as requiring members to maintain levels of retail sales to qualify to receive commissions, to ensure that members are being compensated for sales of products and not for recruiting new members.
 

7


The laws and regulations governing direct selling are modified from time to time, and, like other direct selling companies, we may be subject from time to time to government reviews, examinations or investigations in our various markets related to our direct selling activities. This can require us to make changes to our business model and aspects of our global compensation plan in the markets impacted by such changes and examinations.

At the end of 2005, China adopted new direct selling and anti-pyramiding regulations that are restrictive and contain various limitations, including a restriction on the ability to pay multi-level compensation to independent members and engage in certain member recruitment activities. The regulatory environment in China is complex, and our operations in China can receive regulatory and media attention.
 
The Chinese government scrutinizes activities of direct selling companies. Our business continues to be subject to regulations and examinations by municipal and provincial level regulators. At times, actions by government regulators have impacted our members’ activities in certain locations, and have resulted in a few cases of enforcement actions. In each of these cases, we helped our members with their defense in the legality of their conduct. We expect that our business model will continue to evolve, as we work with our professional advisors and regulators to make any changes that need to be made to comply with the direct selling and other regulations.
       
We believe that neither our Hong Kong-based website nor our e-commerce platform in China require a direct selling license in China, which we currently do not hold. We have previously sought to obtain a direct selling license, and in August 2015 initiated the process for submitting a new preliminary application for a direct selling license in China. If we are able to obtain a direct selling license in China, we believe that the incentives inherent in the direct selling model in China would incrementally benefit our existing business. Increased sales in China that could be derived from obtaining a direct selling license may be partially offset by the higher fixed costs associated with the establishment and maintenance of required service centers and branch offices. We are unable to predict whether and when we will be successful in obtaining a direct selling license to operate in China, and if we are successful, when we will be permitted to conduct direct selling operations and whether such operations would be profitable.
 
Regulation of Our Products
 
Our products and related promotional and marketing activities are subject to extensive governmental regulation by numerous governmental agencies and authorities in the United States, including the U.S. Food and Drug Administration (the “FDA”), the Federal Trade Commission (the “FTC”), the Consumer Product Safety Commission, the United States Department of Agriculture, State Attorneys General and other state regulatory agencies.  In our foreign markets, the products are generally regulated by similar government agencies.

Our personal care products are subject to various laws and regulations that regulate cosmetic products and set forth regulations for determining whether a product can be marketed as a “cosmetic” or requires further approval as an over-the-counter (OTC) cosmetic. In the United States, regulation of cosmetics is under the jurisdiction of the FDA.  The Food, Drug and Cosmetic Act defines cosmetics by their intended use, as “articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body . . . for cleansing, beautifying, promoting attractiveness, or altering the appearance.”  Among the products included in this definition are skin moisturizers, eye and facial makeup preparations, perfumes, lipsticks, fingernail polishes, shampoos, permanent waves, hair colors, toothpastes and deodorants, as well as any material intended for use as a component of a cosmetic product.  Conversely, a product will not be considered a cosmetic, but may be considered a drug if it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or is intended to affect the structure or any function of the body. A product’s intended use can be surmised from marketing or product claims.  The other markets in which we operate have similar regulations.  


8


In Japan, the Ministry of Health, Labour and Welfare regulates the sale and distribution of cosmetics and requires us to have an import business license and to register each personal care product imported into Japan.  In Taiwan, all “medicated” cosmetic products require registration.  In China, personal care products are placed into one of two categories, “general” and “drug.”  Products in both categories require submission of formulas and other information with the health authorities, and drug products require human clinical studies.  The product registration process in China for these products can take from nine to more than 18 months or longer.  Such regulations in any given market can limit our ability to import products and can delay product launches as we go through the registration and approval process for those products.  The sale of cosmetic products is regulated in the European Union under the European Union Cosmetics Directive, which requires a uniform application for foreign companies making personal care product sales. In Peru, this is managed by the governing arm DIGEMID (Dirección General de Medicamentos, Insumos y Drogas) and can take up to three months to fully register as saleable. Similarly, in Mexico, the governing arm is COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) and can also take three to six months to fully register as saleable.
 
The markets in which we operate all have varied regulations that distinguish foods and nutritional health supplements from “drugs” or “pharmaceutical products.”  Because of the varied regulations, some products or ingredients that are recognized as a “food” in certain markets may be treated as a “pharmaceutical” in other markets.  These regulations may require us to either modify a product or refrain from selling the product in a given market. As a result, we must regularly modify the ingredients and/or the levels of ingredients in our products to ensure all applicable regulatory restrictions are addressed.  In some circumstances, the regulations in foreign markets may require us to obtain regulatory approval prior to introduction of a new product or limit our uses of certain ingredients altogether. There has been an increased movement in the United States and other markets to expand the regulation of dietary supplements. This could impose additional restrictions or requirements in the future.  Because of this increased regulatory focus, our internal regulatory staff has grown and review efforts have been enhanced in order to comply with our understanding of current regulations.
 
FDA regulations require current good manufacturing practices (cGMP) for dietary supplements.  The regulations seek to ensure personnel are routinely and properly trained, that dietary supplements are produced in a quality manner, do not contain contaminants or impurities, and are accurately labeled. The regulations include requirements for establishing quality control procedures for us and our vendors and suppliers, designing and constructing manufacturing plants, and testing ingredients and finished products.  The regulations also include requirements for record keeping and handling consumer product complaints.  If dietary supplements contain contaminants or do not contain the type or quantity of dietary ingredient they are represented to contain, the FDA would consider those products to be adulterated or misbranded. We seek to ensure compliance with all regulatory requirements through our periodic manufacturer and warehouse audits, as well as our corrective action request (CAR) program, if needed. The cGMP also extend to logistics where we seek to minimize any safety risks associated with product distribution.
 
Our business is subject to additional FDA regulations, such as those implementing an adverse event reporting system (“AER’s”), which requires us to document and track adverse events and report serious adverse events, which are events involving hospitalization or death, associated with consumers’ use of our products.  
 
Most of our major markets also regulate advertising and product claims regarding the efficacy of products. This is particularly true with respect to our dietary supplements because we typically market them as foods or health functional foods. For example, in the United States, we are unable to claim that any of our nutritional supplements will diagnose, cure, mitigate, treat or prevent disease. In the United States, the Dietary Supplement Health and Education Act, however, permits substantiated, truthful and non-misleading statements of nutritional support to be made in labeling, such as statements describing general well-being resulting from consumption of a dietary ingredient or the role of a nutrient or dietary ingredient in affecting or maintaining a structure or a function of the body. Most of the other markets in which we operate have not adopted similar legislation, so distribution of U.S. products may be subject to more restrictive limitations on the claims we can make about our products in these markets.

China’s 100-Day Campaign Focusing on Health Products and Services
 
On January 8, 2019, the Chinese government announced a comprehensive 100-day campaign focusing on companies involved in the sale of food, equipment, daily necessities, small home electrical appliances and services that are claimed to promote health. The Chinese government ministries in charge of this campaign indicated that they are targeting illegal practices in the industry, particularly the manufacture and sale of counterfeit and substandard products, and false advertising and misleading claims as to the health benefits of products and services. It is understood that the campaign is specifically focused on the business practices of direct selling companies. During the campaign, we understand that the government will not issue any additional direct selling licenses, will cease issuing certifications of quality or other approvals of various healthcare products, and will review its regulatory oversight of the industry. We believe that the campaign will negatively

9


impact our business in China in the short-term, but will benefit us and Chinese consumers in the long-term as purveyors of substandard products are driven from the market. Although we understand the 100-day campaign would have expired on or about April 18, 2019, we are not aware of any information indicating that the campaign has been concluded. See “Item 1A. Risk Factors - Our operations in China are subject to compliance with a myriad of applicable laws and regulations...” and “Item 7 - Management’s Discussion and Analysis of Financial Condition and Results of Operations - Business Overview.”

Other Regulatory Issues
 
As we operate through many subsidiaries in foreign jurisdictions, we are subject to foreign exchange control, transfer pricing and custom laws that regulate the flow of funds between our entities for product purchases, management services and contractual obligations, such as the payment of member commissions. As is the case with most companies that operate in direct sales, we might receive inquiries or scrutiny from time to time from government regulatory authorities regarding the nature of our business and other issues, such as compliance with local direct selling, pyramid selling, transfer pricing, customs, taxation, foreign exchange control, securities and other laws.

Product Warranties and Returns
 
Our refund policies and procedures closely follow industry and country-specific standards, which vary greatly by country. For example, in the United States, the Direct Selling Association recommends that direct sellers permit returns during the twelve-month period following the sale, while in Hong Kong the standard return policy is 14 days following the sale. Our return policies typically conform to local laws or the recommendation of the local direct selling association. In most cases, members who timely return unopened product that is in resalable condition may receive a refund. The amount of the refund may be dependent on the country in which the sale occurred, the timeliness of the return, and any applicable re-stocking fee. NHT Global must be notified of the return in writing and such written requests would be considered a termination notice of the membership. We may alter our return policy in response to special circumstances.
 
Significant Customers

Sales are made to our members and no single customer accounted for 10% or more of our net sales. However, our business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on our net sales and financial results.

Our Industry
 
We are engaged in the direct selling industry, selling wellness, herbal, beauty, lifestyle, home and baby products. More specifically, we are engaged in what is called network marketing or multi-level marketing. This type of organizational structure and approach to marketing and sales include companies selling lifestyle enhancement products, cosmetics and dietary supplements, or selling other types of consumer products. Generally, direct selling is based upon an organizational structure in which independent members purchasing a company’s products are compensated for sales made directly to consumers.
 
Our members are compensated based on sales generated by members they have enrolled and all subsequent members enrolled by their “down-line” network of members. The experience of the direct selling industry has been that once a sizeable network of members is established, new and alternative products and services can be offered to those members for sale to consumers and additional members.
 
Competition
 
The network marketing industry is very diverse, with giant multinational corporations as well as smaller, local operators. Big network marketing companies include Nu Skin Enterprises, Inc., USANA Health Sciences, Inc., and Herbalife, Ltd, which have much greater name recognition and financial resources than we do and also have many more members. They are publicly traded and therefore serve as informational benchmarks, but we don’t overlap with them in terms of marketplace or product range. On the other hand, many medium- and small-sized privately held Chinese, Taiwanese and Hong Kong companies are fierce competitors and are much closer to directly competing with us. Also, a number of our former employees and members now work for competitors, and sometimes try to use relationships and knowledge obtained to compete with us.
 
Our ability to compete with other network marketing companies depends, in significant part, on our success in attracting and retaining members.  There can be no assurance that our programs for attracting and retaining members will be successful.  The pool of individuals interested in network marketing is limited in each market and is reduced to the extent other network

10


marketing companies successfully attract these individuals into their businesses.  Although we believe that we offer an attractive opportunity for our members, there can be no assurance that other network marketing companies will not be able to recruit our existing members or deplete the pool of potential members in a given market.
 
The direct selling channel tends to sell products at a higher price compared to traditional retailers, which poses a degree of competitive risk. There is no assurance that we would continue to compete effectively against retail stores, internet-based retailers or other direct sellers.
 

11


Item 1A. RISK FACTORS

We are exposed to a variety of risks that are present in our business and industry. The following are some of the more significant factors that could affect our business, results of operations and financial condition.
 
We could be adversely affected by management changes or an inability to attract and retain key management, directors and consultants.
 
We incur a low level of overhead and are run by a small number of executives, who rely on a small group of employees. Our future success depends to a significant degree on the skills, experience and efforts of our top management and directors.  We also depend on the ability of our executive officers and other members of senior management to work effectively as a team.  The loss of one or more of our executive officers, members of our senior management or directors could have a material adverse effect on our business, results of operations and financial condition.  Moreover, as our business evolves, we may require additional or different management members, directors or consultants, and there can be no assurance that we will be able to locate, attract and retain them if and when they are needed.

Because our Hong Kong operations account for a substantial portion of our overall business, and substantially all of our Hong Kong business is derived from the sale of products to members in China, any material adverse change in our business relating to either Hong Kong or China would likely have a material adverse impact on our overall business.
 
In 2018 and 2017, approximately 88% and 89% of our revenue, respectively, was generated in Hong Kong. Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. This geographic concentration in our business means that events or conditions that could negatively impact this geographic region or our operations in this region would have a greater adverse impact upon our overall business and financial results than would be the case with a company having greater geographic diversification.  

Our operations in China are subject to compliance with a myriad of applicable laws and regulations, and any actual or alleged violations of those laws or government actions otherwise directed at us could have a material adverse impact on our business and the value of our company.

In contrast to our operations in other parts of the world, our China subsidiary has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license, which we are in the process of applying for, and has also adopted anti-pyramid selling and multilevel marketing legislation. We operate an e-commerce direct selling model in Hong Kong and recognize the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties.  In addition, through a Chinese entity, we sell products in China using an e-commerce retail model. Chinese members may elect to participate in either or both of the Chinese entity and the Hong Kong entity.

We continually evaluate our operations in China and Hong Kong for compliance with applicable laws and regulations, including seeking the input of outside professionals and certain Chinese authorities. This process can and has resulted in the identification of certain matters of potential noncompliance. We work on a continuing basis to satisfactorily address such matters, however there can be no assurance that adequate steps are taken or that applicable laws and regulations are properly interpreted. Should the government authorities determine that our activities violate applicable laws and regulations, including China’s direct selling, pyramid selling or multilevel marketing laws and regulations, or should new laws or regulations be adopted, there could be a material adverse effect on our business, financial condition and results of operations.
 
The Chinese government scrutinizes the activities of direct selling companies. Our business continues to be subject to regulations and examinations by municipal and provincial level regulators. At times, actions by government regulators have impacted our members’ activities in certain locations and have resulted in a few cases of enforcement actions. In each of these cases, we helped our members with their defense of the legality of their conduct.
 

12


Our business operations and the value of our company can be adversely affected by Chinese government scrutiny of our operations, even if that scrutiny does not result in investigations of our operations. For example, one or more parties encouraged the Beijing City governmental authorities to conduct an investigation of our business, which resulted in a meeting in January 2016 involving members of our Beijing office staff, Beijing City governmental officials, and two complainants. Even though the Beijing City governmental officials advised our staff and the complainants at that meeting that there was insufficient evidence to warrant an investigation of us, mischaracterizations of the meeting immediately appeared in several “news reports.” Similarly, a subsequent meeting between several Guangzhou City government officials and members of our Guangzhou office staff that resulted in our providing routine information about our operations to the government officials was mischaracterized in an online posting made immediately following the meeting. Although we remain in regular contact with Chinese government officials and take other steps to address the risks posed by these events, our business and the value of our company remain vulnerable to Chinese government scrutiny of our operations, whether or not initiated by third parties, which scrutiny could result in the Chinese or Hong Kong government taking action against us.

Various other factors could harm our business in Hong Kong and China, such as worsening economic conditions in Hong Kong or China, adverse local publicity, geopolitical or trade tensions between the U.S. and China or other events that may be out of our control. For example, in January 2019, China Central Television (CCTV) aired a segment alleging, among other things, that we conduct an illegal pyramid scheme in China. Several days later, in what we believe was an unrelated development, the Chinese government announced a comprehensive 100-day campaign focusing on companies involved in the sale of food, equipment, daily necessities, small home electrical appliances and services that are claimed to promote health. The Chinese government ministries in charge of this campaign indicated that they are targeting illegal practices in the industry, particularly the manufacture and sale of counterfeit and substandard products, and false advertising and misleading claims as to the health benefits of products and services. It is understood that the campaign is specifically focused on the business practices of direct selling companies. Similarly, during the third quarter of 2007, we learned that the Chinese government was expected to impose a more intense enforcement program against illegal pyramid scheme activities (or “chain sale” activities in transliterated Chinese terms). In January 2019 we, like some of our peers, voluntarily decided to temporarily suspend our member activities, such as product roadshows, product trainings and larger company-sponsored events, in China as we did in 2007. We did this because we have learned that the 100-day campaign was announced in broad outlines by the central government, and the interpretation and enforcement of the campaign was delegated to the provincial and local governments. We consider it a top priority for our business to develop an understanding of and cooperate with all levels and jurisdictions of the government agencies and did not want to run the risk of being inadvertently entangled in the government enforcement actions. Our suspension of member activities currently remains in effect, and it may be necessary or advisable to repeat this or similar actions from time to time in the future, and such periods of reduced activity can and do have a material adverse effect on our business. Although we understand the 100-day campaign would have expired on or about April 18, 2019, we are not aware of any information indicating that the campaign has been concluded.

Although we attempt to work closely with both national and local Chinese governmental agencies in conducting our business, our efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling, pyramid selling or multi-level marketing legislation, subjective interpretations of laws and regulations, and activities by individual members that may violate laws notwithstanding our strict policies prohibiting such activities.

Any determination that our operations or activities, or the activities of our individual members, employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on our future ability to obtain business licenses or expand into new locations, changes to our business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm our business, financial condition and results of operations. 

Our failure to maintain and expand our member relationships could adversely affect our business.
 
We distribute our products through independent members, and we depend upon them directly for all of our sales in most of our markets. Accordingly, our success depends in significant part upon our ability to attract, retain and motivate a large base of members. Our direct selling organization is headed by a relatively small number of key members. The loss of a significant number of members, or the loss of one or more key members, could materially and adversely affect sales of our products and could impair our ability to attract new members. Moreover, the replacement of members could be difficult because, in our efforts to attract and retain members, we compete with other direct selling organizations, including but not limited to those in the personal care, cosmetic product and nutritional supplement industries. Our members may terminate their services with us at any time and, in fact, like most direct selling organizations, we have a high rate of attrition.


13


Our number of active members or their productivity may not increase and could decline in the future.  We cannot accurately predict any fluctuation in the number or the productivity of members because we primarily rely upon existing members to enroll and train new members and to motivate new and existing members. Operating results could be adversely affected if our existing and new business opportunities and products do not generate sufficient economic incentive or interest to retain existing members and to attract new members.
 
The number and productivity of our members could be harmed by several factors, including:

adverse publicity or negative perceptions regarding us, our products, our method of distribution or our competitors;

lack of interest in, or the technical failure of, existing or new products;

lack of interest in our existing compensation plan for members or in enhancements or other changes to that compensation plan;

our actions to enforce our policies and procedures;

regulatory actions or charges or private actions against us or others in our industry;

general economic and business conditions;

changes in management or the loss of one or more key member leaders;

entry of new competitors, or new products or compensation plan enhancements by existing competitors, in our markets; and

potential saturation or maturity levels in a given country or market which could negatively impact our ability to attract and retain members in such market.

We are currently involved in, and may in the future face, lawsuits, claims, and governmental proceedings and inquiries that could harm our business.
 
We are currently, and have in the past, been a party to lawsuits, claims and governmental proceedings and inquiries. As disclosed elsewhere in this report, on January 8, 2019, we and our executive officers were named in a putative securities class action lawsuit alleging in part that we made materially false and misleading statements regarding the legality of our business operations in China. Prosecuting and defending these and any other matters may require significant expense and attention of our management and can expose us to adverse publicity, regardless of the outcome. Further, in the event of an adverse outcome, we could be required to pay substantial damages, fines or penalties and cease or be prevented from conducting certain practices or activities.

Since August 2016, the SEC has been conducting a non-public investigation to determine whether there have been violations of the federal securities laws relating to the trading of our securities. We have fully cooperated with the SEC and have and continue to provide documents in response to subpoenas. The SEC has expressly stated that its document requests should not be construed as an indication that any violation of law has occurred, or as a reflection upon any person, entity, or security. The amount of time needed to resolve this matter is uncertain, and we cannot predict the outcome or whether we will face additional governmental inquiries or other actions. The SEC could bring enforcement actions against us or individuals, including our officers or directors. Such actions, if brought, could result in dispositions, judgments, settlements, fines, injunctions, cease and desist orders, debarment or other civil or criminal penalties. The imposition of any sanctions, fines or the implementation of remedial measures could have a material adverse effect on our business.

Such matters can be complex, can extend for a protracted period of time, and can result in unpredictable expense. There can be no assurance that we will be able to successfully defend or resolve any such litigation, claims or governmental proceedings or inquiries, or that the significant money, time and effort spent in defending these matters, or any related adverse publicity, will not adversely affect our business, financial condition and results of operations.


14


Although virtually all of our members are independent contractors, improper member actions that violate laws or regulations could harm our business.
 
Virtually all of our members are independent contractors and, accordingly, we are not in a position to directly provide the same direction, motivation and oversight as we would if these members were our own employees.  As a result, there can be no assurance that our members will participate in our marketing strategies or plans, accept our introduction of new products, or comply with our member policies and procedures.  Extensive federal, state, local and foreign laws regulate our business, our products and our network marketing program.  Because we operate in a number of foreign countries, our policies and procedures for our members differ due to the different legal requirements of each country in which we do business.  While we have implemented member policies and procedures designed to govern member conduct and to protect the goodwill associated with our trademarks and trade names, it can be difficult to enforce these policies and procedures because of the large number of members and their independent status.  
 
Given the size and diversity of our member force, we experience problems with members from time to time, especially with respect to our members in foreign markets. For example, if our members engage in illegal activities in China, those actions could be attributed to us. Chinese laws regarding how and when members may assemble and the activities that they may conduct, or the conditions under which the activities may be conducted, are subject to interpretations and enforcement that sometimes vary from province to province, among different levels of government, and from time to time. Members can be accused of violating one or more of the laws regulating these activities, notwithstanding training that we attempt to provide. Enforcement measures regarding these violations, which can include arrests, raise the uncertainty and perceived risk associated with conducting this business, especially among those who are aware of the enforcement actions but not the specific activities leading to the enforcement action. We believe that this has led some existing members in China - who are signed up as members in Hong Kong - to leave the business or curtail their selling activities and has led some potential members to choose not to participate. Among other things, we are managing this risk with more training and public relations efforts that are designed, among other things, to distinguish our company from businesses that make no attempt to comply with the law. This environment creates uncertainty about the future of doing this type of business in China generally and under our business model, specifically.

In addition, members often desire to enter a market before we have received approval to do business in order to gain an advantage in the marketplace.  Improper member activity in new geographic markets could result in adverse publicity and can be particularly harmful to our ability to ultimately enter these markets.  Violations by our members of applicable law or of our policies and procedures in dealing with customers could reflect negatively on our products and operations, and harm our business reputation.  In addition, it is possible that a judicial or administrative body could hold us civilly or criminally accountable based on vicarious liability because of the actions of our members.  If any of the above or related events involving our members occur, our business, financial condition, or results of operations could be materially adversely affected.

Direct-selling laws and regulations may prohibit or severely restrict our direct sales efforts and cause our revenue and profitability to decline, and regulators could adopt new regulations that harm our business.
 
Our direct selling system is subject to extensive laws, governmental regulations, administrative determinations, court decisions and similar constraints.  These laws and regulations are generally intended to prevent fraudulent or deceptive schemes, often referred to as “pyramid” schemes, which compensate participants for recruiting additional participants irrespective of product sales, use high pressure recruiting methods and/or do not involve legitimate products. They also seek to ensure that claims regarding the ability of participants to earn money are truthful and substantiated.
 
Complying with these widely varying and sometimes inconsistent rules and regulations can be difficult and may require the devotion of significant resources on our part.  There can be no assurance that we or our members are in compliance with all of these regulations.  Our failure or our members’ failure to comply with these regulations or new regulations could lead to the imposition of significant penalties or claims and could negatively impact our business.  If we are unable to continue business in existing markets or commence operations in new markets because of these laws, our revenue and profitability may decline.
 
We are also subject to the risk that new laws or regulations might be implemented or that current laws or regulations might change, which could require us to change or modify the way we conduct our business in certain markets.  This could be particularly detrimental to us if we have to change or modify the way we conduct business in markets that represent a significant percentage of our revenue.


15


The high level of competition in our industry could adversely affect our business.
 
The business of marketing personal care, cosmetic, nutritional supplements, and lifestyle enhancement products is highly competitive.  This market segment includes numerous manufacturers, members, marketers, and retailers that actively compete for the business of consumers both in the United States and abroad.  The market is highly sensitive to the introduction of new products, which may rapidly capture a significant share of the market.  Sales of similar products by competitors may materially and adversely affect our business, financial condition and results of operations.
 
We are subject to significant competition for the recruitment of members from other direct selling organizations, including those that market similar products.  Many of our competitors are substantially larger than we are, offer a wider array of products, have far greater financial resources and many more active members than we have.  Even more numerous are those medium- and small-sized, all privately held Chinese, Taiwanese and Hong Kong companies that are fierce competitors and are much closer to directly competing with us. Our ability to remain competitive depends, in significant part, on our success in recruiting and retaining members with our products, attractive compensation plan and other incentives.  We believe that we have an attractive product line and that our compensation and incentive programs provide our members with significant earning potential.  However, we cannot be sure that our programs for recruitment and retention of members will be successful.
 
Some of our competitors have employed or otherwise contracted for the services of our former officers, employees, consultants, and members, who may try to use information and contacts obtained while under contract with us for competitive advantage.  While we seek to protect our information through contractual and other means, there can be no assurance that we will timely learn of such activity, have the resources to attempt to stop it, or have adequate remedies available to us.
 
Challenges by third parties to the legality of our business operations could harm our business.

We are also subject to the risk of private party challenges to the legality of our operations, including our direct selling system.  The regulatory requirements concerning direct selling systems generally do not include “bright line” rules and are inherently fact-based and subject to judicial or administrative interpretation. An adverse judicial or administrative determination against us with respect to our direct selling system, or in proceedings not involving us directly but which challenge the legality of other direct selling marketing systems, could have a material adverse effect on our business.  There is also risk that challenges and settlements involving other parties could provide incentives for similar actions by members against us and other direct selling companies.  Moreover, challenges to our business system and operations in important markets may come from short sellers, hedge funds, other investors, bloggers and reporters.  Other companies in our industry have recently faced such challenges.  Any challenges regarding us or others in our industry could harm our business if such challenges result in the imposition of any fines or damages on our business, create adverse publicity, increase scrutiny or investigations of us or our industry, detrimentally affect our efforts to recruit or motivate members and attract customers, or interpret laws in a manner inconsistent with our current business practices.

An increase in the amount of compensation paid to members would reduce profitability.
 
We incur significant expense in the payment of compensation to our members, which represented approximately 46% and 42% of net sales during 2018 and 2017, respectively.  We compensate our members by paying commissions, bonuses, and certain awards and prizes.  Factors impacting the overall commission payout include the growth and depth of the member network, the member retention rate, the type and scope of promotions and incentives, local promotional programs and business development agreements.  Long-term promotions and incentives (lasting up to one year) can, in particular, result in uncertain ultimate cost. Any increase in compensation payments to members as a percentage of net sales will reduce our profitability.  

Our compensation plan includes a cap that may be enforced on member compensation paid out on a weekly dollar limit or as a percentage of product sales. There can be no assurance that enforcement of this cap will ensure profitability (which depends on many other factors).  Moreover, enforcement of this cap could cause key members affected by the cap to leave and join other companies.
 

16


Currency exchange rate fluctuations could lower our revenue and net income.
 
In 2018, 96% of our revenue was recorded by subsidiaries located outside of North America.  Revenue transactions and related commission payments, as well as other incurred expenses, are typically denominated in the local currency.  Accordingly, our international subsidiaries generally use the local currency as their functional currency.  The results of operations of our international subsidiaries are exposed to foreign currency exchange rate fluctuations during consolidation since we translate into U.S. dollars using the average exchanges rates for the period.  As exchange rates vary, revenue and other operating results may differ materially from our expectations.  Additionally, we may record significant gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of inter-company balances.  
 
Our most significant foreign exchange exposure, the Hong Kong dollar, is for now pegged to the U.S. dollar.  We also purchase a significant majority of inventories in U.S. dollars.  Our foreign currency exchange rate exposure to the South Korean won, Taiwan dollar, Japanese yen, Chinese yuan, Russian ruble, Kazakhstani tenge, Singaporean dollar, Malaysian ringgit, Vietnamese dong, Thai baht, Canadian dollar, Mexican peso, Peruvian sol and European euro collectively represented approximately 10% of our revenue in both 2018 and 2017, respectively.  Our foreign currency exchange rate exposure may increase in the near future as we develop opportunities in Southeast Asia, India, Canada, Central America, South America and Europe.  Additionally, our foreign currency exchange rate exposure would significantly increase if the Hong Kong dollar were no longer pegged to the U.S. dollar.  Finally, we also experience indirect exchange rate exposure due to the concentration of our sales to members residing in China and the impact of fluctuations in the value of the Chinese yuan on our members’ purchasing power.

Given our inability to predict the degree of exchange rate fluctuations, we cannot estimate the effect these fluctuations may have upon future reported results, product pricing or our overall financial condition.  Further, to date we have not attempted to reduce our exposure to short-term exchange rate fluctuations by using foreign currency exchange contracts.
 
Changes in tax or duty laws, and unanticipated tax or duty liabilities, could adversely affect our net income.
 
In the course of doing business we may be subject to various taxes, such as sales and use, value-added, and franchise. We are also subject to income taxes in the United States and numerous foreign jurisdictions. We earn a substantial portion of our income in foreign jurisdictions. Economic and political conditions make tax rules in any jurisdiction, including the United States, subject to significant change. There have been recent changes in U.S. tax law that impact how U.S. multinational corporations are taxed on foreign earnings. There have also been proposals to reform foreign tax laws that could significantly affect the Company’s tax position. Although we cannot predict whether or in what form these proposals will pass, several of the proposals considered, if enacted into law, could have an adverse impact on our income tax expense and cash flows.
 
Our parent corporation is domiciled in the United States. Under tax treaties, we are eligible to receive foreign tax credits in the United States for taxes paid abroad. Taxes paid to foreign taxing authorities may exceed the credits available to us, resulting in the payment of a higher overall effective tax rate on our worldwide operations.
 
Our effective income tax rate in the future could be adversely affected by a number of factors, including changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities, changes in tax laws, and the outcome of income tax audits in various jurisdictions around the world.
 
We may also be subject to examinations of our tax returns and other tax matters by the U.S. Internal Revenue Service and other tax authorities and governmental bodies. We regularly assess the likelihood of an adverse outcome resulting from these examinations to determine the adequacy of our provision for taxes, which is subject to significant discretion. There can be no assurance as to the outcome of these examinations. If our effective tax rates were to increase, particularly in the U.S., or if the ultimate determination of taxes owed is for an amount in excess of amounts previously accrued, our financial results or operations could be adversely affected.
 
In addition, our operations are subject to regulations designed to ensure that appropriate levels of customs duties are assessed on the importation of our products. The failure to properly calculate, report and pay such duties when we are subject to them could have a material adverse effect on our financial condition and results of operations. Any change in the laws or regulations regarding such duties, or any interpretation thereof, could result in an increase in the cost of doing business.


17


Transfer pricing regulations affect our business and results of operations.
 
In many countries, including the United States, we are subject to transfer pricing and other tax regulations designed to ensure that appropriate levels of income are reported as earned by our United States or local entities and are taxed accordingly. We have adopted transfer pricing agreements with our subsidiaries to regulate inter-company transfers, which agreements are subject to transfer pricing laws that regulate the flow of funds between the subsidiaries and the parent corporation for product purchases, management services, and contractual obligations, such as the payment of member compensation. There can be no assurance that we will be found to be operating in compliance with transfer pricing laws, or that those laws would not be modified, which, as a result, may require changes in our operating procedures or otherwise may have a material adverse effect on our financial results or operations.

Our products and related activities are subject to extensive government regulation, which could delay, limit or prevent the sale of some of our products in some markets. 
 
The formulation, manufacturing, packaging, labeling, importation, advertising, distribution, sale and storage of certain of our products are subject to extensive regulation by various federal agencies, including the Food and Drug Administration (the “FDA”), the FTC, the Consumer Product Safety Commission and the United States Department of Agriculture and by various agencies of the states, localities and foreign countries in which our products are manufactured, distributed and sold.  For example, the FDA requires us and our suppliers to meet relevant current good manufacturing practice (cGMP) regulations for the preparation, packing and storage of foods and over-the-counter (OTC) drugs.  We are also now required to report serious adverse events associated with consumer use of certain of our products.  Other laws and regulations govern or restrict the claims that may be made about our products and the information that must be included and excluded on labels.
 
In markets outside the United States, prior to commencing operations or marketing new products, we may be required to obtain approvals, licenses, or certifications from a ministry of health or a comparable agency. Moreover, a foreign jurisdiction may pass laws that would prohibit the use of certain ingredients in their particular market.  Compliance with these regulations can create delays and added expense in introducing new products to certain markets.
 
Failure by our members or us to comply with those regulations could lead to the imposition of significant penalties or claims and could materially and adversely affect our business.  If we are not able to satisfy the various regulations, then we would have to cease sales of that product in that market.  In addition, the adoption of new regulations or changes in the interpretation of existing regulations may result in significant compliance costs or discontinuation of product sales and may adversely affect the marketing of our products, resulting in significant loss of revenues.
 
We cannot predict the nature of any future laws, regulations, interpretations, or applications, nor can we determine what effect additional governmental regulations or administrative orders, when and if promulgated, could have on our business.  These potential effects could include, however, requirements for the reformulation of certain products to meet new standards, the recall or discontinuance of certain products, additional recordkeeping and reporting requirements, expanded documentation of the properties of certain products, expanded or different labeling, or additional scientific substantiation.  Any or all of these requirements could have a material adverse effect on our business, financial condition, or results of operations.

Failure of new products to gain member and market acceptance could harm our business.
 
An important component of our business is our ability to develop new products that create enthusiasm among our member force.  If we fail to introduce new products on a timely basis, our member productivity could be harmed.  In addition, if any new products fail to gain market acceptance, are restricted by regulatory requirements, or have quality problems, this would harm our results of operations.  Factors that could affect our ability to continue to introduce new products include, among others, limited capital and human resources, government regulations, proprietary protections of competitors that may limit our ability to offer comparable products and any failure to anticipate changes in consumer tastes and buying preferences.
 
New regulations governing the marketing and sale of nutritional supplements could harm our business.
 
There has been an increasing movement in the United States and other markets to increase the regulation of dietary supplements, which could impose additional restrictions or requirements in the future.  In the United States, for example, some legislators and industry critics continue to push for increased regulatory authority by the FDA over nutritional supplements.  Our business could be harmed if more restrictive legislation is successfully introduced and adopted in the future.  In particular, the adoption of legislation requiring FDA approval of supplements or ingredients could delay or inhibit our ability to introduce new supplements.  We face similar pressures in our other markets, particularly in China where certain government ministries announced in January 2019 a comprehensive 100-day campaign focusing on companies involved in the

18


sale of certain products, including nutritional supplements.  In the United States the FTC Guides Concerning the Use of Endorsements and Testimonials in Advertising (“Guides”) require disclosure of material connections between an endorser and the company they are endorsing and require the disclosure of typical results when these are different from those reported by the endorser.  The requirements and restrictions of the Guides may diminish the impact of our marketing efforts and negatively impact our sales results.  If we or our members fail to comply with these Guides, the FTC could bring an enforcement action against us and we could be fined and/or forced to alter our operations.  Our operations also could be harmed if new laws or regulations are enacted that restrict our ability to market or distribute nutritional supplements or impose additional burdens or requirements on nutritional supplement companies or require us to reformulate our products.
 
Regulations governing the production and marketing of our personal care products could harm our business.
 
Our personal care products are subject to various domestic and foreign laws and regulations that regulate cosmetic products and set forth regulations for determining whether a product can be marketed as a “cosmetic” or requires further approval as an over-the-counter drug.  A determination that our cosmetic products impact the structure or function of the human body, or improper marketing claims by our members, may lead to a determination that such products require pre-market approval as a drug.  Such regulations in any given market can limit our ability to import products and can delay product launches as we go through the registration and approval process for those products.  Furthermore, if we fail to comply with these regulations, we could face enforcement action against us and we could be fined, forced to alter or stop selling our products and/or required to adjust our operations.  Our operations also could be harmed if new laws or regulations are enacted that restrict our ability to market or distribute our personal care products or impose additional burdens or requirements on the contents of our personal care products or require us to reformulate our products.

If we are found not to be in compliance with good manufacturing practices our operations could be harmed.
 
Regulations on good manufacturing practices and adverse event reporting requirements for the nutritional supplement industry are in effect and require good manufacturing processes for us and our vendors, including stringent vendor qualifications, ingredient identification, manufacturing controls and record keeping.   We are also required to report serious adverse events associated with consumer use of our products.  Our operations could be harmed if regulatory authorities make determinations that we or our vendors are not in compliance with the regulations.  A finding of noncompliance may result in administrative warnings, penalties or actions impacting our ability to continue selling certain of our products.  In addition, compliance with these regulations has increased and may further increase the cost of manufacturing certain of our products as we work with our vendors to assure they are qualified and in compliance.
 
Failure to comply with domestic and foreign laws and regulations governing product claims and advertising could harm our business.
 
Our failure to comply with FTC or state regulations, or with regulations in foreign markets that cover our product claims and advertising, including direct claims and advertising by us, as well as claims and advertising by members for which we may be held responsible, may result in enforcement actions and imposition of penalties or otherwise materially and adversely affect the distribution and sale of our products.  Member activities in our existing markets that violate applicable governmental laws or regulations could result in governmental or private actions against us in markets where we operate.  Given the size of our member force, we cannot ensure that our members will comply with applicable legal requirements.
 
Adverse publicity associated with our products, ingredients or network marketing program, or those of similar companies, could harm our financial condition and operating results.
 
Adverse publicity concerning any actual or claimed failure by us or our members to comply with applicable laws and regulations regarding product claims and advertising, good manufacturing practices, the regulation of our network marketing program, the licensing of our products for sale in our target markets or other aspects of our business, whether or not resulting in enforcement actions or the imposition of penalties, could have an adverse effect on our goodwill and could negatively affect our ability to attract, motivate and retain members, which would negatively impact our ability to generate revenue.  There have been several instances, including one recent instance, where adverse publicity in China has harmed our business. See “Risk Factors - Our operations in China are subject to a myriad of applicable laws and regulations…”. Further, we cannot ensure that all members will comply with applicable legal requirements relating to the advertising, labeling, licensing or distribution of our products.
 
In addition, our members’ and consumers’ perception of the safety and quality of our products and ingredients, as well as similar products and ingredients distributed by other companies, can be significantly influenced by media attention, publicized scientific research or findings, widespread product liability claims and other publicity concerning our products or ingredients or

19


similar products and ingredients distributed by other companies.  Adverse publicity, whether or not accurate or resulting from consumers’ use or misuse of our products, that associates consumption of our products or ingredients or any similar products or ingredients with illness or other adverse effects, questions the benefits of our or similar products or claims that any such products are ineffective, inappropriately labeled or have inaccurate instructions as to their use, could negatively impact our reputation or the market demand for our products.

We are subject to risks relating to product concentration and lack of revenue diversification.
 
Although we have in recent years expanded our line of products, we derive more than 10% of our total revenue from each of our Premium Noni Juice and Enhanced Essential Probiotics® products. Further, we currently source each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, we are unable to adequately source or deliver the products, or we are unable to offer the products for any reason without suitable replacements, our business, financial condition and results of operations could be materially and adversely affected. Our future success will also depend on our ability to reduce our dependence on these few products by developing and introducing new products and product or feature enhancements in a timely manner. Even if we are able to develop and commercially introduce new products and enhancements, they may not achieve market acceptance and the revenue generated from these new products and enhancements may not offset the costs, which could substantially impair our business, financial condition and results of operations.
 
We rely on a limited number of independent third parties to manufacture and supply our products.
 
All of our products are manufactured by a limited number of independent third parties.  There is no assurance that our current manufacturers will continue to reliably supply products to us at the level of quality we require.  If a key manufacturer suffers liquidity problems or experiences operational or other problems assisting with our products, our results could suffer.  In the event any of our third-party manufacturers become unable or unwilling to continue to provide the products in required volumes and quality levels at acceptable prices, we will be required to identify and obtain acceptable replacement manufacturing sources or replacement products.  There is no assurance that we will be able to obtain alternative manufacturing sources or products or be able to do so on a timely basis.  An extended interruption in the supply of certain of our products may result in a substantial loss of revenue.  In addition, any actual or perceived degradation of product quality as a result of our reliance on third party manufacturers may have an adverse effect on revenue or result in increased product returns.  
 
Growth may be impeded by the political and economic risks of entering and operating in foreign markets.
 
Our ability to achieve future growth is dependent, in part, on our ability to continue our international expansion efforts.  However, there can be no assurance that we would be able to grow in our existing international markets, enter new international markets on a timely basis, or that new markets would be profitable.  We must overcome significant regulatory and legal barriers before we can begin marketing in any foreign market.
 
Also, it is difficult to assess the extent to which our products and sales techniques would be accepted or successful in any given country.  In addition to significant regulatory barriers, we may also encounter problems conducting operations in new markets with different cultures and legal systems from those elsewhere.  We may be required to reformulate certain of our products before commencing sales in a given country.  Once we have entered a market, we seek to adhere to the regulatory and legal requirements of that market.  No assurance can be given that we would be able to successfully reformulate our products in any of our current or potential international markets to meet local regulatory requirements or attract local customers.  The failure to do so could have a material adverse effect on our business, financial condition, and results of operations.  There can be no assurance that we would be able to obtain and retain necessary permits and approvals.
 
In many markets, other direct selling companies already have significant market penetration, the effect of which could be to desensitize the local member population to a new opportunity or to make it more difficult for us to recruit qualified members. There can be no assurance that, even if we are able to commence operations in foreign countries, there would be a sufficiently large population of potential members inclined to participate in a direct selling system offered by us.  We believe our future success could depend in part on our ability to seamlessly integrate our business methods, including member compensation plan, across all markets in which our products are sold.  There can be no assurance that we would be able to further develop and maintain a seamless compensation program.
 

20


We are subject to anti-bribery laws, including the U.S. Foreign Corrupt Practices Act.
 
We are subject to anti-bribery laws, including the U.S. Foreign Corrupt Practices Act (“FCPA”), which generally prohibit companies and their intermediaries from making improper payments for the purpose of obtaining or retaining business as well as requiring companies and their intermediaries to maintain accurate books and records. In recent years there has been a substantial increase in anti-bribery law enforcement activity by the Department of Justice ("DOJ") and the SEC relating to business operations within certain countries in which we operate, including China. For example, in 2017, a U.S. based direct selling company announced that it was the target of an investigation being conducted by the SEC to determine whether certain activities related to the direct selling company's operations in China violated the FCPA. Also, in 2017, another U.S. based direct selling company announced that it had initiated a voluntary probe of its operations in China to determine if violations of the FCPA had occurred.

Our policies mandate compliance with anti-bribery laws by our employees and agents, including the requirements to
maintain accurate information and internal controls. However, we may be liable for actions of our employees and agents, even if such actions are inconsistent with our policies. Being subject to an investigation by the DOJ or the SEC for an alleged violation of the FCPA could cause us to incur significant expenses and distractions that could adversely affect our business. Violations of the FCPA, or a similar anti-bribery law, may result in criminal or civil sanctions, including contract cancellations or debarment, and loss of reputation, which could have a material adverse effect on our results of operations and financial condition.

Recently enacted tariffs, other potential changes to tariff and import/export regulations, and ongoing trade disputes between the United States and other jurisdictions, particularly China, may have a negative effect on global economic conditions and our business, financial results and financial condition.
 
The United States recently proposed and enacted tariffs on certain items. Further, there have been ongoing discussions and activities regarding changes to other U.S. trade policies and treaties. In response, a number of our markets, including China, are threatening to impose tariffs on U.S. imports, or have already implemented tariffs on U.S. imports or otherwise imposed non-tariff barriers such as slow-walking custom clearance of American-made products in response to these U.S. actions. These developments may have a material adverse effect on global economic conditions and the stability of global financial markets, and they may significantly reduce global trade and, in particular, trade between China and the United States. Any of these factors could depress economic activity, create anti-American consumer sentiment, restrict our access to suppliers or customers and have a material adverse effect on our business, financial condition and results of operations. In addition, any actions by non-U.S. markets to implement further trade policy changes, including limiting foreign investment or trade, increasing regulatory scrutiny or taking other actions which impact U.S. companies' ability to obtain necessary licenses or approvals could negatively impact our business.

These tariffs and other policy changes have just recently been announced and are subject to a number of uncertainties as they are implemented, including future adjustments and changes in the countries excluded from such tariffs. The ultimate reaction of other countries, and the individuals in each of these countries, and the impact of these tariffs or other actions on the United States, China, the global economy and our business, financial condition and results of operations, cannot be predicted at this time.

We may be held responsible for certain taxes or assessments relating to the activities of our members and service providers, which could harm our financial condition and operating results.
 
Our members and service providers are subject to taxation, and in some instances, legislation or governmental agencies impose an obligation on us to collect the taxes, such as value added taxes, and to maintain appropriate records.  In addition, we are subject to the risk in some jurisdictions of being responsible for social security and similar taxes with respect to our members.
 

21


We may be unable to protect or use our intellectual property rights.
 
We rely on trade secret, copyright and trademark laws and confidentiality agreements with employees and third parties, all of which offer only limited protection of our confidential information and trademarks.  Moreover, the laws of some countries in which we market our products may afford little or no effective protection of our intellectual property rights.  The unauthorized copying, use or other misappropriation of our confidential information, trademarks and other intellectual property could enable third parties to benefit from such property without paying us for it.  This could have a material adverse effect on our business, operating results and financial condition.  If we resort to legal proceedings to enforce our intellectual property rights, the proceedings could be burdensome, expensive and result in inadequate remedies.  It is also possible that our use of our intellectual property rights could be found to infringe on prior rights of others and, in that event, we could be compelled to stop or modify the infringing use, which could be burdensome and expensive.
 
We do not have a comprehensive product liability insurance program and product liability claims could hurt our business.
 
Currently, we do not have a comprehensive product liability insurance program, although the insurance carried by our suppliers may cover certain product liability claims against us.  As a marketer of dietary supplements, cosmetics and other products that are ingested by consumers or applied to their bodies, we may become subjected to various product liability claims, including that:
 
our products contain contaminants or unsafe ingredients;

our products include inadequate instructions as to their uses; or

our products include inadequate warnings concerning side effects and interactions with other substances.
 
If our suppliers’ product liability insurance fails to cover product liability claims or other product liability claims, or any product liability claims exceeds the amount of coverage provided by such policies or if we are unsuccessful in any third party claim against the manufacturer or if we are unsuccessful in collecting any judgment that may be recovered by us against the manufacturer, we could be required to pay substantial monetary damages which could materially harm our business, financial condition and results of operations. As a result, we may become required to pay high premiums and accept high deductibles in order to secure adequate insurance coverage in the future.  Especially since we do not have direct product liability insurance, it is possible that product liability claims and the resulting adverse publicity could negatively affect our business.
 
We identified a material weakness in our internal control over financial reporting. If we do not adequately address this material weakness or if other material weaknesses or significant deficiencies in our internal control over financial reporting are discovered, our financial statements could contain material misstatements and our business, operations and stock price may be adversely affected.

As disclosed under “Item 9A. Controls and Procedures” of this report, our management has identified a material weakness in our internal control over financial reporting at December 31, 2018. Under standards established by the Public Company Accounting Oversight Board, a material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis. Although no material misstatement of our historical financial statements was identified, the existence of this or one or more material weaknesses or significant deficiencies could result in material misstatements in our financial statements and we could be required to restate our financial statements. Further, significant costs and resources may be needed to remediate the identified material weakness or any other material weaknesses or internal control deficiencies. If we are unable to remediate, evaluate, and test our internal controls on a timely basis in the future, management will be unable to conclude that our internal controls are effective and our independent registered public accounting firm will be unable to express an unqualified opinion on the effectiveness of our internal controls. If we cannot produce reliable financial reports, investors may lose confidence in our financial reporting, the price of our common stock could be adversely impacted and we could be subject to sanctions or investigations by the SEC, NASDAQ or other regulatory authorities, which could negatively impact our business, financial condition and results of operations.


22


We rely on and are subject to risks associated with our reliance upon information technology systems.
 
Our success is dependent on the accuracy, reliability, and proper use of information processing systems and management information technology.  Our information technology systems are designed and selected to facilitate order entry and customer billing, maintain member records, accurately track purchases and member compensation payments, manage accounting operations, generate reports, and provide customer service and technical support.  Any interruption in these systems could have a material adverse effect on our business, financial condition, and results of operations.
 
There can be no assurance that there will not be delays or interruptions in our information technology services.  An interruption or delay in availability of these services could, if it lasted long enough, prevent us from accepting orders, cause members to leave our business, or otherwise materially adversely affect our business.
 
System disruptions or failures, cybersecurity risks, and compromises of data could harm our business.

Because of our diverse geographic operations and our internationally applicable member compensation plans, our business is highly dependent on the secure and efficient functioning of our information technology systems, and the security of personal and sensitive business data. We collect certain personal information, including payment data, from members and consumers, as well as our employees. We also develop and maintain sensitive and proprietary business information. Any systems failure or interruption, breach in security, or loss of data, whatever the cause, could adversely affect our operations and financial results.

Systems disruptions and data breaches can derive from natural disasters, accidental technological events or human error, but can also result from fraud or malice on the part of external or internal parties.  Our systems, networks and software, like those of other companies, have been and are likely to continue to be, the target of cybersecurity threats and attacks, which may range from isolated or random attempts to sophisticated and targeted measures directed specifically at us. The risk of a systems disruption or data breach, particularly through cyber-attack or cyber intrusion, has increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. A material systems disruption or data breach affecting us could damage our reputation, deter members from purchasing our products, and result in cost and liability to us.

Although we have implemented technical and administrative safeguards to maintain the security and integrity of our information technology systems and data, there can be no assurance that our security efforts and measures will be effective in a continually evolving threat environment. In addition to the risks presented by malicious actors and natural disasters, many systems disruptions and data breaches are reportedly caused by human error. Therefore, despite our security policies and mandatory training, our systems and data are exposed to the risk that human error could either create a vulnerability that could be exploited by an attacker, or expose our systems and data to unintended risk of compromise. In addition, as described below, most of our information technology systems and data are hosted by third-party vendors over which we have limited control. We anticipate that we will be required to expend additional resources in order to continue to enhance our technical and administrative safeguards, and to investigate and remediate any vulnerabilities in our systems, networks and software.

In any case, a data breach or other significant disruption of our information systems or those related to our third party vendors, including as a result of cyber-attacks, could (1) disrupt the proper functioning of our systems and networks and therefore operations, (2) result in the unauthorized access to, and destruction, loss, theft, misappropriation or release of personal, confidential, sensitive or otherwise valuable data or other information, (3) result in a violation of applicable privacy, cybersecurity, data breach notification requirements under applicable laws, regulations and contractual provisions, subjecting us to additional regulatory scrutiny, and exposing us to possible fines, lawsuits and related financial liability, (4) require significant management attention and financial resources to investigate and remedy the breach or disruption, and (5) harm our reputation, cause a decrease in the number of our members and revenue, and otherwise damage our business.  The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.


23


Our systems, software and data reside on third-party servers, exposing us to risks that disruption or intrusion of those servers could temporarily or permanently interrupt our access and damage our business.

Beginning in 2012, most of our systems, software and data reside in the “cloud” on servers operated by third-party vendors to which we have limited access.  We assess the risks presented by these third-party vendors, and our contracts with them contain representations, warranties and other provisions related to the security of our data, and of the systems and software on which we rely. We are, however, limited in our ability to mitigate the risks of a systems disruption or data breach affecting our third-party vendors.  Moreover, any delay or failure in payment of the third-party vendors, disputes with such vendors, or business interruption or failure of the third-party vendors could result in loss of or interruption in access to our systems, software or data.  It is possible that our systems, software and data could in the future be moved to servers of different third parties or to our own servers.  Any such move could result in temporary or permanent loss of access to our systems, software or data.  Any protracted loss of such access would materially and adversely affect our business, financial condition and results of operations.

Terrorist attacks, acts of war, epidemics or natural disasters may seriously harm our business.

Terrorist attacks, acts of war, epidemics or natural disasters may cause damage or disruption to us, our employees, our facilities and our members and customers, which could impact our revenues, expenses and financial condition.  The potential for future terrorist attacks, the national and international responses to terrorist attacks, and other acts of war or hostility, such as challenges to Chinese sovereignty claims in the South China Sea or Chinese objection to the Taiwan independence movement and the resultant tension in the Taiwan Strait, could materially and adversely affect our business, results of operations, and financial condition in ways that we currently cannot predict.  Additionally, epidemics such as outbreaks of avian influenza, or natural disasters, whether or not as severe as the Indian Ocean tsunami that occurred in December 2004, may adversely affect our business, financial condition and results of operations.

We may experience negative cash flows, which may require that we seek debt or equity financing and could have a significant adverse effect on our business and threaten our solvency.
 
We experienced substantial negative cash flows during the years ended December 31, 2009 and 2008, primarily due to declines in our revenues greater than the decreases in expenditures we could manage. If we again experience negative cash flows, any resulting decreasing cash balance could impair our ability to support our operations and we may be required to seek debt or equity financing. However, we may not be able to obtain additional debt or equity financing on satisfactory terms, or at all, and any new financing could have a dilutive effect to our existing stockholders. Negative cash flows would have a material adverse effect on our business, results of operations and financial condition, as well as our stock price, and could eventually threaten our solvency. Negative cash flows and any related adverse market perception may also negatively affect our ability to attract new members and/or sell our products. There can be no assurance that we will be successful in maintaining an adequate level of cash resources.
 
Disappointing quarterly revenue or operating results could cause the price of our common stock to fall.
     
Our quarterly revenue and operating results are difficult to predict and may fluctuate significantly from quarter to quarter.  If our quarterly revenue or operating results fall below the expectations of investors or securities analysts, the price of our common stock could fall substantially.
 
Our common stock is particularly subject to volatility because of the industry in which we operate.
 
The market prices of securities of direct selling companies have been extremely volatile, and have experienced fluctuations that have often been unrelated or disproportionate to the operating performance of such companies.  These broad market fluctuations could adversely affect the market price of our common stock.
 
Our common stock continues to experience wide fluctuations in trading volumes and prices. This may make it more difficult for holders of our common stock to sell shares when they want and at prices they find attractive.
 
The public market for our common stock has historically been very volatile experiencing wide fluctuations in trading volumes and prices. There are a number of factors that may contribute to this volatility, including the following:

active participation of speculative traders in our stock (including short sellers);

market rumors regarding our business operations;

24



government scrutiny of our business;

adverse publicity related to our business or industry; and

fluctuations in our operating results.

This market volatility for our stock may make it more difficult for holders of our stock to sell shares when they want and at prices they find attractive. There can be no assurance that a larger or more liquid market will be developed or maintained for our common stock.
 
Future sales by us or our existing stockholders could depress the market price of our common stock.
 
If we or our existing stockholders sell a large number of shares of our common stock, the market price of our common stock could decline significantly.  Further, even the perception in the public market that we or our existing stockholders might sell shares of common stock could depress the market price of our common stock.
 
Item 1B. UNRESOLVED STAFF COMMENTS

Not applicable.

Item 2. PROPERTIES
 
In January 2019, we relocated our corporate headquarters from Rolling Hills Estates, California, to Hong Kong. We renewed our lease for 7,300 square feet of office space in Hong Kong in November 2017 with a term expiring in February 2021, and in May 2018 we entered into a lease for 2,300 square feet of additional office space in the same location in Hong Kong with a term expiring in February 2021.

We continue to lease 4,900 square feet of office space in Rolling Hills Estates, California with a term expiring in September 2025. To help further develop the market for our products in North America, we lease 2,400, 1,600 and 2,000 square feet of retail space in Monterey Park, California, Richmond, British Columbia, and Metuchen, New Jersey, respectively. The Monterey Park, Richmond and Metuchen locations have terms expiring in August 2020, February 2021, and November 2022, respectively.

In February 2017, we entered into a lease for 9,000 square feet of office and retail space in Peru with a term expiring in July 2019. We lease nine branch offices throughout China, and additional office space in Japan, Taiwan, South Korea, Singapore, Malaysia, Vietnam, Indonesia, Thailand, and the Cayman Islands. We also lease a multi-purpose facility and factory in Zhongshan, China and 11 service stations throughout the city of Guangzhou, China that serve or will in the future serve the needs of our Chinese consumers. We contract with third parties for fulfillment and distribution operations in all of our international markets. We believe that our existing office space is in good condition, and is suitable and adequate for the conduct of our business.
 

25


Item 3. LEGAL PROCEEDINGS

On January 8, 2019, the Company and its two executive officers were named in a putative securities class action filed in the United States District Court for the Central District of California, captioned Kauffman v. Natural Health Trends Corp., Case No. 2:19-cv-00163.  The complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between April 27, 2016 and January 5, 2019, inclusive, under (i) Section 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”) and Rule 10b-5 promulgated thereunder against the Company and Chris T. Sharng and Timothy S. Davidson (together, the “Individual Defendants”), and (ii) Section 20(a) of the Exchange Act against the Individual Defendants. The complaint alleges, in part, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multilevel marketing business.  The complaint seeks an indeterminate amount of damages, plus interest and costs.  Defendants believe that these claims are without merit and intend to vigorously defend against them.

Item 4. MINE SAFETY DISCLOSURES

Not applicable.

Part II
Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market Information
Our common stock is currently traded on the NASDAQ Capital Market (“Nasdaq”) under the symbol “NHTC.” On April 22, 2019, the closing price of our common stock as reported by Nasdaq was $11.22 per share.

Holders of Record
At April 22, 2019, there were approximately 110 record holders of our common stock (although we believe that the number of beneficial owners of our common stock is substantially greater).

Item 6. SELECTED FINANCIAL DATA

Not applicable under smaller reporting company disclosure rules.


26


Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Business Overview
 
We are an international direct-selling and e-commerce company. Subsidiaries controlled by us sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. Our wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. We also operate in Russia and Kazakhstan through our engagement with a local service provider. See Note 11 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of this report for further information about our net sales by geographic area.
 
As of December 31, 2018, we were conducting business through 97,840 active members, compared to 95,670 in 2017. We consider a member “active” if they have placed at least one product order with us during the preceding year. Our priority is to focus our resources in our most promising markets, which we consider to be Greater China and countries where our existing members have the connections to recruit prospects and sell our products, such as Southeast Asia, India, South America and Europe.
 
We generate approximately 96% of our net sales from subsidiaries located outside the Americas, with sales of our Hong Kong subsidiary representing 88% of net sales in the latest fiscal year. Because of the size of our foreign operations, operating results can be impacted negatively or positively by factors such as foreign currency fluctuations, and economic, political and business conditions around the world. In addition, our business is subject to various laws and regulations, in particular, regulations related to direct selling activities that create uncertain risks for our business, including improper claims or activities by our members and potential inability to obtain necessary product registrations. For further information regarding some of the risks associated with the conduct of our business in China, see “Item 1A. Risk Factors,” and more specifically under the captions “Risk Factors - Because our Hong Kong operations account for a substantial portion of our overall business...” and “Risk Factors - Our operations in China are subject to compliance with a myriad of applicable laws and regulations...”.
 
China has been and continues to be our most important business development project. We operate an e-commerce direct selling model in Hong Kong that generates revenue derived from the sale of products to members in Hong Kong and elsewhere, including China. Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. Through a separate Chinese entity, we operate an e-commerce retail platform in China. We believe that neither of these activities require a direct selling license in China, which we do not currently hold. We have previously sought to obtain a direct selling license, and in August 2015 initiated the process for submitting a new preliminary application for a direct selling license in China. If we are able to obtain a direct selling license in China, we believe that the incentives inherent in the direct selling model in China would incrementally benefit our existing business. We do not expect that any increased sales in China derived from obtaining a direct selling license would initially be material and, in any event may be partially offset by the higher fixed costs associated with the establishment and maintenance of required service centers, branch offices, manufacturing facilities, certification programs and other legal requirements. We are unable to predict whether and when we will be successful in obtaining a direct selling license to operate in China, and if we are successful, when we will be permitted to conduct direct selling operations and whether such operations would be profitable.

To date, the recently enacted tariffs and the trade disputes between the United States and China have not materially impacted our business, although they may have negatively impacted the value of the Chinese yuan, which has in turn negatively affected our Hong Kong revenues because the prices at which our Chinese members can purchase our products have effectively increased. In the event the trade disputes between the United States and China continue or intensify, our business could be negatively impacted in the future. For more information, see “Item 1A. Risk Factors - Recently enacted tariffs, other potential changes to tariff and import/export regulations, and ongoing trade disputes between the United States and other jurisdictions, particularly China, may have a negative effect on global economic conditions and our business, financial results and financial condition.”

On January 8, 2019, the Chinese government announced a comprehensive 100-day campaign focusing on companies involved in the sale of food, equipment, daily necessities, small home electrical appliances and services that are claimed to promote health. The Chinese government ministries in charge of this campaign indicated that they are targeting illegal practices in the industry, particularly the manufacture and sale of counterfeit and substandard products, and false advertising and misleading claims as to the health benefits of products and services. It is understood that the campaign is specifically focused on the business practices of direct selling companies. During the campaign, we understand that the government will not issue any additional direct selling licenses, will cease issuing certifications of quality or other approvals of various

27


healthcare products, and will review its regulatory oversight of the industry. We believe that the campaign will negatively impact our business in China in the short-term, but will benefit us and Chinese consumers in the long-term as purveyors of substandard products are driven from the market. The short-term impact of the campaign may have a significant impact on our business, as we, like some of our peers, voluntarily decided in January 2019 to temporarily suspend our member activities, such as product roadshows, product trainings and larger company-sponsored events, in China. We did this because we have learned that the 100-day campaign was announced in broad outlines by the central government, and the interpretation and enforcement of the campaign was delegated to the provincial and local governments. We consider it a top priority for our business to develop an understanding of and cooperate with all levels and jurisdictions of the government agencies, and did not want to run the risk of being inadvertently entangled in government enforcement actions. Although we understand the 100-day campaign would have expired on or about April 18, 2019, we are not aware of any information indicating that the campaign has been concluded. In any case, these recent events and our currently effective suspension of member activities are negatively impacting our business in Hong Kong and China, and we expect that Hong Kong net sales (substantially all of which were derived from products shipped to members residing in China) for the first half of 2019, and possibly beyond, will be substantially lower than comparable periods in 2018. This anticipated decline in revenue will likely be greater than our ability to correspondingly reduce expenses, which could result in negative cash flows and a decreasing cash balance. See “Item 1A. Risk Factors - Our operations in China are subject to compliance with a myriad of applicable laws and regulations...”.

Income Statement Presentation
 
We mainly derive revenue from sales of products. Substantially all of our product sales are to independent members at published wholesale prices. Product sales are recognized when the products are shipped and title passes to independent members, which generally is upon our delivery to the carrier that completes delivery to the members. We estimate and accrue a reserve for product returns based on our return policies and historical experience. We bill members for shipping charges and recognize the freight revenue in net sales. We have elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrue for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Event and training revenue is deferred and recognized as the event or training occurs.
 
Cost of sales consists primarily of products purchased from third-party manufacturers, freight cost for transporting products to our foreign subsidiaries and shipping products to members, import duties, packing materials, product royalties, costs of promotional materials sold to our members at or near cost, and provisions for slow moving or obsolete inventories. Cost of sales also includes purchasing costs, receiving costs, inspection costs and warehousing costs.
 
Member commissions are our most significant expense and are classified as an operating expense. Under our compensation plan, members are paid weekly commissions by our subsidiary in which they are enrolled, generally in their home country currency, for product purchases by their down-line member network across all geographic markets. Our China subsidiary maintains an e-commerce retail platform and does not pay commissions, although our Chinese members may participate in our compensation plan through our other subsidiaries. This “seamless” compensation plan enables a member located in one country to enroll other members located in other countries where we are authorized to conduct our business. Currently, there are basically two ways in which our members can earn income:

through commissions paid on the accumulated bonus volume from product purchases made by their down-line members and customers; and

through retail profits on sales of products purchased by members at wholesale prices and resold at retail prices (for purchasers in some of our smaller markets and purchasers from our China subsidiary, sales are for personal consumption only and income may not be earned through retail profits).
 
Each of our products is designated a specified number of bonus volume points. Commissions are based on total personal and group bonus volume points per weekly sales period. Bonus volume points are essentially a percentage of a product’s wholesale price. As the member’s business expands from successfully enrolling other members who in turn expand their own businesses by selling product to other members, the member receives higher commissions from purchases made by an expanding down-line network. In some of our markets, to be eligible to receive commissions, a member may be required to make nominal monthly or other periodic purchases of our products. Certain of our subsidiaries do not require these nominal purchases for a member to be eligible to receive commissions. In determining commissions, the number of levels of down-line members included within the member’s commissionable group increases as the number of memberships directly below the member increases.


28


Under our current compensation plan, certain of our commission payouts may be limited to a hard cap dollar amount per week or a specific percentage of total product sales. In some markets, commissions may be further limited. In some markets, we also pay certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Members can also earn additional income, trips and other prizes in specific time-limited promotions and contests we hold from time to time. Member commissions are dependent on the sales mix and, for each of fiscal 2018 and 2017 represented 46% and 42%, respectively, of net sales. Occasionally, we make modifications and enhancements to our compensation plan to help motivate members, which can have an impact on member commissions. We may also enter into performance-based agreements for business or market development, which can result in additional compensation to specific members.
 
Selling, general and administrative expenses consist of administrative compensation and benefits, travel, credit card fees and assessments, professional fees, certain occupancy costs, and other corporate administrative expenses (including stock-based compensation). In addition, this category includes selling, marketing, and promotion expenses (including the costs of member training events and conventions that are designed to increase both product awareness and member recruitment). Because our various member conventions are not always held at the same time each year, interim period comparisons will be impacted accordingly. 

The functional currency of our international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into accumulated other comprehensive income.
 
Sales by our foreign subsidiaries are generally transacted in the respective local currencies and are translated into U.S. dollars using average rates of exchange for each monthly accounting period to which they relate.  Most of our product purchases from third-party manufacturers are transacted in U.S. dollars.  Consequently, our sales and net earnings are affected by changes in currency exchange rates, with sales and earnings generally increasing with a weakening U.S. dollar and decreasing with a strengthening U.S. dollar. 

Results of Operations
 
The following table sets forth our operating results as a percentage of net sales for the periods indicated:
 
Year Ended December 31,
 
2018
 
2017
Net sales
100.0
%
 
100.0
%
Cost of sales
20.5

 
19.6

Gross profit
79.5

 
80.4

Operating expenses:
 
 
 
Commissions expense
45.6

 
42.3

Selling, general and administrative expenses
16.3

 
16.3

Total operating expenses
61.9

 
58.6

Income from operations
17.6

 
21.8

Other income, net
0.4

 
0.2

Income before income taxes
18.0

 
22.0

Income tax provision
1.8

 
10.0

Net income
16.2
%
 
12.0
%
 

29


Net Sales

The following table sets forth revenue by market for the periods indicated (in thousands):
 
Year Ended December 31,
 
2018
 
2017
Americas1
$
6,982

 
3.6
%
 
$
5,794

 
2.9
%
Hong Kong2
169,452

 
88.3

 
174,926

 
88.5

China
7,744

 
4.0

 
7,282

 
3.7

Taiwan
3,964

 
2.1

 
5,591

 
2.8

South Korea
493

 
0.3

 
466

 
0.2

Japan
204

 
0.1

 
129

 
0.1

Singapore
169

 
0.1

 
184

 
0.1

Malaysia
390

 
0.2

 

 

Russia and Kazakhstan
868

 
0.4

 
913

 
0.5

Europe
1,644

 
0.9

 
2,278

 
1.2

Total
$
191,910

 
100.0
%
 
$
197,563

 
100.0
%
_____________________________ 
1 United States, Canada, Mexico and Peru.
2 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.

 
Net sales were $191.9 million for the year ended December 31, 2018 compared with $197.6 million a year ago, a decrease of $5.7 million, or 3%.  Hong Kong net sales, substantially all of which were derived from the sale of products shipped to members residing in China, decreased $5.5 million, or 3%, over the prior year. The sales decrease was primarily attributable to current challenging market conditions of increased global trade tensions, China’s slowing economy and a weaker Chinese currency.
 
Outside of our Hong Kong business, net sales decreased $179,000, or 1%, compared with the prior year, driven by a 29% decrease in our Taiwan business and offset by a 21% increase in Americas.
 
As of December 31, 2018, deferred revenue was $6.8 million, which primarily consisted of $4.6 million in unshipped product orders and $1.9 million pertaining to auto ship advances.
 
Gross Profit
 
Gross profit was 79.5% of net sales for the year ended December 31, 2018 compared with 80.4% of net sales for the year ended December 31, 2017. The gross profit margin percentage decrease was primarily due to lower event revenue and product promotions in our China e-commerce business, our Noni Juice promotions and higher freight costs.
 
Commissions
 
Commissions were 45.6% of net sales for the year ended December 31, 2018 compared with 42.3% of net sales for the year ended December 31, 2017. The increase as a percentage of net sales was primarily due to higher costs for supplemental on-going cash and other incentive programs.
 
Selling, General and Administrative Expenses
 
Selling, general and administrative expenses were $31.3 million for the year ended December 31, 2018 compared with $32.2 million for the year ended December 31, 2017. Selling, general and administrative expenses decreased by $912,000, or 3%, mainly due to decreases in professional fees as compared to the year ended December 31, 2017.
 

30


Income Taxes
 
An income tax provision of $3.5 million was recognized for the year ended December 31, 2018 compared with $19.8 million for the year ended December 31, 2017. The decrease is due primarily to the impact of the one-time transition tax on the December 31, 2017 tax year as a result of the enactment of the Tax Cuts and Jobs Act (the “Tax Act”) on December 22, 2017 by the U.S. government. One major provision of the Tax Act, however, increased our effective tax rate for the year ended December 31, 2018. The Global Intangible Low-Taxed Income (“GILTI”) provision, effective for the year ended December 31, 2018, subjects U.S. taxpayers owning at least 10% of a foreign controlled corporation to current taxation on the earnings and profits of the foreign corporation. We have accounted for GILTI as a current period expense (“period cost method”).

Liquidity and Capital Resources
 
At December 31, 2018, our cash and cash equivalents totaled $132.7 million. Total cash and cash equivalents decreased by $2.6 million at December 31, 2018, as compared to December 31, 2017. We consider all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2018, we had $85.3 million in available-for-sale investments classified as cash equivalents. In addition, cash and cash equivalents included $11.1 million held in banks located in China subject to foreign currency controls.
 
At December 31, 2018, the ratio of current assets to current liabilities was 3.49 to 1.00 and we had $107.1 million of working capital. Working capital as of December 31, 2018 decreased $2.2 million compared to our working capital as of December 31, 2017, due primarily to the decrease in cash and cash equivalents as stated above and an increase in accrued commissions of $1.3 million when comparing the periods.

Cash provided by operations during 2018 was $29.7 million compared to $26.6 million during 2017. The increase in operating cash flows resulted primarily from lower employee-related costs and eWallet balances paid during 2018, partially offset by an increase in inventories and inventory-related deposits as we build up our inventory in Greater China to enhance our ability to navigate the challenging and uncertain international trade environment.

Cash flows used in investing activities totaled $214,000 during 2018 and consisted primarily of buildout costs in our Hong Kong and California offices and capitalizable software development costs. Cash flows used in investing activities totaled $278,000 during the year ended December 31, 2017 and consisted primarily of capitalizable software development costs and buildout costs for our expansion into Peru and Vietnam.

Cash flows used in financing activities during 2018 consisted solely of the following cash dividend payments (in thousands, except per share amounts) to holders of our common stock:
Declaration Date
 
Per Share
 
Amount
 
Record Date
 
Payment Date
October 21, 2018 (special)
 
$
0.18

 
$
2,048

 
November 13, 2018
 
November 23, 2018
October 21, 2018
 
0.16

 
1,820

 
November 13, 2018
 
November 23, 2018
July 18, 2018 (special)
 
0.25

 
2,844

 
August 14, 2018
 
August 24, 2018
July 18, 2018
 
0.15

 
1,707

 
August 14, 2018
 
August 24, 2018
April 17, 2018 (special)
 
1.76

 
20,022

 
May 15, 2018
 
May 25, 2018
April 17, 2018
 
0.14

 
1,592

 
May 15, 2018
 
May 25, 2018
February 6, 2018
 
0.13

 
1,479

 
February 27, 2018
 
March 9, 2018
Total
 
$
2.77

 
$
31,512

 
 
 
 

Subsequent to December 31, 2018, on January 27, 2019, the Board of Directors declared a quarterly cash dividend of $0.16, as well as a special cash dividend of $0.08 on each share of common stock outstanding. The dividends were paid on March 15, 2019 to stockholders of record on March 5, 2019. Declaration and payment of any future dividends on shares of common stock will be at the discretion of our Board of Directors.

Cash flows used in financing activities during 2017 consisted solely of dividend payments totaling $17.2 million.

We believe that our existing internal liquidity, supported by cash on hand and cash flows from operations should be adequate to fund normal business operations and address our financial commitments for the foreseeable future.
 

31


We do not have any significant unused sources of liquid assets. If necessary, we may attempt to generate more funding from the capital markets, but currently do not believe that will be necessary.

Our priority is to focus our resources on investing in our most important markets, which we consider to be Greater China and countries where our existing members may have the connections to recruit prospects and sell our products, such as Southeast Asia, India, South America and Europe. We will continue to invest in our Mainland China entity for such purposes as establishing China-based manufacturing capabilities, increasing public awareness of our brand and our products, sourcing more Chinese-made products, building a chain of service stations, opening additional Healthy Lifestyle Centers or branch offices, adding local staffing and other requirements for a China direct selling license application.

Quarterly Results of Operations (Unaudited)

The following table sets forth unaudited quarterly operating results for each of the last eight fiscal quarters. The information for each of these quarters has been prepared on the same basis as the audited annual financial statements included elsewhere in this annual report and, in the opinion of management, includes all adjustments, which includes only normal recurring adjustments, necessary for the fair statement of the results of operations for these periods. This data should be read in conjunction with our audited consolidated financial statements and related notes included in “Item 8. Financial Statements and Supplementary Data” of this annual report. These quarterly operating results are not necessarily indicative of our operating results for any future period.
 
2018
 
2017
 
4th
Quarter
 
3rd
Quarter
 
2nd
Quarter
 
1st
Quarter
 
4th
Quarter
1
 
3rd
Quarter
 
2nd
Quarter
 
1st
Quarter
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(In Thousands, Except Per Share Data)
Net sales
$
41,590

 
$
47,043

 
$
50,910

 
$
52,367

 
$
46,092

 
$
40,132

 
$
51,465

 
$
59,874

Gross profit
32,769

 
37,117

 
40,511

 
42,146

 
36,668

 
31,949

 
41,672

 
48,629

Income from operations
5,733

 
7,847

 
10,108

 
10,044

 
8,686

 
8,514

 
12,867

 
12,992

Net income (loss)
5,559

 
7,629

 
9,023

 
8,824

 
(4,488
)
 
7,338

 
10,303

 
10,425

Net income (loss) per common share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic
0.49

 
0.67

 
0.80

 
0.78

 
(0.40
)
 
0.65

 
0.92

 
0.93

Diluted
0.49

 
0.67

 
0.80

 
0.78

 
(0.40
)
 
0.65

 
0.91

 
0.93

_____________________________ 
1 Reflects the impact of the Tax Cuts and Jobs Act of 2017 enacted in December 2017.

Contractual Obligations

The following table summarizes our contractual obligations as of December 31, 2018 and the expected effect on our cash flow and liquidity in future periods (in thousands):
 
 
Total
 
2019
 
2020-2021
 
2022-2023
 
Thereafter
Operating leases
 
$
4,455

 
$
1,796

 
$
1,792

 
$
540

 
$
327

Purchase obligations
 
280

 
280

 

 

 

Long-term incentive compensation
 
9,034

 
1,226

 
3,093

 
4,715

 

Tax Cut & Jobs Act repatriation tax liability
 
18,600

 
1,617

 
3,235

 
4,650

 
9,098

Other commitments
 
157

 
70

 
87

 

 

Total
 
$
32,526

 
$
4,989

 
$
8,207

 
$
9,905

 
$
9,425


We have entered into non-cancelable operating lease agreements for locations within the United States and for our international subsidiaries, with expirations through September 2025 totaling $4.5 million.
 
In May 2013, we entered into an exclusive distribution agreement with one of our suppliers to purchase their product through July 2016 which automatically renews annually unless terminated 90 days prior to the termination date. To maintain exclusivity, we are required to purchase a minimum of $40,000 of product per month until the termination date. As of December 31, 2018, we were in compliance with the exclusivity provision.
 

32


In recognition of the achievement of specified performance goals, financial rewards are awarded under our 2014 Long-Term Incentive Plan with cash payments through December 2023. See Note 1 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of this report for additional information.

On December 22, 2017, the U.S. Tax Cuts and Jobs Act (the “Tax Act”) was signed into law. The Tax Act significantly revised the U.S. corporate income tax regime by, among other things, lowering the U.S. corporate tax rate from 35% to 21% effective January 1, 2018, implementing a territorial tax system and imposing a one-time repatriation tax on deemed repatriated earnings of foreign subsidiaries and an annual tax on the earnings and profits of any greater than 10% owned foreign controlled corporations. We are subject to this annual tax, resulting in a federal income tax liability as of December 31, 2018 in the amount of $2.9 million, net of foreign tax credits. In 2017, we were subject to the one-time repatriation tax, resulting in a federal income tax liability of $20.2 million. The Company made an election to spread the payment of the one-time repatriation tax liability over an eight year installment period. Under the election, 8% of the installment payments are due in each of the first five years, 15% in the sixth year, 20% in the seventh year, and the remaining 25% due in the eighth year. As a result of the Tax Act adoption of a territorial tax regime, any foreign source portion of a qualified dividend received by a 10% U.S. corporate shareholder is exempt from U.S. tax, therefore resulting in any future repatriation having a minimal effect on our tax liability.

We have evaluated our tax positions and have determined that there are no uncertain tax positions for the current year or years prior.
 
We have employment agreements with certain members of our management team that can be terminated by either the employee or us upon four weeks’ notice.  The employment agreements entered into with the management team contain provisions that guarantee the payments of specified amounts in the event of a change in control, as defined, or if the employee is terminated without cause, as defined, or terminates employment for good reason, as defined.

Critical Accounting Policies and Estimates 
 
A summary of our significant accounting policies is provided in Note 1 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of this report. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.
 
Critical accounting policies and estimates are defined as both those that are material to the portrayal of our financial condition and results of operations and as those that require management’s most subjective judgments.  Management believes our critical accounting policies and estimates are those related to revenue recognition, as well as those used in the determination of liabilities related to member commissions and income taxes.

Revenue Recognition.  All revenue is recognized when the performance obligations under a contract are satisfied. Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon our delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” We primarily receive payment by credit card at the time members place orders. Our sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. Amounts received for unshipped product are recorded as deferred revenue. Such amounts totaled $4.6 million and $2.4 million at December 31, 2018 and 2017, respectively. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs.
 
Additionally, deferred revenue includes advances for auto ship orders. In certain markets, when a member’s cumulative commission income reaches a certain threshold, a percentage of the member’s weekly commission is held back as an advance and applied to an auto ship order once the accumulated amount of the advances is sufficient to pay for the pre-selected auto ship package of the member.  Such advances were $1.9 million and $1.7 million at December 31, 2018 and 2017, respectively.
 
Commissions. Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of our products are designated a specified number of bonus volume points, which is essentially a

33


percentage of the product’s wholesale price.  We accrue commissions when earned and as the related revenue is recognized and pay commissions on product sales generally two weeks following the end of the weekly sales period.
 
Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  For each individual incentive, we estimate the total number of qualifiers as well as the expected per qualifier cost and accrue all costs associated with incentives throughout the qualification period. We regularly review and update, if necessary, the estimates of both qualifiers and cost as more information is obtained during the qualification period. Any resulting change in total cost is recognized over the remaining qualification period. Long-term promotions and incentives (lasting up to one year) can, in particular, result in uncertain ultimate cost. Accrued commissions, including the estimated cost of our international recognition incentive program and other supplemental programs, totaled $12.5 million and $11.2 million at December 31, 2018 and 2017, respectively.
 
Income Taxes.  Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory rates for the years in which the temporary differences are expected to be recovered or settled. We evaluate the probability of realizing the future benefits of any of our deferred tax assets and record a valuation allowance when we believe a portion or all of our deferred tax assets may not be realized. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Based on the technical merits of our tax position, tax benefits may be recognized if we determine it is more likely than not that our position will be sustained on examination by tax authorities. The complex nature of these estimates requires us to anticipate the likely application of tax law and make judgments on the largest benefit that has a greater than fifty percent likelihood of being realized prior to the completion and filing of tax returns for such periods. As of December 31, 2018, we do not have a valuation allowance against our U.S. deferred tax assets. We maintain a valuation allowance in certain foreign jurisdictions with an overall tax loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

Provision for income taxes depends on the statutory tax rates in each of the jurisdictions in which we operate. As a result of capital return activities, we determined that a portion of our current undistributed foreign earnings are no longer deemed reinvested indefinitely by our non-U.S. subsidiaries. For state income tax purposes, we will continue to periodically reassess the needs of our foreign subsidiaries and update our indefinite reinvestment assertion as necessary. The Tax Act, enacted on December 22, 2017 by the U.S. government, required a one-time repatriation tax on certain un-repatriated earnings of foreign subsidiaries at a rate of 15.5% tax on post-1986 foreign earnings held in cash and an 8% rate on all other post-1986 earnings. Due to the adoption of a territorial tax regime, any foreign source portion of a qualified dividend received by a 10% U.S. corporate shareholder is exempt from U.S. federal tax, therefore resulting in any future repatriation having a minimal effect on our effective tax rate. To the extent that additional foreign earnings are not deemed permanently reinvested, we expect to recognize additional income tax provision at the applicable U.S. state corporate tax rate(s). As of December 31, 2018, we have accrued tax liabilities for earnings that we plan to repatriate out of accumulated earnings in future periods for state tax purposes only. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of December 31, 2018.

We estimate what our effective tax rate will be for the full fiscal year at each interim reporting period and record a quarterly tax provision based on that estimated effective tax rate. Throughout the year that estimated rate may change based on variations in our business, changes in our corporate structure, changes in the geographic mix and amount of income, applicable tax laws and regulations, communications with tax authorities, as well as our estimated and actual level of annual pre-tax income. We adjust our income tax provision in the reporting period in which the change in our estimated rate occurs so that the year-to-date provision is consistent with the anticipated annual tax rate. 

Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable under smaller reporting company disclosure rules.


34


Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

NATURAL HEALTH TRENDS CORP.
 
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
 

35


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  
To the Shareholders and Board of Directors of
Natural Health Trends Corp.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Natural Health Trends Corp. (the “Company”) as of December 31, 2018 and 2017, the related consolidated statements of operations, comprehensive income, stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2018, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2018, in conformity with accounting principles generally accepted in the United States of America.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) ("PCAOB"), the Company's internal control over financial reporting as of December 31, 2018, based on the criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013 and our report dated April 26, 2019, expressed an adverse opinion on the effectiveness of the Company’s internal control over financial reporting because of the existence of a material weakness.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.



/s/ Marcum LLP

Marcum LLP

We have served as the Company’s auditor since 2017.

Los Angeles, CA
April 26, 2019

36


NATURAL HEALTH TRENDS CORP.
 
CONSOLIDATED BALANCE SHEETS
(In Thousands, Except Share Data)
 
December 31,
 
2018
 
2017
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
132,653

 
$
135,311

Inventories
12,165

 
8,398

Other current assets
5,369

 
7,534

Total current assets
150,187

 
151,243

Property and equipment, net
934

 
1,149

Goodwill
1,764

 
1,764

Restricted cash
2,998

 
3,167

Deferred tax asset
1,207

 
1,435

Other assets
831

 
796

Total assets
$
157,921

 
$
159,554

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
1,631

 
$
1,751

Income taxes payable
287

 
309

Accrued commissions
12,502

 
11,170

Other accrued expenses
6,121

 
7,605

Deferred revenue
6,795

 
4,455

Amounts held in eWallets
14,611

 
15,152

Other current liabilities
1,137

 
1,479

Total current liabilities
43,084

 
41,921

Income taxes payable
16,982

 
19,052

Deferred tax liability
186

 
56

Long-term incentive
7,808

 
7,904

Total liabilities
68,060

 
68,933

Commitments and contingencies

 

Stockholders’ equity:
 
 
 
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2018 and 2017

 

Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2018 and 2017
13

 
13

Additional paid-in capital
86,415

 
86,683

Retained earnings
44,431

 
44,908

Accumulated other comprehensive loss
(1,250
)
 
(413
)
Treasury stock, at cost; 1,603,322 and 1,637,524 shares at December 31, 2018 and 2017, respectively
(39,748
)
 
(40,570
)
Total stockholders’ equity
89,861

 
90,621

Total liabilities and stockholders’ equity
$
157,921


$
159,554

 
See accompanying notes to consolidated financial statements.

37


NATURAL HEALTH TRENDS CORP.
 
CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands, Except Per Share Data)
 
Year Ended December 31,
 
2018
 
2017
Net sales
$
191,910

 
$
197,563

Cost of sales
39,367

 
38,645

Gross profit
152,543


158,918

Operating expenses:
 
 
 
Commissions expense
87,502

 
83,638

Selling, general and administrative expenses
31,309

 
32,221

Total operating expenses
118,811

 
115,859

Income from operations
33,732

 
43,059

Other income, net
789

 
367

Income before income taxes
34,521

 
43,426

Income tax provision
3,486

 
19,848

Net income
$
31,035


$
23,578

Net income per common share:
 
 
 
Basic
$
2.75

 
$
2.10

Diluted
$
2.74

 
$
2.09

Weighted-average number of common shares outstanding:
 
 
 
Basic
11,304

 
11,251

Diluted
11,318

 
11,267

Cash dividends declared per common share
$
2.77

 
$
1.52

 
See accompanying notes to consolidated financial statements.


38


NATURAL HEALTH TRENDS CORP.
 
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In Thousands)
 
Year Ended December 31,
 
2018
 
2017
Net income
$
31,035

 
$
23,578

Other comprehensive income (loss), net of tax:
 
 
 
Foreign currency translation adjustments
(831
)
 
677

Release of cumulative translation adjustment

 
(258
)
Net change in foreign currency translation adjustment
(831
)
 
419

Unrealized losses on available-for-sale securities
(6
)
 
(25
)
Comprehensive income
$
30,198

 
$
23,972

 
See accompanying notes to consolidated financial statements.


39


NATURAL HEALTH TRENDS CORP.
 
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In Thousands, Except Share Data)
 
Preferred Stock
 
Common Stock
 
Additional
Paid-In
Capital
 
Retained Earnings
 
Accumulated
Other
Comprehensive
(Loss) Income
 
Treasury Stock
 
 
 
Shares
 
Amount
 
Shares
 
Amount
 
 
 
 
Shares
 
Amount
 
Total
BALANCE, December 31, 2016

 
$

 
12,979,414

 
$
13

 
$
86,574

 
$
38,548

 
$
(807
)
 
(1,692,218
)
 
$
(41,889
)
 
$
82,439

Net income

 

 

 

 

 
23,578

 

 

 

 
23,578

Restricted stock forfeiture

 

 

 

 
(5
)
 

 

 
(1,566
)
 
(33
)
 
(38
)
Common stock issued

 

 

 

 
79

 

 

 
56,260

 
1,352

 
1,431

Dividends declared

 

 

 

 

 
(17,218
)
 

 

 

 
(17,218
)
Elimination of CTA upon dissolution

 

 

 

 

 

 
(258
)
 

 

 
(258
)
Foreign currency translation adjustments

 

 

 

 

 

 
677

 

 

 
677

Unrealized losses on available-for-sale securities

 

 

 

 

 

 
(25
)
 

 

 
(25
)
Stock-based compensation

 

 

 

 
35

 

 

 

 

 
35

BALANCE, December 31, 2017

 

 
12,979,414

 
13

 
86,683

 
44,908

 
(413
)
 
(1,637,524
)
 
(40,570
)
 
90,621

Net income

 

 

 

 

 
31,035

 

 

 

 
31,035

Common stock issued

 

 

 

 
(268
)
 

 

 
34,202

 
822

 
554

Dividends declared

 

 

 

 

 
(31,512
)
 

 

 

 
(31,512
)
Foreign currency translation adjustments

 

 

 

 

 

 
(831
)
 

 

 
(831
)
Unrealized losses on available-for-sale securities

 

 

 

 

 

 
(6
)
 

 

 
(6
)
BALANCE, December 31, 2018

 
$

 
12,979,414

 
$
13

 
$
86,415

 
$
44,431

 
$
(1,250
)
 
(1,603,322
)
 
$
(39,748
)
 
$
89,861

 
See accompanying notes to consolidated financial statements. 

40


NATURAL HEALTH TRENDS CORP.
 
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands)
 
Year Ended December 31,
 
2018
 
2017
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
Net income
$
31,035

 
$
23,578

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation and amortization
424

 
536

Stock-based compensation

 
35

Cumulative translation adjustment realized in net income

 
(258
)
Deferred income taxes
358

 
(1,644
)
Changes in assets and liabilities:
 
 
 
Inventories
(3,879
)
 
2,843

Other current assets
2,065

 
(3,399
)
Other assets
(55
)
 
(61
)
Accounts payable
(116
)
 
(392
)
Income taxes payable
(2,077
)
 
18,676

Accrued commissions
1,410

 
(2,417
)
Other accrued expenses
(883
)
 
(6,033
)
Deferred revenue
2,359

 
(481
)
Amounts held in eWallets
(509
)
 
(3,875
)
Other current liabilities
(326
)
 
(179
)
Long-term incentive
(96
)
 
(324
)
Net cash provided by operating activities
29,710

 
26,605

CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
Purchases of property and equipment
(214
)
 
(278
)
Net cash used in investing activities
(214
)
 
(278
)
CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
Dividends paid
(31,512
)
 
(17,218
)
Net cash used in financing activities
(31,512
)
 
(17,218
)
Effect of exchange rates on cash, cash equivalents and restricted cash
(811
)
 
485

Net (decrease) increase in cash, cash equivalents and restricted cash
(2,827
)

9,594

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period
138,478

 
128,884

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period
$
135,651

 
$
138,478

 
 
 
 
SUPPLEMENTAL CASH FLOW DISCLOSURE:
 
 
 
Cash paid for income taxes, net
$
3,130

 
$
6,772

Issuance of treasury stock for employee awards, net
$
554

 
$
1,393


See accompanying notes to consolidated financial statements.

41


NATURAL HEALTH TRENDS CORP.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
1.     NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Nature of Operations
 
Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.
 
The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.

In January 2019, the Company relocated its corporate headquarters from Rolling Hills Estates, California to Hong Kong.

Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.
 
Reclassification

Certain prior year balances in the statement of operations have been reclassified to conform to current year presentation. Additionally, in accordance with the adoption of Accounting Standards Update (“ASU”) No. 2016-18, Statement of Cash Flows - Restricted Cash, the Company has included amounts classified as restricted cash or restricted cash equivalents with cash and cash equivalents when reconciling beginning-of-period and end-of-period total cash, cash equivalents and restricted cash amounts, as presented in its consolidated statements of cash flows.

Use of Estimates
 
The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.

The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.


42


Cash and Cash Equivalents
 
Cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes, bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at December 31, 2018 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive loss in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.

The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within two to five days.

The Company maintains certain cash balances at several institutions located in the United States, Hong Kong and Malaysia which at times may exceed insured limits.  The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.

Restricted Cash
 
In June 2015, the Company funded a bank deposit account in the amount of CNY 20 million ($2.9 million and $3.1 million at December 31, 2018 and 2017, respectively) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund.

The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely.
 
Inventories
 
Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.
 
Property and Equipment
 
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years for office equipment, office software and capitalized internal-use software development costs and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are included in the statement of operations as selling, general and administrative expenses. Such expense totaled $424,000 and $536,000 during 2018 and 2017, respectively.
 
The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value.
 

43


Goodwill
 
The Company assesses qualitative factors in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, through this qualitative assessment, the conclusion is made that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, a two-step impairment test is performed. The Company’s policy is to test for impairment annually during the fourth quarter. Considerable management judgment is necessary to measure fair value. The Company did not recognize any impairment charges for goodwill during the periods presented.
 
Income Taxes
 
The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than not recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are no uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided for state income tax purposes on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.

Amounts Held in eWallets
 
The Company requires commission payments of certain members in Hong Kong to be first recorded into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability.

Long-Term Incentive
 
Financial rewards earned under the 2014 Long-Term Incentive Plan (the “LTI Plan”) are recognized over the performance period as specified performance or other goals are achieved or exceeded. In accordance with the LTI Plan, fifty percent of any cash payment earned is payable in thirty-five equal consecutive monthly installments commencing in February of the calendar year immediately following the conclusion of the performance period and the remaining fifty percent of the payment earned is payable in thirty-five equal consecutive monthly installments commencing in February 2021 and ending in December 2023. As of December 31, 2018, unpaid installments for long-term incentive compensation total $9.0 million, of which $7.8 million is reflected on the balance sheet as a non-current liability and $1.2 million is reflected in other accrued expenses.

At the sole discretion of the Compensation Committee of the Company’s Board of Directors, distributions under the LTI Plan are made in cash, or alternatively awarded in the form of common stock or other common stock rights having an equivalent cash value under the terms of the Natural Health Trends Corp. 2016 Equity Incentive Plan. A determination of the form of distribution, if any, is made by the Compensation Committee subsequent to the end of each calendar year. As such, amounts earned are considered non-equity awards. See Note 7 for grant information of distributions settled in common stock.
 
Foreign Currency
 
The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into accumulated other comprehensive income.
 
Aggregate transaction gains or losses, including gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of certain inter-company balances, are included in the statement of operations as other income and expense. Loss on foreign exchange totaling $739,000 and $451,000 was recognized during 2018 and 2017, respectively.
 

44


Commissions
 
Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and as the related revenue is recognized and pays commissions on product sales generally two weeks following the end of the weekly sales period.
 
In some markets, the Company also pays certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.
 
From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. The Company also enters into performance-based agreements for business or market development, which may result in additional compensation to specific members.

Operating Leases

The Company leases its physical properties under operating leases. Certain lease agreements include rent holidays and incentives. The Company recognizes rent holiday periods on a straight-line basis over the lease term beginning when the Company has the right to the leased space.

Stock-Based Compensation
 
Stock-based compensation expense is determined based on the grant date fair value of each award, net of estimated forfeitures which are derived from historical experience, and is recognized on a straight-line basis over the requisite service period for the award.
 
Net Income Per Common Share
 
Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.

Certain Risks and Concentrations
 
A substantial portion of the Company’s sales are generated in Hong Kong (see Note 11). Substantially all of the Company’s Hong Kong revenues are derived from the sale of products that are delivered to members in China. In contrast to the Company’s operations in other parts of the world, the Company’s China subsidiary has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license, which the Company has applied for, and has also adopted anti-pyramid selling and multilevel marketing legislation. The Company operates an e-commerce direct selling model in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail model. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate separately or in both.

The Company continually evaluates its operations in China and Hong Kong for compliance with applicable laws and regulations, including seeking the input of outside professionals and certain Chinese authorities. This process can and has resulted in the identification of certain matters of potential noncompliance. The Company works on a continuing basis to satisfactorily address such matters, however there can be no assurance that adequate steps are taken or that applicable laws and regulations are properly interpreted. Should the government authorities determine that the Company’s activities violate applicable laws and regulations, including China’s direct selling, pyramid selling or multilevel marketing laws and regulations, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.
 

45


Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling, pyramid selling or multi-level marketing legislation, and subjective interpretations of laws and regulations. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.

No single market other than Hong Kong had net sales greater than 10% of total sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of its net sales. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.

The Company’s Premium Noni Juice and Enhanced Essential Probiotics® products each account for more than 10% of the Company’s total revenue. The Company currently sources each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected.

Fair Value of Financial Instruments
 
The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.
 
Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

Recently Issued and Adopted Accounting Pronouncements

In November 2016, the FASB issued ASU No. 2016-18 that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard was effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted the new standard effective January 1, 2018 using the retrospective transition method. Its adoption did not have a material impact on the Company’s consolidated financial statements.

In February 2016, the FASB established Topic 842, Leases, by issuing ASU No. 2016-02, which requires lessees to recognize the rights and obligations created by leases on the balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-11, Targeted Improvements, ASU No. 2018-10, Codification Improvements to Topic 842, and ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842. The new standard establishes a right-of-use model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations.

The new standard will be effective January 1, 2019. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. If an entity chooses the second option, the transition requirements for existing leases also apply to leases entered into between the date of initial application and the effective date. The entity must also recast its comparative period financial statements and provide the disclosures required by the new standard for the comparative periods. The Company expects to adopt the new standard on January 1, 2019 using the effective date as our date of initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019.


46


The new standard provides a number of optional practical expedients in transition. The Company expects to elect the “package of practical expedients”, which permits entities not to reassess under the new lease standard prior conclusions about lease identification, lease classification and initial direct costs. The Company does not expect to elect the use-of-hindsight or the practical expedient pertaining to land easements.

While the Company continues to assess all of the effects of adoption, it currently believes that most significant effects relate to the recognition of new ROU assets and lease liabilities on our balance sheet for office operating leases and providing significant new disclosures about our leasing activities. On adoption, the Company expects to recognize an operating lease liability of $4.6 million, with corresponding ROU assets of the same amount based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases.

The new standard also provides practical expedients for an entity’s ongoing accounting. The Company currently expects to elect the short-term leases recognition exemption for all leases that qualify. This means that the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets and lease liabilities for existing short-term leases of those assets in transition. The Company also currently expects to elect the practical expedient to not separate lease and nonlease components for its leases.

In May 2014, the FASB issued ASU No. 2014-09, Revenue From Contracts With Customers, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. In July 2015, the FASB approved the deferral of the effective date for annual reporting periods beginning after December 15, 2017, including interim reporting periods. The Company adopted the new standard effective January 1, 2018 using the modified retrospective transition method. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. See Note 2 for additional information.

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.
 
2. REVENUE

Revenue Recognition

All revenue is recognized when the performance obligations under a contract are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.
 
Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 5% of sales. Sales returns were 2% of sales for both the years ended December 31, 2018 and 2017, respectively.  No material changes in estimates have been recognized during the periods presented. See Note 4 for additional information.
 
The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.
 
Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.

47


 
Deferred Revenue

The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are considered a contract liability and are recorded as deferred revenue. The increase in deferred revenue for the year ended December 31, 2018 is primarily due to $4.5 million of cash payments received for unshipped product primarily towards the end of the year offset by $2.4 million of revenue recognized during the year that was included in deferred revenue as of December 31, 2017. See Note 4 for additional information.

Disaggregation of Revenue

The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to some consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through the engagement of a third-party service provider. See Note 11 for additional information.

Arrangements with Multiple Performance Obligations

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.

Practical Expedients

The Company generally expenses sales commissions when incurred because the amortization period would be one year or less. These costs are recorded in commissions expense.

The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less.

3.     NET INCOME PER COMMON SHARE

The following table illustrates the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):
 
Year Ended December 31,
 
2018
 
2017
 
Income
 
Shares
 
Per Share
 
Income
 
Shares
 
Per Share
Basic net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
31,035

 
11,304

 
$
2.75

 
$
23,578

 
11,251

 
$
2.10

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 
14

 
 

 

 
16

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
31,035

 
11,318

 
$
2.74

 
$
23,578

 
11,267

 
$
2.09



Certain non-vested restricted stock is anti-dilutive upon applying the treasury stock method since the amount of compensation cost for future service results in the hypothetical repurchase of shares exceeding the actual number of shares to be vested. Non-vested restricted stock totaling 2,232 shares were not included for the year ended December 31, 2017 as their effect would have been anti-dilutive.


48


4.     BALANCE SHEET COMPONENTS

The components of certain balance sheet amounts are as follows (in thousands):
 
December 31,
 
2018
 
2017
Cash and cash equivalents:
 
 
 
Cash
$
47,323

 
$
61,703

Cash equivalents
85,330

 
73,608

 
132,653

 
135,311

Restricted cash
2,998

 
3,167

 
$
135,651

 
$
138,478

 
 
 
 
Inventories:
 
 
 
Finished goods
$
11,171

 
$
7,779

Raw materials
1,145

 
799

Reserve for obsolescence
(151
)
 
(180
)
 
$
12,165

 
$
8,398

Property and equipment:
 
 
 
Office equipment
$
537

 
$
530

Office software
918

 
916

Machinery
29

 
30

Furniture and fixtures
319

 
276

Leasehold improvements
1,022

 
957

Construction in progress (including internal-use software development costs)
19

 
10

Property and equipment, at cost
2,844

 
2,719

Accumulated depreciation and amortization
(1,910
)
 
(1,570
)
 
$
934

 
$
1,149

Other accrued expenses:
 
 
 
Sales returns
$
801

 
$
614

Employee-related expense
4,051

 
5,568

Warehousing, inventory-related and other
1,269

 
1,423

 
$
6,121

 
$
7,605

Deferred revenue:
 

 
 

Unshipped product
$
4,574

 
$
2,411

Auto ship advances
1,876

 
1,665

Other
345

 
379

 
$
6,795

 
$
4,455


As of December 31, 2018, cash and cash equivalents include $11.1 million held in banks located within China subject to foreign currency controls.


49


5.     FAIR VALUE MEASUREMENTS

Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):
 
December 31, 2018
 
December 31, 2017
 
Adjusted Cost
 
Gross Unrealized Gains/Losses
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Gains/Losses
 
Fair Value
Municipal bonds and notes
$
12,149

 
$
(7
)
 
$
12,142

 
$
13,320

 
$
(1
)
 
$
13,319

Corporate debt securities
51,862

 
(26
)
 
51,836

 
49,432

 
(24
)
 
49,408

Financial institution instruments
21,352

 

 
21,352

 
10,881

 

 
10,881

Total available-for-sale investments
$
85,363

 
$
(33
)
 
$
85,330

 
$
73,633

 
$
(25
)
 
$
73,608


 
Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits.

FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs that are not corroborated by market data.

The tables below present the Company’s hierarchy for assets measured at fair value on a recurring basis as of December 31, 2018 and 2017.

 
December 31, 2018
 
Level 1
 
Level 2
 
Level 3
 
Total
Amounts included in cash and cash equivalents
$
85,330

 
$

 
$

 
$
85,330

Total assets measured at fair value on a recurring basis
$
85,330

 
$

 
$

 
$
85,330


 
December 31, 2017
 
Level 1
 
Level 2
 
Level 3
 
Total
Amounts included in cash and cash equivalents
$
73,608

 
$

 
$

 
$
73,608

Total assets measured at fair value on a recurring basis
$
73,608

 
$

 
$

 
$
73,608



6.     COMMITMENTS AND CONTINGENCIES
 
Operating Leases
 
The Company has entered into non-cancelable operating lease agreements for locations within the United States and for its international subsidiaries, with expirations through September 2025. Rent expense in connection with operating leases was $2.2 million and $2.0 million during 2018 and 2017, respectively.
 

50


Future minimum lease obligations as of December 31, 2018 are as follows (in thousands):
2019
$
1,796

2020
1,340

2021
452

2022
332

2023
208

Thereafter
327

Total minimum lease obligations
$
4,455



Purchase Commitment

In May 2013, the Company entered into an exclusive distribution agreement with one of its suppliers to purchase its product through July 2016 which automatically renews annually unless terminated 90 days prior to the termination date. To maintain exclusivity, the Company is required to purchase a minimum of $40,000 of product per month until the termination date. As of December 31, 2018, the Company was in compliance with the exclusivity provision.
 
Employment Agreements
 
The Company has employment agreements with certain members of its management team that can be terminated by either the employee or the Company upon four weeks’ notice.  The employment agreements entered into with the management team contain provisions that guarantee the payments of specified amounts in the event of a change in control, as defined, or if the employee is terminated without cause, as defined, or terminates employment for good reason, as defined.

Securities Class Actions

On January 8, 2019, the Company and its two executive officers were named in a putative securities class action filed in the United States District Court for the Central District of California, captioned Kauffman v. Natural Health Trends Corp., Case No. 2:19-cv-00163.  The complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between April 27, 2016 and January 5, 2019, inclusive, under (i) Section 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”) and Rule 10b-5 promulgated thereunder against the Company and Chris T. Sharng and Timothy S. Davidson (together, the “Individual Defendants”), and (ii) Section 20(a) of the Exchange Act against the Individual Defendants. The complaint alleges, in part, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multilevel marketing business.  The complaint seeks an indeterminate amount of damages, plus interest and costs.  Defendants believe that these claims are without merit and intend to vigorously defend against them.

In January 2016, two putative securities class action complaints were filed against the Company and its top executives in the United States District Court for the Central District of California. On March 29, 2016, the court consolidated these actions under the caption Ford v. Natural Health Trends Corp., Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class. On April 2, 2018, the court approved a class-wide settlement of the action in the amount of $1.75 million, which was fully funded by the Company’s insurers. On April 6, 2018, the court entered a Final Judgment and Order of Dismissal With Prejudice.

Shareholder Derivative Claims

In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: Zhou v. Sharng. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: Kleinfeldt v. Sharng. On November 10, 2017, the parties to both the Zhou and Kleinfeldt actions entered into a Memorandum of Understanding (“MOU”) to resolve both actions, subject to the negotiation of a written settlement agreement and approval by the federal court in the Kleinfeldt matter.  On July 16, 2018, the court granted final approval of the settlement and entered judgment in the Kleinfeldt matter.  In exchange for full releases, the settlement required the Company to implement certain corporate governance reforms and included an award of $250,000 in attorneys’ fees to plaintiffs’ counsel, all of which was fully funded by the Company’s insurers. On August 9, 2018, plaintiff filed a request to voluntarily dismiss the Zhou action, which was entered by the court on August 30, 2018.

51



Other Matters

The Company is currently involved in a legal matter with one of its vendors and an outside party. Per the royalty agreement with the vendor, the Company believes that it is fully indemnified in the event of an unfavorable outcome and any potential settlement costs related to the matter would be fully covered by the Company’s vendor.

Since August 2016, the SEC has been conducting a non-public investigation to determine whether there have been violations of the federal securities laws relating to the trading of the Company’s securities. The Company has fully cooperated with the SEC and has and continues to provide documents in response to subpoenas. The SEC has expressly stated that its document requests should not be construed as an indication that any violation of law has occurred, or as a reflection upon any person, entity, or security. The amount of time needed to resolve this matter is uncertain, and the Company cannot predict the outcome or whether it will face additional governmental inquiries or other actions.

7.     STOCKHOLDERS’ EQUITY
 
Authorized Shares
 
The Company is authorized to issue two classes of capital stock consisting of up to 5,000,000 shares of preferred stock, $0.001 par value, and 50,000,000 shares of common stock, $0.001 par value.
 
Dividends
 
The following tables summarize the Company’s cash dividend activity during 2018 and 2017 (in thousands, except per share data):
Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 21, 2018 (special)
 
$
0.18

 
$
2,048

 
November 23, 2018
October 21, 2018
 
0.16

 
1,820

 
November 23, 2018
July 18, 2018 (special)
 
0.25

 
2,844

 
August 24, 2018
July 18, 2018
 
0.15

 
1,707

 
August 24, 2018
April 17, 2018 (special)
 
1.76

 
20,022

 
May 25, 2018
April 17, 2018
 
0.14

 
1,592

 
May 25, 2018
February 6, 2018
 
0.13

 
1,479

 
March 9, 2018
 
 
$
2.77

 
$
31,512

 
 
Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 30, 2017 (special)
 
$
0.15

 
$
1,701

 
November 24, 2017
October 30, 2017
 
0.12

 
1,360

 
November 24, 2017
July 31, 2017 (special)
 
0.25

 
2,833

 
August 31, 2017
July 31, 2017
 
0.11

 
1,246

 
August 31, 2017
April 24, 2017 (special)
 
0.35

 
3,964

 
May 19, 2017
April 24, 2017
 
0.10

 
1,133

 
May 19, 2017
January 24, 2017 (special)
 
0.35

 
3,962

 
March 3, 2017
January 24, 2017
 
0.09

 
1,019

 
March 3, 2017
 
 
$
1.52

 
$
17,218

 
 


Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.


52


Stock Repurchases

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. No shares of the Company’s common stock were repurchased by the Company during 2018 or 2017. As of December 31, 2018, $32.0 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

Restricted Stock

No stock-based compensation was recognized during 2018. Stock-based compensation expense totaled approximately $35,000 during 2017.

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. As of December 31, 2018, 2,359,671 shares remained available for issuance under the 2016 Plan.

On February 1, 2018, the Company granted 34,202 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2017 performance incentives totaling $554,000. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances.

On January 24, 2017, the Company granted 56,260 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2016 performance incentives totaling $1.4 million. The shares vest on a quarterly basis over three years and are subject to forfeiture in the event of the employee’s termination of service to the Company under specified circumstances.

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2016
38,256

 
$
34.13

Granted
56,260

 
25.44

Vested
(35,336
)
 
29.58

Forfeited
(1,148
)
 
28.55

Nonvested at December 31, 2017
58,032

 
28.59

Granted
34,202

 
16.19

Vested
(46,748
)
 
26.31

Nonvested at December 31, 2018
45,486

 
21.61




53


The following table summarizes the Company’s other restricted stock activity:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2016
22,348

 
$
12.15

Vested
(21,930
)
 
12.15

Forfeited
(418
)
 
12.28

Nonvested at December 31, 2017

 



Accumulated Other Comprehensive Loss

The changes in accumulated other comprehensive loss by component for 2018 were as follows (in thousands):
 
Foreign Currency Translation Adjustment
 
Unrealized Losses on Available-For-Sale Investments
 
Total
Balance, December 31, 2017
$
(386
)
 
$
(27
)
 
$
(413
)
Other comprehensive loss
(831
)
 
(6
)
 
(837
)
Balance, December 31, 2018
$
(1,217
)
 
$
(33
)
 
$
(1,250
)


8.     INCOME TAXES
 
The components of income before income taxes consist of the following (in thousands):
 
Year Ended December 31,
 
2018
 
2017
Domestic
$
(3,391
)
 
$
(2,965
)
Foreign
37,912

 
46,391

Income before income taxes
$
34,521

 
$
43,426


 
The components of the income tax provision consist of the following (in thousands):
 
Year Ended December 31,
 
2018
 
2017
Current:
 
 
 
Federal
$
1,815

 
$
20,277

State
13

 
2

Foreign
1,300

 
1,216

Total current taxes
3,128

 
21,495

Deferred taxes
358

 
(1,647
)
Income tax provision
$
3,486

 
$
19,848




54


A reconciliation of the reported income tax provision to the provision that would result from applying the domestic federal statutory tax rate to pretax income is as follows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
Income tax at federal statutory rate
$
7,249

 
$
15,200

Effect of permanent differences
346

 
459

Tax Cut & Jobs Act one-time transition tax
(738
)
 
20,792

Global Intangible Low Taxed Income
3,964

 

Tax Cut & Jobs Act federal rate change
(6
)
 
954

Change in valuation allowance
(9
)
 
(43
)
Foreign rate differential
(6,541
)
 
(15,002
)
Foreign tax credits
(786
)
 
(2,738
)
Other reconciling items
7

 
226

Income tax provision
$
3,486

 
$
19,848


 
Income before income taxes and the statutory tax rate for each country that materially contributed to the foreign rate differential presented above is as follows (in thousands):
 
 
 
Year Ended December 31,
 
Statutory Tax Rate
 
2018
 
2017
Cayman Islands
%
 
$
31,560

 
$
39,954

Hong Kong
16.5
%
 
3,545

 
3,315

China
25.0
%
 
2,725

 
2,584


Deferred income taxes consist of the following (in thousands):
 
December 31,
 
2018
 
2017
Deferred tax assets:
 
 
 
Net operating losses
$
183

 
$
192

Stock-based compensation
191

 
270

Accrued expenses
1,062

 
1,374

Other
11

 
6

Total deferred tax assets
1,447

 
1,842

Valuation allowance
(183
)
 
(192
)
Net deferred tax assets
1,264

 
1,650

Deferred tax liabilities:
 
 
 
Foreign earnings
(2
)
 
(4
)
Other
(241
)
 
(267
)
Total deferred tax liabilities
(243
)
 
(271
)
Net deferred tax assets
$
1,021

 
$
1,379


The effective income tax rate for the year ended December 31, 2018 was impacted by recording the effect of the Tax Cuts and Jobs Act (the “Tax Act”), enacted on December 22, 2017 by the U.S. government. The Tax Act makes broad and complex changes to the Internal Revenue Code of 1986, as amended, which has affected the Company’s year ended December 31, 2018, including, but not limited to, requiring an annual tax on the earnings and profits of any greater than 10% owned foreign controlled corporation.

On December 22, 2017, the Securities and Exchange Commission staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provided a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740,

55


Income Taxes. In accordance with the expiration of the SAB 118 measurement period, we completed the assessment of the income tax effect of the Tax Act by the fourth quarter of tax year 2018. All adjustments recorded to the provisional amounts have been included as an adjustment to income tax expense.

As a result of the Tax Act, the Company recorded additional income tax expense due to the Global Intangible Low Taxed Income inclusion on current earnings and profits of greater than 10% owned foreign controlled corporations (“GILTI”). To determine the amount of GILTI inclusion, the Company must determine, in addition to other factors, the current earnings of foreign controlled corporations, as well as the amount of foreign taxes paid by the foreign entities. The law provides that corporate taxpayers may benefit from a 50% reduction in the GILTI inclusion, which effectively reduces the 21% U.S. corporate tax rate on the foreign income to an effective rate of 10.5%. The GILTI inclusion further provides for a foreign tax credit in connection with the foreign taxes paid. The Company recorded a tax expense for GILTI of $2.9 million, net of $1.0 million foreign tax credits.

As of December 31, 2018, the Company does not have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets.

As of December 31, 2018, the Company has a valuation allowance against certain foreign deferred tax assets. The Company is recording a valuation allowance in foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

As of December 31, 2018, the Company has no U.S. federal net operating loss or credit carryforwards as any attributes generated are expected to be fully utilized to offset tax in the current year. At December 31, 2018, the Company has foreign net operating loss carryforwards of approximately $1.2 million in various jurisdictions with various expirations.

As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings is no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate. As of December 31, 2018, the Company has recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods. Due to the Tax Act, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to no impact on federal tax expense. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of December 31, 2018.

The Company and its subsidiaries file tax returns in the United States, California, New Jersey and Texas and various foreign jurisdictions. During the fourth quarter of 2018, the Company was notified that it was selected for audit of the 2016 tax year by the U.S. Internal Revenue Service. For purposes of this audit, fiscal years 2007 through 2016 are open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. No adjustments have been proposed at this time. The Company is no longer subject to state income tax examinations for years prior to 2014. The Taiwan Taxation Administration closed the audit for the 2016 tax year with immaterial tax adjustments that have been recorded in the foreign income tax provision. No other jurisdictions are currently examining any income tax returns of the Company.

9.     RELATED PARTY TRANSACTIONS
 
The Company is a party to a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called ReStor™. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. Under this agreement, the Company agreed to pay BHS a price per unit royalty in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States.  The Company recognized royalties of $327,000 and $306,000 during 2018 and 2017, respectively.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice or, under certain circumstances, with no notice. Otherwise, the agreement terminates March 31, 2020.

During each of 2018 and 2017, the Company procured in China and arranged for shipment to The Aberdeen Group, LLC (“Aberdeen”), one order of apparel products.  Aberdeen is owned 40% by Sharng Holdings, which is wholly-owned by the Company’s president, Chris T. Sharng, and his wife, 40% by Mr. Broady, and 20% by an unrelated third party.  In each instance

56


Aberdeen promptly paid the Company for the product and shipping cost incurred. Such orders were in the amount of $3,700 and $3,800 during 2018 and 2017, respectively.  Given the Company’s provision of such product sourcing services to Aberdeen, Aberdeen also paid the Company a market-based fee consistent with the provision of such services of $450. The Company analyzed the nature of the transactions with Aberdeen to determine whether they could be construed a violation under the guidelines of Section 402 of the Sarbanes-Oxley Act of 2002. The Company, through advice from its legal counsel, concluded that there is not a reasonable possibility that the transactions with Aberdeen would be deemed a violation of Section 402. This relationship between the Company and Aberdeen ceased in early 2019.

10.     EMPLOYEE BENEFIT PLANS
 
     The Company has a 401(k) defined contribution plan which permits participating employees in the United States to defer up to a maximum of 90% of their compensation, subject to limitations established by the Internal Revenue Service. Employees age 21 and older are eligible to contribute to the plan starting the first day of the following month of employment.  Participating employees are eligible to receive discretionary matching contributions and profit sharing, subject to certain conditions, from the Company.  In 2018 and 2017, the Company matched employee deferral contributions up to 4.5% of salary, which vested 100% immediately. No profit sharing has been paid under the plan. The Company recorded compensation expense of $87,000 and $101,000 for 2018 and 2017, respectively, related to its matching contributions to the plan. Certain of the Company’s employees located outside the United States participate in employee benefit plans that are statutory in nature.

11.    SEGMENT INFORMATION
 
The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to some consumers through an e-commerce platform, and the Russia and Kazakhstan market where the Company’s engagement of a third-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment.

There is no separate segment manager who is held accountable by the Company’s chief operating decision-makers, or anyone else, for operations, operating results and planning for the China market or the Russia and Kazakhstan market on a stand-alone basis, and neither market is material for the periods presented. As such, the Company believes that all operating segments should be aggregated into a single reportable segment for disclosure purposes.
 
The Company’s net sales by geographic area are as follows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
Net sales from external customers:
 
 
 
United States
$
3,637

 
$
3,348

Canada
1,710

 
1,938

Peru
1,635

 
508

Hong Kong1
169,452

 
174,926

China
7,744

 
7,282

Taiwan
3,964

 
5,591

South Korea
493

 
466

Russia and Kazakhstan
868

 
913

Europe
1,644

 
2,278

Other foreign countries
763

 
313

Total net sales
$
191,910

 
$
197,563


_____________________________ 
1 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.
 

57


The Company’s net sales by product and service are as follows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
Net sales by product and service:
 
 
 
Product sales
$
181,865

 
$
187,591

Freight and other
13,329

 
13,676

Less: sales returns
(3,284
)
 
(3,704
)
Total net sales
$
191,910

 
$
197,563


 
Due to system constraints, it is impracticable for the Company to separately disclose sales by product category for the years presented.

The Company’s long-lived assets by geographic area are as follows (in thousands):
 
December 31,
 
2018
 
2017
Long-lived assets:
 
 
 
United States
$
521

 
$
648

Hong Kong
145

 
78

China
61

 
112

Other foreign countries
207

 
311

Total long-lived assets
$
934

 
$
1,149


 
12.     SUBSEQUENT EVENTS

On January 27, 2019, the Board of Directors declared a quarterly cash dividend of $0.16, as well as a special cash dividend of $0.08 on each share of common stock outstanding. The dividends were paid on March 15, 2019 to stockholders of record on March 5, 2019. Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

On February 1, 2019, the Company granted 22,603 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2018 performance incentives totaling $377,000. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances.


58


Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

Not applicable.
 
Item 9A. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures
 
Management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of December 31, 2018. Our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation and as disclosed in “Management’s Annual Report on Internal Control over Financial Reporting” below, the principal executive officer and principal financial officer concluded that due to a material weakness in internal control over financial reporting, our disclosure controls and procedures were not effective as of December 31, 2018.

The material weakness identified is related to the ineffective design of controls over the completeness and accuracy of information used to recognize revenues, which could affect the appropriate cut-off surrounding revenue and deferred revenues. No material financial statement misstatement was identified in relation to this material weakness in our internal control over financial reporting. Management, including our principal executive officer and principal financial officer, believes the consolidated financial statements included in this Annual Report on Form 10-K, fairly represent in all material respects our financial condition, results of operations and cash flows for the periods at and for the periods presented in accordance with U.S. GAAP.

Management’s Annual Report on Internal Control over Financial Reporting
 
Management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our Board of Directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:
 
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;

provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.
 
 Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
 
Management evaluates the effectiveness of our internal control over financial reporting by using the criteria established in Internal Control – Integrated Framework (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).  Based on this criteria, management concluded that our internal control over financial reporting as of December 31, 2018 was not effective due to the material weakness described below. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

Management identified a deficiency related to the design effectiveness of the Company’s controls surrounding the determination of the appropriate revenue recognition date. Specifically, the Company did not timely review and appropriately

59


document shipping information provided by its third-party logistics (“3PL”) facilities. Furthermore, the Company did not test a sufficient sample of individual shipping documents, as provided by its 3PLs, to determine and conclude that the shipping date agreed with the date revenues were recognized. Although the control deficiency identified resulted in no material misstatements to the consolidated financial statements, this deficiency creates a reasonable possibility that a material misstatement to the consolidated financial statements will not be prevented or detected on a timely basis and represents a material weakness in the Company’s internal control over financial reporting. As a result, management concluded that our internal control over financial reporting was not effective at December 31, 2018.

Changes in Internal Control over Financial Reporting
 
Other than with respect to the remediation efforts discussed below, there were no changes in internal control over financial reporting that occurred during the quarter ended December 31, 2018 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

Remediation Efforts to Address Material Weaknesses

Management, with oversight from the Audit Committee, implemented a plan intended to remediate the material weakness related to our proprietary web-based system identified as of December 31, 2017. The remediation plan included the enhancement of controls to ensure that the system change management log is adequately backed up, secured and sufficiently maintained, as well as the periodic review and testing of user access rights and permissions.

During the fourth quarter of 2018, we completed monthly reviews of programming changes made in September 2018 to further enhance user access rights and permissions. As the information technology general control deficiencies were fully remediated during the quarter, management concluded that the material weakness in the Company’s internal control over financial reporting related to its proprietary web-based system was successfully remediated as of December 31, 2018.

Management, with oversight from the Audit Committee, intends to remediate the material weakness identified as of December 31, 2018 related to the Company’s review of shipment documentation provided by its 3PLs by obtaining and documenting a sufficient sample of product orders during each quarterly period and ensuring that the underlying shipment documentation agrees with the shipment date as provided by the 3PLs.  This remediation plan commenced during the first quarter of 2019.  We expect that the remediation of this material weakness will be fully complete during the second quarter of 2019.

We will develop additional controls and procedures for continued improvement in our control environment, including compensating review controls for our proprietary web-based system, as deemed necessary.
 
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
ON INTERNAL CONTROL OVER FINANCIAL REPORTING

To the Shareholders and Board of Directors of
Natural Health Trends Corp.

Adverse Opinion on Internal Control over Financial Reporting

We have audited Natural Health Trends Corp.’s (the "Company") internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, because of the effect of the material weakness described in the following paragraph on the achievement of the objectives of the control criteria, the Company has not maintained effective internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

A material weakness is a control deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis. The following material weakness has been identified and included in “Management's Annual Report on Internal Control Over Financial Reporting”.

As of December 31, 2018, management identified a material weakness related to the ineffective design of controls over the completeness and accuracy of information used to recognize revenues, which could affect the appropriate cut-off surrounding revenue and deferred revenues. 

60



This material weakness was considered in determining the nature, timing and extent of audit tests applied in our audit of the fiscal December 31, 2018 consolidated financial statements, and this report does not affect our report dated April 26, 2019 on those consolidated financial statements.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated balance sheets as of December 31, 2018 and 2017 and the related consolidated statements of operations, comprehensive income, stockholders’ equity, and cash flows for each of the two years then in the period December 31, 2018 of the Company and our report dated April 26, 2019 expressed an unqualified opinion on those financial statements.

Basis for Opinion

The Company's management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying “Management Annual Report on Internal Control Over Financial Reporting”. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of the inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that degree of compliance with the policies or procedures may deteriorate.




/s/ Marcum LLP
Marcum LLP

Los Angeles, CA
April 26, 2019

Item 9B. OTHER INFORMATION

None.
 
Part III 
 

61


Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2018.
 
Item 11. EXECUTIVE COMPENSATION

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2018.
 
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
 
The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2018.
 
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
 
The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2018.
 
Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2018.
 
Part IV
 
Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

Documents filed as part of this Form 10-K:
 
1.
Financial Statements. See Index to Consolidated Financial Statements under “Item 8. Financial Statements and Supplementary Data” of this report.
2.
Financial Statement Schedules. Financial statement schedules have been omitted because they are not required, not applicable, or because the required information is shown in the financial statements or notes thereto.
3.
Exhibits. The exhibits listed on the accompanying Exhibit Index are filed as a part of, and are incorporated by reference into, this report. We will furnish any of the exhibits referenced in the accompanying Exhibit Index to a requesting shareholder upon payment of a fee equal to our reasonable expenses in furnishing such exhibit(s).

Item 16. FORM 10-K SUMMARY

None.


62


SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
  
 
NATURAL HEALTH TRENDS CORP.
 
 
 
Date: April 26, 2019
/s/ Chris T. Sharng
 
Chris T. Sharng
 
President
 
(Principal Executive Officer)
 
POWER OF ATTORNEY
 
KNOW ALL MEN BY THESE PRESENTS that each of Natural Health Trends Corp., a Delaware corporation, and the undersigned directors and officers of Natural Health Trends Corp., hereby constitutes and appoints Chris T. Sharng and Timothy S. Davidson, or any one of them, its, his or her true and lawful attorney-in-fact and agent, for it, him or her and in its, his or her name, place and stead, in any and all capacities, with full power to act alone, to sign any and all amendments to this report, and to file each such amendment to the report, with all exhibits thereto, and any and all other documents in connection therewith, with the Securities and Exchange Commission, hereby granting unto said attorney-in-fact and agent full power and authority to do and perform any and all acts and things requisite and necessary to be done in and about the premises as fully to all intents and purposes as it, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.
 
Pursuant to the requirements of the Securities Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 
Signature
 
Title
 
Date
 
 
 
 
 
/s/ Chris T. Sharng
 
President and Director
 
April 26, 2019
Chris T. Sharng
 
(Principal Executive Officer)
 
 
 
 
 
 
 
/s/ Timothy S. Davidson
 
Senior Vice President and Chief Financial Officer
 
April 26, 2019
Timothy S. Davidson
 
(Principal Financial and Accounting Officer)
 
 
 
 
 
 
 
/s/ Randall A. Mason
 
Chairman of the Board and Director
 
April 26, 2019
Randall A. Mason
 
 
 
 
 
 
 
 
 
/s/ George K. Broady
 
Director
 
April 26, 2019
George K. Broady
 
 
 
 
 
 
 
 
 
/s/ Kin Y. Chung
 
Director
 
April 26, 2019
Kin Y. Chung
 
 
 
 
 
 
 
 
 
/s/ Yiu T. Chan
 
Director
 
April 26, 2019
Yiu T. Chan
 
 
 
 

63


EXHIBIT INDEX
(Pursuant to Item 601 of Regulation S-K)
Exhibit
Number
 
 
Exhibit Description
3.1
 
3.3
 
Amended and Restated Bylaws of Natural Health Trends Corp. effective March 27, 2018 (incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed on March 28, 2018).
4.1
 
+10.1
 
+10.2
 
+10.3
 
+10.4
 
+10.5
 
+10.6
 
+10.7
 
+10.8
 
+10.9
 
21.1
 
24.1
 
31.1
 
31.2
 
32.1
 
 
 
 
 
 
 
101.INS
 
Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH
 
XBRL Taxonomy Extension Schema
101.CAL
 
XBRL Taxonomy Extension Calculation
101.DEF
 
XBRL Taxonomy Extension Definition
101.LAB
 
XBRL Taxonomy Extension Labels
101.PRE
 
XBRL Taxonomy Extension Presentation
 
 
+ Management contract or compensatory plan

EX-21.1 2 q42018ex21-1.htm EXHIBIT 21.1 Exhibit


Exhibit 21.1
  
SUBSIDIARIES OF THE REGISTRANT
AS OF DECEMBER 31, 2018
 
NATURAL HEALTH TRENDS CORP.
A DELAWARE CORPORATION
 
Name
 
Jurisdiction
 
 
 
NHT Global, Inc.
 
United States (Delaware)
NHTC International, LLC
 
United States (Delaware)
NHT Global (Canada) Company 
 
Canada
NHTC Holding Company
 
Cayman Islands
NHTC Trading Company
 
Cayman Islands
NHT Global Taiwan Company
 
Cayman Islands
NHT Global CIS Company
 
Cayman Islands
NHT Global (China) Commodities Co., Ltd.
 
China
NHT Global (Zhongshan) Cosmetics Co., Ltd.
 
China
NHT Global Hong Kong Limited
 
Hong Kong
Natural Health Trends Japan, Inc.
 
Japan
NHTC Global Singapore Pte. Ltd.
 
Singapore
NHTC Wellness Products Malaysia Sdn. Bhd.
 
Malaysia
NHTK Ltd.
 
South Korea
NHT Global Europe S.R.L.
 
Italy
NHT Global Peru S.A.C.
 
Peru
Natural Health Trends (Thailand) Ltd.
 
Thailand
NHT Global Limited Company
 
Vietnam
PT Natural Health Trends Indonesia
 
Indonesia
NHTC (India) Private Limited
 
India
 
The names of omitted subsidiaries when considered in the aggregate as a single subsidiary do not constitute a significant subsidiary as of the end of the year covered by this report.



EX-31.1 3 q42018ex31-1.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
 
CERTIFICATION
 
I, Chris T. Sharng, certify that:
 
1.     I have reviewed this report on Form 10-K of Natural Health Trends Corp.;
 
2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.      The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
5.     The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
Date: April 26, 2019
 
/s/ Chris T. Sharng
 
 
 
Chris T. Sharng
 
 
 
President
 
 
 
(Principal Executive Officer)
 


EX-31.2 4 q42018ex31-2.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
 
CERTIFICATION
 
I, Timothy S. Davidson, certify that:
 
1.     I have reviewed this report on Form 10-K of Natural Health Trends Corp.;
 
2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.      The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
5.     The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
Date: April 26, 2019
 
/s/ Timothy S. Davidson
 
 
 
Timothy S. Davidson
 
 
 
Senior Vice President and Chief Financial Officer
 
 
 
(Principal Financial Officer)
 


EX-32.1 5 q42018ex32-1.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
 
CERTIFICATIONS PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Annual Report of Natural Health Trends Corp. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Chris T. Sharng, the Principal Executive Officer, and Timothy S. Davidson, the Principal Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:
 
1.        The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
2.        The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
  
Date: April 26, 2019
 
/s/ Chris T. Sharng
 
 
 
Chris T. Sharng
 
 
 
President
 
 
 
(Principal Executive Officer)
 
 
 
Date: April 26, 2019
 
/s/ Timothy S. Davidson
 
 
 
Timothy S. Davidson
 
 
 
Senior Vice President and Chief Financial Officer
 
 
 
(Principal Financial Officer)
 
  
The foregoing certifications are not deemed filed with the United States Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. 



EX-101.SCH 6 nhtc-20181231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2104100 - Disclosure - BALANCE SHEET COMPONENTS link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - BALANCE SHEET COMPONENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - BALANCE SHEET COMPONENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Lease Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - EMPLOYEE BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - EMPLOYEE BENEFIT PLANS (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - FAIR VALUE MEASUREMENTS - Assets Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - FAIR VALUE MEASUREMENTS - Available-for-sale Investments Included in Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - INCOME TAXES - Components of Income Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - INCOME TAXES - Components of Income Tax Provision (Details) link:presentationLink link:calculationLink link:definitionLink 2408407 - Disclosure - INCOME TAXES - Deferred Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2408406 - Disclosure - INCOME TAXES - Foreign Rate Differentials (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - INCOME TAXES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408405 - Disclosure - INCOME TAXES - Reconciliation of Provision for Income Tax (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - NET INCOME PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - NET INCOME PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - NET INCOME PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - SEGMENT INFORMATION - Long-live Assets by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - SEGMENT INFORMATION - Net Sales by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - SEGMENT INFORMATION - Net Sales by Product and Service (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - STOCKHOLDERS' EQUITY - Changes in Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - STOCKHOLDERS' EQUITY - Dividend Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 nhtc-20181231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 nhtc-20181231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 nhtc-20181231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Income Tax Disclosure [Abstract] Income Tax Foreign Rate Differential [Table] Income Tax Foreign Rate Differential [Table] Income Tax Foreign Rate Differential components Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Cayman Islands Cayman Islands Tax Information Authority [Member] Hong Kong Inland Revenue, Hong Kong [Member] China State Administration of Taxation, China [Member] Income Tax Foreign Rate Differential [Line Items] Income Tax Foreign Rate Differential [Line Items] [Line Items] for Income Tax Foreign Rate Differential components Statutory Tax Rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Foreign income tax Income (Loss) from Continuing Operations before Income Taxes, Foreign Fair Value Disclosures [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Cash equivalents Cash Equivalents [Member] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Municipal bonds and notes Municipal Bonds and Notes [Member] Long-term and short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments. Corporate debt securities Corporate Debt Securities [Member] Financial institution instruments Financial Institution Instruments [Member] Information pertaining to financial institution instruments. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Adjusted Cost Available-for-sale Securities, Amortized Cost Basis Gross Unrealized Gains/Losses Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax Fair Value Available-for-sale Securities Segment Reporting [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Product sales Product [Member] Freight and other Shipping and Handling [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Total net sales Revenue from Contract with Customer, Excluding Assessed Tax Less: sales returns Contract with Customer, Refund Liability, Sales Returns Contract with Customer, Refund Liability, Sales Returns Subsequent Events [Abstract] SUBSEQUENT EVENTS Subsequent Events [Text Block] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Equity [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2016 Plan Equity Incentive 2016 Plan [Member] Equity Incentive 2016 Plan Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Restricted Stock Restricted Stock [Member] Other Restricted Stock Other Restricted Stock [Member] Other Restricted Stock Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Nonvested, beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Nonvested, ending balance (in shares) Wtd. Avg. Price at Date of Issuance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Nonvested, beginning balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Nonvested, ending balance (in dollars per share) Income tax at federal statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Effect of permanent differences Effect of permanent differences Effect of permanent differences. Tax Cut & Jobs Act one-time transition tax Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Transition Tax on Accumulated Foreign Earnings, Amount Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Transition Tax on Accumulated Foreign Earnings, Amount Global Intangible Low Taxed Income Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Global Intangible Low-tax Income (GILTI), Amount Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Global Intangible Low-tax Income (GILTI), Amount Tax Cut & Jobs Act federal rate change Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Foreign tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount Other reconciling items Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Income tax provision Income Tax Expense (Benefit) Earnings Per Share [Abstract] Schedule of Computation of Basic and Diluted Income per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND COMMITMENTS Commitments and Contingencies Disclosure [Text Block] Statement of Comprehensive Income [Abstract] Net income Net Income (Loss) Attributable to Parent Other comprehensive income (loss), net of tax: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Release of cumulative translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax Net change in foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Unrealized losses on available-for-sale securities Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Deferred tax assets: Deferred Tax Assets, Gross [Abstract] Net operating losses Deferred Tax Assets, Operating Loss Carryforwards Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Accrued expenses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Other Deferred Tax Assets, Other Total deferred tax assets Deferred Tax Assets, Gross Valuation allowance Deferred Tax Assets, Valuation Allowance Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Foreign earnings Deferred Tax Liabilities, Undistributed Foreign Earnings Other Deferred Tax Liabilities, Other Total deferred tax liabilities Deferred Tax Liabilities, Gross Net deferred tax assets Deferred Tax Assets, Net Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States UNITED STATES Hong Kong HONG KONG China CHINA Other foreign countries Other Foreign Countries [Member] Represents other foreign countries. Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Total long-lived assets Long-Lived Assets Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Preferred Stock Preferred Stock [Member] Common Stock Common Stock [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Retained Earnings Retained Earnings [Member] Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Treasury Stock Treasury Stock [Member] Statement [Line Items] Statement [Line Items] Preferred stock, beginning balance (in shares) Preferred Stock, Shares Outstanding Common stock, beginning balance (in shares) Common Stock, Shares, Issued Treasury stock, beginning balance (in shares) Treasury Stock, Shares Stockholders' equity, beginning balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Restricted stock forfeiture Stock Issued During Period, Value, Restricted Stock Award, Forfeitures Restricted stock forfeiture (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Common stock issued Stock Issued During Period, Value, Share-based Compensation, Gross Common stock issued (in shares) Stock Issued During Period, Shares, Share-based Compensation, Gross Dividends declared Dividends Elimination of CTA upon dissolution Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Preferred stock, ending balance (in shares) Common stock, ending balance (in shares) Treasury stock, beginning balance (in shares) Stockholders' equity, ending balance Document And Entity Information Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Entity Public Float Entity Public Float Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Accounting Policies [Abstract] Principles of Consolidation Consolidation, Policy [Policy Text Block] Reclassification Reclassification, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Amounts Held in eWallets Amounts Held in Distributor eWallets [Policy Text Block] Represents the policy of amounts held in customer eWallets. Long-Term Incentive Compensation Related Costs, Policy [Policy Text Block] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Commissions Commissions, Policy [Policy Text Block] Operating Leases Lessee, Leases [Policy Text Block] Stock-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Net Income Per Common Share Earnings Per Share, Policy [Policy Text Block] Certain Risks and Concentrations Concentration Risk, Credit Risk, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Recently Issued and Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value, Measurements, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Total Fair Value, Inputs, Level 1, 2 and 3 [Member] Amounts included in cash and cash equivalents Total assets measured at fair value on a recurring basis Assets, Fair Value Disclosure Stockholders' Equity Note [Abstract] Special dividend per common share (in dollars per share) Common Stock, Special Dividends, Per Share, Cash Paid Common Stock, Special Dividends, Per Share, Cash Paid Special dividend amount Special Dividends, Common Stock, Cash Special Dividends, Common Stock, Cash Dividend per common share (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Dividend amount Dividends, Cash Payment Date Dividends Payable, Date to be Paid Balance Sheet Components [Abstract] Balance Sheet Components [Abstract] BALANCE SHEET COMPONENTS Supplemental Balance Sheet Disclosures [Text Block] Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation Stock-based compensation Share-based Compensation Cumulative translation adjustment realized in net income Cumulative Translation Adjustment Realized In Net Income Represents cumulative translation adjustment realized in net income. Deferred income taxes Deferred Income Tax Expense (Benefit), Excluding Effects of Foreign Exchange Deferred Income Tax Expense (Benefit), Excluding Effects of Foreign Exchange Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Inventories Increase (Decrease) in Inventories Other current assets Increase (Decrease) in Other Current Assets Other assets Increase (Decrease) in Other Noncurrent Assets Accounts payable Increase (Decrease) in Accounts Payable Income taxes payable Increase (Decrease) in Income Taxes Payable Accrued commissions Increase (Decrease) in Accrued Liabilities Other accrued expenses Increase (Decrease) in Other Accrued Liabilities Deferred revenue Increase (Decrease) in Contract with Customer, Liability Amounts held in eWallets Increase (Decrease) in Capitalized Contract Cost Liability Increase (Decrease) in Capitalized Contract Cost Liability Other current liabilities Increase (Decrease) in Other Current Liabilities Long-term incentive Increase (Decrease) in Deferred Compensation Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Dividends paid Payments of Dividends Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rates on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Net (decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period SUPPLEMENTAL CASH FLOW DISCLOSURE: Supplemental Cash Flow Information [Abstract] Cash paid for income taxes, net Income Taxes Paid, Net Issuance of treasury stock for employee awards, net Stock Issued Retirement Benefits [Abstract] EMPLOYEE BENEFIT PLANS Pension and Other Postretirement Benefits Disclosure [Text Block] INCOME TAXES Income Tax Disclosure [Text Block] Canada CANADA Peru PERU Taiwan TAIWAN, PROVINCE OF CHINA South Korea KOREA, REPUBLIC OF Russia and Kazakhstan Russia and Kazakhstan [Domain] Russia and Kazakhstan [Domain] Europe Europe [Member] Schedule of Additional Balance Sheet Components Schedule of Additional Balance Sheet Components [Table Text Block] Schedule of Additional Balance Sheet Components [Table Text Block] NET INCOME PER COMMON SHARE Earnings Per Share [Text Block] Condensed Balance Sheet Statement [Table] Condensed Balance Sheet Statement [Table] Cash Cash [Member] Contract with Customer, Arrangement Type [Axis] Contract with Customer, Arrangement Type [Axis] Contract with Customer, Arrangement Type Contract with Customer, Arrangement Type [Domain] Contract with Customer, Arrangement Type [Domain] [Domain] for Contract with Customer, Arrangement Type Unshipped product Unshipped Product [Member] Represents unshipped product. Auto ship advances Auto Ship Advances [Member] Represents Auto Ship advances. Other Other Revenue [Member] Other Revenue Condensed Balance Sheet Statements, Captions [Line Items] Condensed Balance Sheet Statements, Captions [Line Items] Cash and cash equivalents: Cash and Cash Equivalents [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Restricted cash Restricted Cash, Noncurrent Cash, cash equivalents and restricted cash Inventories: Inventory Disclosure [Abstract] Finished goods Inventory, Finished Goods, Gross Raw materials Inventory, Raw Materials and Supplies, Gross Reserve for obsolescence Inventory Valuation Reserves Inventories, net Inventory, Net Property and equipment: Property, Plant and Equipment [Abstract] Office equipment Office equipment Represents other equipment. Office software Capitalized Computer Software, Gross Machinery Machinery and Equipment, Gross Furniture and fixtures Furniture and Fixtures, Gross Leasehold improvements Leasehold Improvements, Gross Construction in progress (including internal-use software development costs) Construction in Progress, Gross Property and equipment, at cost Property, Plant and Equipment, Gross Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net Other accrued expenses: Other accrued expenses: Represents other accrued expenses abstract. Sales returns Accrued Sales Returns Accrued Sales Returns Employee-related expense Accrued Employee Benefits, Current Warehousing, inventory-related and other Accrued Warehousing And Inventory Related Expense Accrued Warehousing And Inventory Related Expense Other accrued expenses Other Accrued Liabilities, Current Deferred revenue: Deferred Revenue [Abstract] Deferred revenue Contract with Customer, Liability, Current Statement of Financial Position [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Treasury stock, shares (in shares) STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Cash dividends declared per common stock outstanding (in dollars per share) Common Stock, Dividends, Per Share, Declared Special cash dividend declared per common stock outstanding (in dollars per share) Common Stock, Special Dividends,Per Share, Declared Special dividends declared during the period for each share of common stock outstanding. Cash dividends paid per common stock outstanding (in dollars per share) Special cash dividend paid per common stock outstanding (in dollars per share) Number of shares granted (in shares) Shares vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Value of shares granted Stock Issued During Period, Value, Restricted Stock Award, Gross Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Class of Stock [Line Items] Class of Stock [Line Items] Number of classes of stock Number Of Classes Of Stock Number Of Classes Of Stock Authorized amount of shares to be repurchased Stock Repurchase Program, Authorized Amount Repurchase of common stock (in shares) Treasury Stock, Shares, Acquired Remaining authorized repurchase amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Stock-based compensation expense recognized Allocated Share-based Compensation Expense Number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of shares available for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Unrealized Losses on Available-For-Sale Investments Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Total Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Balance, December 31, 2017 Accumulated Other Comprehensive Income (Loss), Net of Tax Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Balance, December 31, 2018 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Description and Basis of Presentation [Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Software Software and Software Development Costs [Member] Furniture and Fixtures Furniture and Fixtures [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Premium Noni Juice Premium Noni Juice [Member] Premium Noni Juice Enhanced Essential Probiotics Enhanced Essential Probiotics [Member] Enhanced Essential Probiotics Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Product Concentration Risk Product Concentration Risk [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Sales Revenue, Product Line Sales Revenue, Product Line [Member] Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain] Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain] Long-Term Incentive Plan, Payment Commencing in February of the Calendar Year Immediately Following the Conclusion of the Performance Period Long-Term Incentive Plan, Payment Commencing in February of the Calendar Year Immediately Following the Conclusion of the Performance Period [Member] Represents the Long-Term Incentive Plan (the “LTI Plan”), payments commencing in February of the calendar year immediately following the conclusion of the performance period. Long-Term Incentive Plan, Payment Commencing in February 2021 and Ending in December 2023 Long-Term Incentive Plan, Payment Commencing in February 2021 and Ending in December 2023 [Member] Represents the Long-Term Incentive Plan (the “LTI Plan”), payments commencing in February 2021 and ending in December 2023. Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Non-current Liability Noncurrent Liabilities [Member] Noncurrent Liabilities Other Accrued Expenses Other Accrued Expenses [Member] Other Accrued Expenses Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Scenario, Forecast Scenario, Forecast [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] ASU 2016-02 Accounting Standards Update 2016-02 [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Period to receive cash proceeds from credit card processors Cash and Cash Equivalents, Period to Receive Cash Proceeds From Credit Card Processors Cash and Cash Equivalents, Period to Receive Cash Proceeds From Credit Card Processors Restricted cash Restricted Cash and Cash Equivalents Percentage of restricted cash required as collateral Restricted Cash, Collateral Requirement Percentage Restricted Cash, Collateral Requirement Percentage Depreciation and amortization expenses Property, and equipment useful life Property, Plant and Equipment, Useful Life Long-term incentive plan, percentage of award payable in cash nhtc_DeferredCompensationRewardPaymentPercentage Represents the percentage of deferred compensation award payable. Long-term incentive plan, number of installments nhtc_DeferredCompensationRewardPayableEqualConsecutiveMonthlyInstallments Represents the number of equal consecutive monthly installments of deferred compensation award payable. Total long-term incentive compensation Deferred Compensation Cash-based Arrangements, Liability, Current and Noncurrent Non-current long-term incentive compensation Deferred Compensation Cash-based Arrangements, Liability, Classified, Noncurrent Current long-term incentive compensation Deferred Compensation Cash-based Arrangements, Liability, Current Loss on foreign exchange Foreign Currency Transaction Gain (Loss), Unrealized Concentration risk percentage (more than) Concentration Risk, Percentage Operating lease liability Operating Lease, Liability Operating lease ROU assets Operating Lease, Right-of-Use Asset Schedule of Income Before Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Components of Income Tax Provision Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of Income Tax Foreign Rate Differential Income Tax Foreign Rate Differential [Table Text Block] [Table Text Block] for Income Tax Foreign Rate Differential components Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Dividends Payable Schedule of Dividends Payable [Table Text Block] Schedule of Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Schedule of Changes in Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] U.S. Federal Domestic Tax Authority [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Additional income tax expense due to GILTI Tax Cuts And Jobs Act Of 2017, Global Intangible Low-taxed Income (GILTI), Income Tax Expense Tax Cuts And Jobs Act Of 2017, Global Intangible Low-taxed Income (GILTI), Income Tax Expense Foreign tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount Net operating loss carryforwards Operating Loss Carryforwards Foreign net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Maximum compensation percentage Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage Age requirement for 401(k) contributions Age Requirement For 401K Contributions Represents age requirement for 401K contributions. Employer matching contribution, percent of employees' gross pay Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Employers matching contribution, immediate vesting percentage Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage Defined contribution plan, cost recognized Defined Contribution Plan, Cost Schedule of Available-for-sale Investments Available-for-sale Securities [Table Text Block] Schedule of Company's Hierarchy for Assets Measured on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Rent expense for operating leases Operating Leases, Rent Expense Number of days to provide notification to terminate purchase commitment agreement Purchase Commitment Agreement, Period to Provide Notice of Termination Purchase Commitment Agreement, Period to Provide Notice of Termination Minimum monthly purchase amount nhtc_PurchaseCommitmentMonthlyAmountMinimum Represents the monthly purchase minimum the Company is required to purchase until the termination date. Loss Contingencies [Table] Loss Contingencies [Table] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Employment Agreements Employment Agreements [Member] Employment Agreements Securities Class Actions Securities Class Action [Member] Securities Class Action [Member] Shareholder Derivative Claims Shareholder Derivative Claim [Member] shareholder derivative claim [Member] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Executive Officers Executive Officer [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Number of weeks (months) to provide notice of termination of agreement by either party Employment Agreement, Number of Weeks To Provide Termination Notice by Parties Employment Agreement, Number of Weeks To Provide Termination Notice by Parties Number of parties named in putative securities class action suit Loss Contingency, Number of Defendants Number of complaints filed Loss Contingency, New Claims Filed, Number Number of lead plaintiffs named Loss Contingency, Number of Plaintiffs Litigation settlement amount Litigation Settlement, Amount Awarded to Other Party Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Foreign Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 2019 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2020 Operating Leases, Future Minimum Payments, Due in Two Years 2020 Operating Leases, Future Minimum Payments, Due in Three Years 2022 Operating Leases, Future Minimum Payments, Due in Four Years 2023 Operating Leases, Future Minimum Payments, Due in Five Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total minimum lease obligations Operating Leases, Future Minimum Payments Due Income Statement [Abstract] Net sales Cost of sales Cost of Goods and Services Sold Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Commissions expense Sales Commissions and Fees Selling, general and administrative expenses Selling, General and Administrative Expense Total operating expenses Operating Expenses Income from operations Operating Income (Loss) Other income, net Other Nonoperating Income (Expense) Income tax provision Net income Net income per common share: Basic (in dollars per share) Earnings Per Share, Basic Diluted (in dollars per share) Earnings Per Share, Diluted Weighted-average number of common shares outstanding: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Cash dividends declared per common share (in dollars per share) Schedule of Net Sales by Geographic Area Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Schedule of Net Sales by Product and Service Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Long-lived Assets by Geographic Area Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] Earnings Per Share, Basic [Abstract] Earnings Per Share, Basic [Abstract] Net income available to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Net income available to common stockholders, Shares (in shares) Net income available to common stockholders, Per Share (in dollars per share) Effect of dilutive securities: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Non-vested restricted stock (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Diluted net income per common share: Earnings Per Share, Diluted [Abstract] Net income available to common stockholders plus assumed conversions Net Income (Loss) Available to Common Stockholders, Diluted Net income available to common stockholders plus assumed conversions, Shares (in shares) Net income available to common stockholders plus assumed conversions, Per Share (in dollars per share) Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Revenue from Contract with Customer [Abstract] Sales return policy term Revenue From Contract With Customer, Sales Returns Policy Term Revenue From Contract With Customer, Sales Returns Policy Term Historical sales returns rate Revenue From Contract With Customers, Historical Sales Returns Percentage Revenue From Contract With Customers, Historical Sales Returns Percentage Actual sales returns rate Revenue From Contract With Customers, Sales Returns Percentage Revenue From Contract With Customers, Sales Returns Percentage Cash payments received toward unshipped products Contract With Customer, Liability, Increase From Cash Receipts Contract With Customer, Liability, Increase From Cash Receipts Revenue recognized that was included in deferred revenue in prior year Contract with Customer, Liability, Revenue Recognized Schedule of Future Minimum Rental Payments for Operating Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Current Federal Tax Expense (Benefit) State Current State and Local Tax Expense (Benefit) Foreign Current Foreign Tax Expense (Benefit) Total current taxes Current Income Tax Expense (Benefit) Deferred taxes Deferred Income Tax Expense (Benefit) ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Inventories Other current assets Other Assets, Current Total current assets Assets, Current Property and equipment, net Goodwill Goodwill Deferred tax asset Deferred Income Tax Assets, Net Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Current assets: Accounts Payable, Current Income taxes payable Accrued Income Taxes, Current Accrued commissions Accrued Liabilities, Current Other accrued expenses Amounts held in eWallets Capitalized Contract Costs, Liability, Current Capitalized Contract Costs, Liability, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Income taxes payable Accrued Income Taxes, Noncurrent Deferred tax liability Deferred Income Tax Liabilities, Net Long-term incentive Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2018 and 2017 Preferred Stock, Value, Issued Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2018 and 2017 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Retained earnings Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Treasury stock, at cost; 1,603,322 and 1,637,524 shares at December 31, 2018 and 2017, respectively Treasury Stock, Value Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity REVENUE Revenue from Contract with Customer [Text Block] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Axis] Related Party Transaction [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Royalty Agreement and License Royalty Agreement and License [Member] Royalty Agreement and License Shipment of Apparel Products Shipment of Apparel Products [Member] Shipment of Apparel Products Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] BHS Broady Health Sciences [Member] Represents Broady Health Sciences. Aberdeen The Aberdeen Group, LLC [Member] The Aberdeen Group, LLC ReStor ReStore [Member] Represents a product called ReStore™. Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Affiliated Entity Affiliated Entity [Member] Director Director [Member] President and Wife President and His Wife [Member] President and His Wife Ownership [Axis] Ownership [Axis] Ownership [Domain] Ownership [Domain] Sharng Holdings Sharng Holdings [Member] Sharng Holdings Related Party Transaction [Line Items] Related Party Transaction [Line Items] Percentage of common stock outstanding (more than) Common Stock, Percentage of Beneficial Stock Outstanding Common Stock, Percentage of Beneficial Stock Outstanding Royalty expense Royalty Expense Number of days for termination notice Number Of Days Termination Notice Represents number of days termination notice. Number of product orders Number of Product Orders Number of Product Orders Ownership interest percentage by parent Noncontrolling Interest, Ownership Percentage by Parent Ownership interest by unrelated third party Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Amount of product orders shipped Related Party Transaction, Amounts of Transaction Market-based fee paid be related party Related Party Transaction, Other Revenues from Transactions with Related Party EX-101.PRE 10 nhtc-20181231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 nhtc2018123110k_htm.xml IDEA: XBRL DOCUMENT 0000912061 2018-01-01 2018-12-31 0000912061 2018-06-30 0000912061 2019-04-22 0000912061 2018-12-31 0000912061 2017-12-31 0000912061 2017-01-01 2017-12-31 0000912061 us-gaap:RetainedEarningsMember 2016-12-31 0000912061 us-gaap:TreasuryStockMember 2017-12-31 0000912061 us-gaap:RetainedEarningsMember 2017-12-31 0000912061 us-gaap:TreasuryStockMember 2016-12-31 0000912061 us-gaap:PreferredStockMember 2017-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000912061 us-gaap:CommonStockMember 2016-12-31 0000912061 us-gaap:CommonStockMember 2018-12-31 0000912061 us-gaap:RetainedEarningsMember 2018-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000912061 us-gaap:TreasuryStockMember 2018-12-31 0000912061 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000912061 us-gaap:PreferredStockMember 2018-12-31 0000912061 us-gaap:CommonStockMember 2017-12-31 0000912061 us-gaap:PreferredStockMember 2016-12-31 0000912061 us-gaap:TreasuryStockMember 2017-01-01 2017-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000912061 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000912061 us-gaap:TreasuryStockMember 2018-01-01 2018-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000912061 2016-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000912061 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0000912061 us-gaap:AccountingStandardsUpdate201602Member us-gaap:ScenarioForecastMember us-gaap:SubsequentEventMember 2019-01-01 0000912061 nhtc:NoncurrentLiabilitiesMember 2018-12-31 0000912061 country:KR 2018-12-31 0000912061 country:CN 2015-06-30 0000912061 country:CN 2017-12-31 0000912061 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0000912061 nhtc:PremiumNoniJuiceMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2018-01-01 2018-12-31 0000912061 country:CN 2018-12-31 0000912061 nhtc:OtherAccruedExpensesMember 2018-12-31 0000912061 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2018-01-01 2018-12-31 0000912061 srt:MinimumMember 2018-01-01 2018-12-31 0000912061 srt:MaximumMember 2018-01-01 2018-12-31 0000912061 nhtc:LongTermIncentivePlanPaymentCommencingInFebruary2021AndEndingInDecember2023Member 2018-12-31 0000912061 nhtc:EnhancedEssentialProbioticsMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2018-01-01 2018-12-31 0000912061 nhtc:LongTermIncentivePlanPaymentCommencingInFebruary2021AndEndingInDecember2023Member 2017-12-31 0000912061 nhtc:LongTermIncentivePlanPaymentCommencingInFebruaryOfTheCalendarYearImmediatelyFollowingTheConclusionOfThePerformancePeriodMember 2018-12-31 0000912061 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-01-01 2018-12-31 0000912061 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2018-01-01 2018-12-31 0000912061 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-01-01 2018-12-31 0000912061 nhtc:AutoShipAdvancesMember 2018-12-31 0000912061 nhtc:UnshippedProductMember 2018-12-31 0000912061 nhtc:OtherRevenueMember 2017-12-31 0000912061 nhtc:UnshippedProductMember 2017-12-31 0000912061 us-gaap:CashMember 2018-12-31 0000912061 us-gaap:CashMember 2017-12-31 0000912061 nhtc:AutoShipAdvancesMember 2017-12-31 0000912061 nhtc:OtherRevenueMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember 2017-12-31 0000912061 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000912061 us-gaap:FairValueInputsLevel12And3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel12And3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000912061 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000912061 us-gaap:FairValueInputsLevel12And3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel12And3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000912061 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000912061 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember nhtc:FinancialInstitutionInstrumentsMember 2017-12-31 0000912061 us-gaap:CashEquivalentsMember nhtc:MunicipalBondsAndNotesMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember nhtc:MunicipalBondsAndNotesMember 2017-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000912061 us-gaap:CashEquivalentsMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000912061 us-gaap:CashEquivalentsMember nhtc:FinancialInstitutionInstrumentsMember 2018-12-31 0000912061 2013-05-31 0000912061 nhtc:SecuritiesClassActionMember 2018-04-02 2018-04-02 0000912061 nhtc:ShareholderDerivativeClaimMember 2018-07-16 2018-07-16 0000912061 2013-05-01 2013-05-31 0000912061 nhtc:SecuritiesClassActionMember us-gaap:SubsequentEventMember us-gaap:ExecutiveOfficerMember 2019-01-08 2019-01-08 0000912061 nhtc:SecuritiesClassActionMember 2016-03-29 2016-03-29 0000912061 nhtc:SecuritiesClassActionMember 2016-01-01 2016-01-31 0000912061 nhtc:EmploymentAgreementsMember 2018-01-01 2018-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2018-01-01 2018-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2018-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-01-01 2017-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2016-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2018-02-01 2018-02-01 0000912061 2016-01-12 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:CommonStockMember 2018-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-01-24 2017-01-24 0000912061 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0000912061 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:CommonStockMember 2016-04-07 0000912061 2015-07-28 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-12-31 0000912061 2018-11-23 2018-11-23 0000912061 2018-08-24 2018-08-24 0000912061 2018-05-25 2018-05-25 0000912061 2018-03-09 2018-03-09 0000912061 nhtc:OtherRestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-12-31 0000912061 nhtc:OtherRestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-01-01 2017-12-31 0000912061 nhtc:OtherRestrictedStockMember nhtc:EquityIncentive2016PlanMember 2016-12-31 0000912061 2017-08-31 2017-08-31 0000912061 2017-05-19 2017-05-19 0000912061 2017-11-24 2017-11-24 0000912061 2017-03-03 2017-03-03 0000912061 2017-01-01 2017-06-30 0000912061 us-gaap:DomesticCountryMember 2018-12-31 0000912061 us-gaap:InlandRevenueHongKongMember 2018-01-01 2018-12-31 0000912061 us-gaap:CaymanIslandsTaxInformationAuthorityMember 2018-01-01 2018-12-31 0000912061 us-gaap:StateAdministrationOfTaxationChinaMember 2018-01-01 2018-12-31 0000912061 us-gaap:StateAdministrationOfTaxationChinaMember 2017-01-01 2017-12-31 0000912061 us-gaap:InlandRevenueHongKongMember 2017-01-01 2017-12-31 0000912061 us-gaap:CaymanIslandsTaxInformationAuthorityMember 2017-01-01 2017-12-31 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2018-01-01 2018-12-31 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember 2018-01-01 2018-12-31 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2018-12-31 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:SharngHoldingsMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2018-12-31 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2017-01-01 2017-12-31 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember 2015-04-29 2015-04-29 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember us-gaap:DirectorMember 2013-02-28 0000912061 nhtc:BroadyHealthSciencesMember nhtc:ReStoreMember nhtc:RoyaltyAgreementandLicenseMember srt:AffiliatedEntityMember 2017-01-01 2017-12-31 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember nhtc:PresidentandHisWifeMember 2018-12-31 0000912061 nhtc:TheAberdeenGroupLLCMember nhtc:ShipmentofApparelProductsMember srt:AffiliatedEntityMember 2017-12-31 0000912061 country:US 2018-01-01 2018-12-31 0000912061 country:HK 2017-01-01 2017-12-31 0000912061 srt:EuropeMember 2017-01-01 2017-12-31 0000912061 country:PE 2017-01-01 2017-12-31 0000912061 country:CA 2017-01-01 2017-12-31 0000912061 country:TW 2018-01-01 2018-12-31 0000912061 country:CN 2018-01-01 2018-12-31 0000912061 nhtc:RussiaandKazakhstanDomain 2018-01-01 2018-12-31 0000912061 country:CA 2018-01-01 2018-12-31 0000912061 srt:EuropeMember 2018-01-01 2018-12-31 0000912061 nhtc:RussiaandKazakhstanDomain 2017-01-01 2017-12-31 0000912061 country:KR 2018-01-01 2018-12-31 0000912061 country:KR 2017-01-01 2017-12-31 0000912061 country:US 2017-01-01 2017-12-31 0000912061 country:PE 2018-01-01 2018-12-31 0000912061 country:TW 2017-01-01 2017-12-31 0000912061 nhtc:OtherForeignCountriesMember 2017-01-01 2017-12-31 0000912061 country:CN 2017-01-01 2017-12-31 0000912061 nhtc:OtherForeignCountriesMember 2018-01-01 2018-12-31 0000912061 country:HK 2018-01-01 2018-12-31 0000912061 nhtc:OtherForeignCountriesMember 2018-12-31 0000912061 country:US 2017-12-31 0000912061 nhtc:OtherForeignCountriesMember 2017-12-31 0000912061 country:HK 2018-12-31 0000912061 country:US 2018-12-31 0000912061 country:HK 2017-12-31 0000912061 us-gaap:ShippingAndHandlingMember 2017-01-01 2017-12-31 0000912061 us-gaap:ProductMember 2017-01-01 2017-12-31 0000912061 us-gaap:ProductMember 2018-01-01 2018-12-31 0000912061 us-gaap:ShippingAndHandlingMember 2018-01-01 2018-12-31 0000912061 us-gaap:SubsequentEventMember 2019-01-27 2019-01-27 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember us-gaap:SubsequentEventMember 2019-02-01 2019-02-01 0000912061 us-gaap:SubsequentEventMember 2019-03-15 2019-03-15 pure nhtc:defendant nhtc:plaintiff nhtc:order utreg:Rate nhtc:class shares iso4217:USD iso4217:USD shares iso4217:CNY nhtc:installment nhtc:claim false --12-31 FY 2018 0000912061 Yes false Accelerated Filer false true No No P5D P2D 0.08 35 35 0.5 0.5 P1M 2 1 P1Y 0.02 0.16 0.001 50000000 12979414 12979414 0.10 2 2 2 4600000 0.001 5000000 0 0 0 0 P7Y P5Y P5Y P3Y P3Y P3Y P3Y 1637524 1603322 0 10-K 2018-12-31 NATURAL HEALTH TRENDS CORP. 182584301 11398695 132653000 135311000 12165000 8398000 5369000 7534000 150187000 151243000 934000 1149000 1764000 1764000 2998000 3167000 1207000 1435000 831000 796000 157921000 159554000 1631000 1751000 287000 309000 12502000 11170000 6121000 7605000 6795000 4455000 14611000 15152000 1137000 1479000 43084000 41921000 16982000 19052000 186000 56000 7808000 7904000 68060000 68933000 0 0 13000 13000 86415000 86683000 44431000 44908000 -1250000 -413000 39748000 40570000 89861000 90621000 157921000 159554000 191910000 197563000 39367000 38645000 152543000 158918000 87502000 83638000 31309000 32221000 118811000 115859000 33732000 43059000 789000 367000 34521000 43426000 3486000 19848000 31035000 23578000 2.75 2.10 2.74 2.09 11304000 11251000 11318000 11267000 2.77 1.52 31035000 23578000 -831000 677000 0 258000 -831000 419000 -6000 -25000 30198000 23972000 0 0 12979414 13000 86574000 38548000 -807000 1692218 -41889000 82439000 23578000 23578000 5000 1566 33000 38000 79000 56260 1352000 1431000 17218000 17218000 258000 258000 677000 677000 -25000 -25000 35000 35000 0 0 12979414 13000 86683000 44908000 -413000 1637524 -40570000 90621000 31035000 31035000 -268000 34202 822000 554000 31512000 31512000 -831000 -831000 -6000 -6000 0 0 12979414 13000 86415000 44431000 -1250000 1603322 -39748000 89861000 31035000 23578000 424000 536000 0 35000 0 258000 358000 -1644000 3879000 -2843000 -2065000 3399000 55000 61000 -116000 -392000 -2077000 18676000 1410000 -2417000 -883000 -6033000 2359000 -481000 -509000 -3875000 -326000 -179000 -96000 -324000 29710000 26605000 214000 278000 -214000 -278000 31512000 17218000 -31512000 -17218000 -811000 485000 -2827000 9594000 138478000 128884000 135651000 138478000 3130000 6772000 554000 1393000 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Nature of Operations</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2019, the Company relocated its corporate headquarters from Rolling Hills Estates, California to Hong Kong.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassification</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain prior year balances in the statement of operations have been reclassified to conform to current year presentation. Additionally, in accordance with the adoption of Accounting Standards Update (“ASU”) No. 2016-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows - Restricted Cash</span><span style="font-family:inherit;font-size:10pt;">, the Company has included amounts classified as restricted cash or restricted cash equivalents with cash and cash equivalents when reconciling beginning-of-period and end-of-period total cash, cash equivalents and restricted cash amounts, as presented in its consolidated statements of cash flows.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes, bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 320, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Debt and Equity Securities</span><span style="font-family:inherit;font-size:10pt;">. As such, the Company determined its investments in debt securities held at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive loss in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within two to five days. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company maintains certain cash balances at several institutions located in the United States, Hong Kong and Malaysia which at times may exceed insured limits.  The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2015, the Company funded a bank deposit account in the amount of CNY </span><span style="font-family:inherit;font-size:10pt;"><span>20 million</span></span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and 2017, respectively) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> collateral before processing transactions, which must be maintained indefinitely.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans. </span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> years for office equipment, office software and capitalized internal-use software development costs and </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;"> years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are included in the statement of operations as selling, general and administrative expenses. Such expense totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$424,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$536,000</span></span><span style="font-family:inherit;font-size:10pt;"> during 2018 and 2017, respectively.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assesses qualitative factors in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, through this qualitative assessment, the conclusion is made that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, a two-step impairment test is performed. The Company’s policy is to test for impairment annually during the fourth quarter. Considerable management judgment is necessary to measure fair value. The Company did not recognize any impairment charges for goodwill during the periods presented.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than not recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are no uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided for state income tax purposes on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Amounts Held in eWallets</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company requires commission payments of certain members in Hong Kong to be first recorded into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-Term Incentive</span></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial rewards earned under the 2014 Long-Term Incentive Plan (the “LTI Plan”) are recognized over the performance period as specified performance or other goals are achieved or exceeded. In accordance with the LTI Plan, </span><span style="font-family:inherit;font-size:10pt;">fifty percent</span><span style="font-family:inherit;font-size:10pt;"> of any cash payment earned is payable in </span><span style="font-family:inherit;font-size:10pt;">thirty-five</span><span style="font-family:inherit;font-size:10pt;"> equal consecutive monthly installments commencing in February of the calendar year immediately following the conclusion of the performance period and the remaining </span><span style="font-family:inherit;font-size:10pt;">fifty percent</span><span style="font-family:inherit;font-size:10pt;"> of the payment earned is payable in </span><span style="font-family:inherit;font-size:10pt;">thirty-five</span><span style="font-family:inherit;font-size:10pt;"> equal consecutive monthly installments commencing in February 2021 and ending in December 2023. As of December 31, 2018, unpaid installments for long-term incentive compensation total </span><span style="font-family:inherit;font-size:10pt;"><span>$9.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$7.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> is reflected on the balance sheet as a non-current liability and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> is reflected in other accrued expenses.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the sole discretion of the Compensation Committee of the Company’s Board of Directors, distributions under the LTI Plan are made in cash, or alternatively awarded in the form of common stock or other common stock rights having an equivalent cash value under the terms of the Natural Health Trends Corp. 2016 Equity Incentive Plan. A determination of the form of distribution, if any, is made by the Compensation Committee subsequent to the end of each calendar year. As such, amounts earned are considered non-equity awards. See Note 7 for grant information of distributions settled in common stock. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign Currency</span></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into accumulated other comprehensive income.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate transaction gains or losses, including gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of certain inter-company balances, are included in the statement of operations as other income and expense. Loss on foreign exchange totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$739,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$451,000</span></span><span style="font-family:inherit;font-size:10pt;"> was recognized during </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Commissions</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and as the related revenue is recognized and pays commissions on product sales generally two weeks following the end of the weekly sales period.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In some markets, the Company also pays certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. The Company also enters into performance-based agreements for business or market development, which may result in additional compensation to specific members.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Leases</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company leases its physical properties under operating leases. Certain lease agreements include rent holidays and incentives. The Company recognizes rent holiday periods on a straight-line basis over the lease term beginning when the Company has the right to the leased space.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense is determined based on the grant date fair value of each award, net of estimated forfeitures which are derived from historical experience, and is recognized on a straight-line basis over the requisite service period for the award. </span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net Income Per Common Share</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Certain Risks and Concentrations</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A substantial portion of the Company’s sales are generated in Hong Kong (see Note 11). Substantially all of the Company’s Hong Kong revenues are derived from the sale of products that are delivered to members in China. In contrast to the Company’s operations in other parts of the world, the Company’s China subsidiary has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license, which the Company has applied for, and has also adopted anti-pyramid selling and multilevel marketing legislation. The Company operates an e-commerce direct selling model in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail model. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate separately or in both.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company continually evaluates its operations in China and Hong Kong for compliance with applicable laws and regulations, including seeking the input of outside professionals and certain Chinese authorities. This process can and has resulted in the identification of certain matters of potential noncompliance. The Company works on a continuing basis to satisfactorily address such matters, however there can be no assurance that adequate steps are taken or that applicable laws and regulations are properly interpreted. Should the government authorities determine that the Company’s activities violate applicable laws and regulations, including China’s direct selling, pyramid selling or multilevel marketing laws and regulations, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling, pyramid selling or multi-level marketing legislation, and subjective interpretations of laws and regulations. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No single market other than Hong Kong had net sales greater than 10% of total sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of its net sales. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Premium Noni Juice</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Enhanced Essential Probiotics</span><span style="font-family:inherit;font-size:12pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">®</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">products each account for more than </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s total revenue. The Company currently sources each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Issued and Adopted Accounting Pronouncements</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18 that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard was effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted the new standard effective January 1, 2018 using the retrospective transition method. Its adoption did not have a material impact on the Company’s consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB established Topic 842, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, by issuing ASU No. 2016-02, which requires lessees to recognize the rights and obligations created by leases on the balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;">, ASU No. 2018-10, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842</span><span style="font-family:inherit;font-size:10pt;">, and ASU No. 2018-01, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-family:inherit;font-size:10pt;">. The new standard establishes a right-of-use model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new standard will be effective January 1, 2019. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. If an entity chooses the second option, the transition requirements for existing leases also apply to leases entered into between the date of initial application and the effective date. The entity must also recast its comparative period financial statements and provide the disclosures required by the new standard for the comparative periods. The Company expects to adopt the new standard on January 1, 2019 using the effective date as our date of initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new standard provides a number of optional practical expedients in transition. The Company expects to elect the “package of practical expedients”, which permits entities not to reassess under the new lease standard prior conclusions about lease identification, lease classification and initial direct costs. The Company does not expect to elect the use-of-hindsight or the practical expedient pertaining to land easements.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While the Company continues to assess all of the effects of adoption, it currently believes that most significant effects relate to the recognition of new ROU assets and lease liabilities on our balance sheet for office operating leases and providing significant new disclosures about our leasing activities. On adoption, the Company expects to recognize an operating lease liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, with corresponding ROU assets of the same amount based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new standard also provides practical expedients for an entity’s ongoing accounting. The Company currently expects to elect the short-term leases recognition exemption for all leases that qualify. This means that the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets and lease liabilities for existing short-term leases of those assets in transition. The Company also currently expects to elect the practical expedient to not separate lease and nonlease components for its leases.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue From Contracts With Customers</span><span style="font-family:inherit;font-size:10pt;">, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. In July 2015, the FASB approved the deferral of the effective date for annual reporting periods beginning after December 15, 2017, including interim reporting periods. The Company adopted the new standard effective January 1, 2018 using the modified retrospective transition method. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. See Note 2 for additional information.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements. Principles of Consolidation<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. Reclassification<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain prior year balances in the statement of operations have been reclassified to conform to current year presentation. Additionally, in accordance with the adoption of Accounting Standards Update (“ASU”) No. 2016-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows - Restricted Cash</span><span style="font-family:inherit;font-size:10pt;">, the Company has included amounts classified as restricted cash or restricted cash equivalents with cash and cash equivalents when reconciling beginning-of-period and end-of-period total cash, cash equivalents and restricted cash amounts, as presented in its consolidated statements of cash flows.</span></div><br/> Use of Estimates<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected. Cash and Cash Equivalents<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes, bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 320, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Debt and Equity Securities</span><span style="font-family:inherit;font-size:10pt;">. As such, the Company determined its investments in debt securities held at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive loss in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within two to five days. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company maintains certain cash balances at several institutions located in the United States, Hong Kong and Malaysia which at times may exceed insured limits.  The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk. Restricted Cash<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2015, the Company funded a bank deposit account in the amount of CNY </span><span style="font-family:inherit;font-size:10pt;"><span>20 million</span></span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and 2017, respectively) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span> collateral before processing transactions, which must be maintained indefinitely. 20000000 2900000 3100000 1 Inventories<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans. Property and Equipment<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> years for office equipment, office software and capitalized internal-use software development costs and </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;"> years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are included in the statement of operations as selling, general and administrative expenses. Such expense totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$424,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$536,000</span></span><span style="font-family:inherit;font-size:10pt;"> during 2018 and 2017, respectively.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value. 424000 536000 Goodwill<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>The Company assesses qualitative factors in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, through this qualitative assessment, the conclusion is made that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, a two-step impairment test is performed. The Company’s policy is to test for impairment annually during the fourth quarter. Considerable management judgment is necessary to measure fair value. The Company did not recognize any impairment charges for goodwill during the periods presented. Income Taxes<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than not recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are no uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided for state income tax purposes on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.</span></div><br/> Amounts Held in eWallets<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>The Company requires commission payments of certain members in Hong Kong to be first recorded into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability. Long-Term Incentive<div style="line-height:120%;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial rewards earned under the 2014 Long-Term Incentive Plan (the “LTI Plan”) are recognized over the performance period as specified performance or other goals are achieved or exceeded. In accordance with the LTI Plan, </span><span style="font-family:inherit;font-size:10pt;">fifty percent</span><span style="font-family:inherit;font-size:10pt;"> of any cash payment earned is payable in </span><span style="font-family:inherit;font-size:10pt;">thirty-five</span><span style="font-family:inherit;font-size:10pt;"> equal consecutive monthly installments commencing in February of the calendar year immediately following the conclusion of the performance period and the remaining </span><span style="font-family:inherit;font-size:10pt;">fifty percent</span><span style="font-family:inherit;font-size:10pt;"> of the payment earned is payable in </span><span style="font-family:inherit;font-size:10pt;">thirty-five</span><span style="font-family:inherit;font-size:10pt;"> equal consecutive monthly installments commencing in February 2021 and ending in December 2023. As of December 31, 2018, unpaid installments for long-term incentive compensation total </span><span style="font-family:inherit;font-size:10pt;"><span>$9.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$7.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> is reflected on the balance sheet as a non-current liability and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> is reflected in other accrued expenses.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>At the sole discretion of the Compensation Committee of the Company’s Board of Directors, distributions under the LTI Plan are made in cash, or alternatively awarded in the form of common stock or other common stock rights having an equivalent cash value under the terms of the Natural Health Trends Corp. 2016 Equity Incentive Plan. A determination of the form of distribution, if any, is made by the Compensation Committee subsequent to the end of each calendar year. As such, amounts earned are considered non-equity awards. See Note 7 for grant information of distributions settled in common stock. 9000000.0 7800000 1200000 Foreign Currency<div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into accumulated other comprehensive income.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Aggregate transaction gains or losses, including gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of certain inter-company balances, are included in the statement of operations as other income and expense. -739000 -451000 Commissions<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and as the related revenue is recognized and pays commissions on product sales generally two weeks following the end of the weekly sales period.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In some markets, the Company also pays certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. The Company also enters into performance-based agreements for business or market development, which may result in additional compensation to specific members. Operating Leases<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company leases its physical properties under operating leases. Certain lease agreements include rent holidays and incentives. The Company recognizes rent holiday periods on a straight-line basis over the lease term beginning when the Company has the right to the leased space. Stock-Based Compensation<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Stock-based compensation expense is determined based on the grant date fair value of each award, net of estimated forfeitures which are derived from historical experience, and is recognized on a straight-line basis over the requisite service period for the award. Net Income Per Common Share<div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares. Certain Risks and Concentrations<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A substantial portion of the Company’s sales are generated in Hong Kong (see Note 11). Substantially all of the Company’s Hong Kong revenues are derived from the sale of products that are delivered to members in China. In contrast to the Company’s operations in other parts of the world, the Company’s China subsidiary has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license, which the Company has applied for, and has also adopted anti-pyramid selling and multilevel marketing legislation. The Company operates an e-commerce direct selling model in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail model. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate separately or in both.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company continually evaluates its operations in China and Hong Kong for compliance with applicable laws and regulations, including seeking the input of outside professionals and certain Chinese authorities. This process can and has resulted in the identification of certain matters of potential noncompliance. The Company works on a continuing basis to satisfactorily address such matters, however there can be no assurance that adequate steps are taken or that applicable laws and regulations are properly interpreted. Should the government authorities determine that the Company’s activities violate applicable laws and regulations, including China’s direct selling, pyramid selling or multilevel marketing laws and regulations, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling, pyramid selling or multi-level marketing legislation, and subjective interpretations of laws and regulations. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No single market other than Hong Kong had net sales greater than 10% of total sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of its net sales. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">The Company’s </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Premium Noni Juice</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Enhanced Essential Probiotics</span><span style="font-family:inherit;font-size:12pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">®</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">products each account for more than </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span> of the Company’s total revenue. The Company currently sources each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected. 0.10 Fair Value of Financial Instruments<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items. Recently Issued and Adopted Accounting Pronouncements<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18 that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard was effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted the new standard effective January 1, 2018 using the retrospective transition method. Its adoption did not have a material impact on the Company’s consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB established Topic 842, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, by issuing ASU No. 2016-02, which requires lessees to recognize the rights and obligations created by leases on the balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;">, ASU No. 2018-10, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842</span><span style="font-family:inherit;font-size:10pt;">, and ASU No. 2018-01, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-family:inherit;font-size:10pt;">. The new standard establishes a right-of-use model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new standard will be effective January 1, 2019. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. If an entity chooses the second option, the transition requirements for existing leases also apply to leases entered into between the date of initial application and the effective date. The entity must also recast its comparative period financial statements and provide the disclosures required by the new standard for the comparative periods. The Company expects to adopt the new standard on January 1, 2019 using the effective date as our date of initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new standard provides a number of optional practical expedients in transition. The Company expects to elect the “package of practical expedients”, which permits entities not to reassess under the new lease standard prior conclusions about lease identification, lease classification and initial direct costs. The Company does not expect to elect the use-of-hindsight or the practical expedient pertaining to land easements.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While the Company continues to assess all of the effects of adoption, it currently believes that most significant effects relate to the recognition of new ROU assets and lease liabilities on our balance sheet for office operating leases and providing significant new disclosures about our leasing activities. On adoption, the Company expects to recognize an operating lease liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, with corresponding ROU assets of the same amount based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new standard also provides practical expedients for an entity’s ongoing accounting. The Company currently expects to elect the short-term leases recognition exemption for all leases that qualify. This means that the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets and lease liabilities for existing short-term leases of those assets in transition. The Company also currently expects to elect the practical expedient to not separate lease and nonlease components for its leases.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue From Contracts With Customers</span><span style="font-family:inherit;font-size:10pt;">, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. In July 2015, the FASB approved the deferral of the effective date for annual reporting periods beginning after December 15, 2017, including interim reporting periods. The Company adopted the new standard effective January 1, 2018 using the modified retrospective transition method. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. See Note 2 for additional information.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements. 4600000 REVENUE<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All revenue is recognized when the performance obligations under a contract are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature. </span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from </span><span style="font-family:inherit;font-size:10pt;"><span>14</span></span><span style="font-family:inherit;font-size:10pt;"> days to one year, and their historical return rates, which range from </span><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>5%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales. Sales returns were </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales for both the years ended December 31, 2018 and 2017, respectively.  No material changes in estimates have been recognized during the periods presented. See Note 4 for additional information. </span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.</span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority. </span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred Revenue</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are considered a contract liability and are recorded as deferred revenue. The increase in deferred revenue for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> is primarily due to </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of cash payments received for unshipped product primarily towards the end of the year offset by </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of revenue recognized during the year that was included in deferred revenue as of December 31, 2017. See Note 4 for additional information. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Disaggregation of Revenue</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to some consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through the engagement of a third-party service provider. See Note 11 for additional information.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Arrangements with Multiple Performance Obligations</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Practical Expedients</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company generally expenses sales commissions when incurred because the amortization period would be one year or less. These costs are recorded in commissions expense. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less. Revenue Recognition<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All revenue is recognized when the performance obligations under a contract are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature. </span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from </span><span style="font-family:inherit;font-size:10pt;"><span>14</span></span><span style="font-family:inherit;font-size:10pt;"> days to one year, and their historical return rates, which range from </span><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>5%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales. Sales returns were </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales for both the years ended December 31, 2018 and 2017, respectively.  No material changes in estimates have been recognized during the periods presented. See Note 4 for additional information. </span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.</span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority. </span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred Revenue</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are considered a contract liability and are recorded as deferred revenue. The increase in deferred revenue for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> is primarily due to </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of cash payments received for unshipped product primarily towards the end of the year offset by </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of revenue recognized during the year that was included in deferred revenue as of December 31, 2017. See Note 4 for additional information. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Disaggregation of Revenue</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to some consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through the engagement of a third-party service provider. See Note 11 for additional information.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Arrangements with Multiple Performance Obligations</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Practical Expedients</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company generally expenses sales commissions when incurred because the amortization period would be one year or less. These costs are recorded in commissions expense. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less. P14D 0.01 0.05 0.02 4500000 2400000 NET INCOME PER COMMON SHARE<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table illustrates the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,035</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.75</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,578</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,251</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.10</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,035</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,318</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.74</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,267</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.09</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">Certain non-vested restricted stock is anti-dilutive upon applying the treasury stock method since the amount of compensation cost for future service results in the hypothetical repurchase of shares exceeding the actual number of shares to be vested. Non-vested restricted stock totaling </span><span style="font-family:inherit;font-size:10pt;"><span>2,232</span></span><span style="font-family:inherit;font-size:10pt;"> shares were not included for the year ended December 31, </span><span style="font-family:inherit;font-size:10pt;">2017</span> as their effect would have been anti-dilutive. The following table illustrates the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,035</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.75</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,578</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,251</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.10</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,035</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,318</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.74</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,267</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.09</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 31035000 11304000 2.75 23578000 11251000 2.10 14000 16000 31035000 11318000 2.74 23578000 11267000 2.09 2232 BALANCE SHEET COMPONENTS<div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of certain balance sheet amounts are as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,703</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,330</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132,653</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135,311</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,998</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,167</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135,651</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138,478</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,171</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,779</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>799</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reserve for obsolescence</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(151</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(180</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,165</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,398</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>537</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>530</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office software</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>918</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>916</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Machinery</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>319</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,022</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>957</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress (including internal-use software development costs)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,844</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,719</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,910</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,570</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>934</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,149</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>801</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>614</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee-related expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,051</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,568</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warehousing, inventory-related and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,269</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,423</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,121</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,605</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unshipped product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,574</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,411</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Auto ship advances</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,876</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>345</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,795</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, cash and cash equivalents include </span><span style="font-family:inherit;font-size:10pt;"><span>$11.1 million</span></span> held in banks located within China subject to foreign currency controls. The components of certain balance sheet amounts are as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,703</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,330</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132,653</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135,311</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,998</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,167</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135,651</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138,478</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,171</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,779</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>799</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reserve for obsolescence</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(151</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(180</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,165</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,398</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>537</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>530</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office software</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>918</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>916</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Machinery</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>319</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,022</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>957</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress (including internal-use software development costs)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,844</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,719</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,910</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,570</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>934</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,149</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>801</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>614</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee-related expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,051</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,568</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warehousing, inventory-related and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,269</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,423</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,121</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,605</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unshipped product</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,574</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,411</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Auto ship advances</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,876</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>345</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,795</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 47323000 61703000 85330000 73608000 132653000 135311000 2998000 3167000 135651000 138478000 11171000 7779000 1145000 799000 151000 180000 12165000 8398000 537000 530000 918000 916000 29000 30000 319000 276000 1022000 957000 19000 10000 2844000 2719000 1910000 1570000 934000 1149000 801000 614000 4051000 5568000 1269000 1423000 6121000 7605000 4574000 2411000 1876000 1665000 345000 379000 6795000 4455000 11100000 FAIR VALUE MEASUREMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Gains/Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Gains/Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal bonds and notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,149</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,142</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,320</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,319</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,862</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(26</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,836</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,432</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,408</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial institution instruments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,352</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,352</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,881</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,881</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total available-for-sale investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,363</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">FASB Topic 820, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:inherit;font-size:10pt;">, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1: Quoted market prices in active markets for identical assets or liabilities.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3: Unobservable inputs that are not corroborated by market data.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The tables below present the Company’s hierarchy for assets measured at fair value on a recurring basis as of December 31, 2018 and 2017.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts included in cash and cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value on a recurring basis</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts included in cash and cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value on a recurring basis</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Gains/Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Gains/Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal bonds and notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,149</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,142</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,320</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,319</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,862</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(26</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,836</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,432</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,408</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial institution instruments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,352</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,352</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,881</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,881</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total available-for-sale investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,363</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 12149000 -7000 12142000 13320000 -1000 13319000 51862000 -26000 51836000 49432000 -24000 49408000 21352000 0 21352000 10881000 0 10881000 85363000 -33000 85330000 73633000 -25000 73608000 The tables below present the Company’s hierarchy for assets measured at fair value on a recurring basis as of December 31, 2018 and 2017.<div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts included in cash and cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value on a recurring basis</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts included in cash and cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value on a recurring basis</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 85330000 0 0 85330000 85330000 0 0 85330000 73608000 0 0 73608000 73608000 0 0 73608000 COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Leases</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has entered into non-cancelable operating lease agreements for locations within the United States and for its international subsidiaries, with expirations through September 2025. Rent expense in connection with operating leases was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> during </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease obligations as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,796</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,340</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>452</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>208</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>327</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Purchase Commitment</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2013, the Company entered into an exclusive distribution agreement with one of its suppliers to purchase its product through July 2016 which automatically renews annually unless terminated </span><span style="font-family:inherit;font-size:10pt;"><span>90</span></span><span style="font-family:inherit;font-size:10pt;"> days prior to the termination date. To maintain exclusivity, the Company is required to purchase a minimum of </span><span style="font-family:inherit;font-size:10pt;"><span>$40,000</span></span><span style="font-family:inherit;font-size:10pt;"> of product per month until the termination date. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company was in compliance with the exclusivity provision.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Employment Agreements</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has employment agreements with certain members of its management team that can be terminated by either the employee or the Company upon four weeks’ notice.  The employment agreements entered into with the management team contain provisions that guarantee the payments of specified amounts in the event of a change in control, as defined, or if the employee is terminated without cause, as defined, or terminates employment for good reason, as defined.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Securities Class Actions</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 8, 2019, the Company and its two executive officers were named in a putative securities class action filed in the United States District Court for the Central District of California, captioned </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kauffman v. Natural Health Trends Corp.</span><span style="font-family:inherit;font-size:10pt;">, Case No. 2:19-cv-00163.  The complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between April 27, 2016 and January 5, 2019, inclusive, under (i) Section 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”) and Rule 10b-5 promulgated thereunder against the Company and Chris T. Sharng and Timothy S. Davidson (together, the “Individual Defendants”), and (ii) Section 20(a) of the Exchange Act against the Individual Defendants. The complaint alleges, in part, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multilevel marketing business.  The complaint seeks an indeterminate amount of damages, plus interest and costs.  Defendants believe that these claims are without merit and intend to vigorously defend against them.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, two putative securities class action complaints were filed against the Company and its top executives in the United States District Court for the Central District of California. On March 29, 2016, the court consolidated these actions under the caption Ford v. Natural Health Trends Corp., Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi &amp; Korsinsky LLP as co-Lead Counsel for the purported class. On April 2, 2018, the court approved a class-wide settlement of the action in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.75 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was fully funded by the Company’s insurers. On April 6, 2018, the court entered a Final Judgment and Order of Dismissal With Prejudice.</span></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Shareholder Derivative Claims</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou v. Sharng</span><span style="font-family:inherit;font-size:10pt;">. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt v. Sharng. </span><span style="font-family:inherit;font-size:10pt;">On November 10, 2017, the parties to both the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt</span><span style="font-family:inherit;font-size:10pt;"> actions entered into a Memorandum of Understanding (“MOU”) to resolve both actions, subject to the negotiation of a written settlement agreement and approval by the federal court in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt</span><span style="font-family:inherit;font-size:10pt;"> matter.  On July 16, 2018, the court granted final approval of the settlement and entered judgment in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt</span><span style="font-family:inherit;font-size:10pt;"> matter.  In exchange for full releases, the settlement required the Company to implement certain corporate governance reforms and included an award of </span><span style="font-family:inherit;font-size:10pt;"><span>$250,000</span></span><span style="font-family:inherit;font-size:10pt;"> in attorneys’ fees to plaintiffs’ counsel, all of which was fully funded by the Company’s insurers. On August 9, 2018, plaintiff filed a request to voluntarily dismiss the Zhou action, which was entered by the court on August 30, 2018.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Matters</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is currently involved in a legal matter with one of its vendors and an outside party. Per the royalty agreement with the vendor, the Company believes that it is fully indemnified in the event of an unfavorable outcome and any potential settlement costs related to the matter would be fully covered by the Company’s vendor. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Since August 2016, the SEC has been conducting a non-public investigation to determine whether there have been violations of the federal securities laws relating to the trading of the Company’s securities. The Company has fully cooperated with the SEC and has and continues to provide documents in response to subpoenas. The SEC has expressly stated that its document requests should not be construed as an indication that any violation of law has occurred, or as a reflection upon any person, entity, or security. The amount of time needed to resolve this matter is uncertain, and the Company cannot predict the outcome or whether it will face additional governmental inquiries or other actions. 2200000 2000000.0 Future minimum lease obligations as of <span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,796</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,340</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>452</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>208</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>327</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1796000 1340000 452000 332000 208000 327000 4455000 P90D 40000 1750000 250000 STOCKHOLDERS’ EQUITY<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Authorized Shares</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is authorized to issue </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> classes of capital stock consisting of up to </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>5,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock, </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$0.001</span></span><span style="font-family:inherit;font-size:10pt;"> par value, and </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>50,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$0.001</span></span><span style="font-family:inherit;font-size:10pt;"> par value. </span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Dividends</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize the Company’s cash dividend activity during </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Common Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 21, 2018 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,048</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 23, 2018</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 21, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,820</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 23, 2018</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 18, 2018 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,844</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 24, 2018</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 18, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,707</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 24, 2018</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 17, 2018 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,022</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 25, 2018</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 17, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,592</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 25, 2018</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 6, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,479</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 9, 2018</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.77</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,512</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Common Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 30, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,701</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 24, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,360</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 24, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 31, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 31, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 31, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 19, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 19, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,962</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 3, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,019</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 3, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.52</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,218</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Repurchases</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. </span><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock were repurchased by the Company during 2018 or 2017. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$32.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> stock-based compensation was recognized during 2018. Stock-based compensation expense totaled approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$35,000</span></span><span style="font-family:inherit;font-size:10pt;"> during </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to </span><span style="font-family:inherit;font-size:10pt;"><span>2,500,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>2,359,671</span></span><span style="font-family:inherit;font-size:10pt;"> shares remained available for issuance under the 2016 Plan. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 1, 2018, the Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>34,202</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2017 performance incentives totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$554,000</span></span><span style="font-family:inherit;font-size:10pt;">. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 24, 2017, the Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>56,260</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2016 performance incentives totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;">. The shares vest on a quarterly basis over three years and are subject to forfeiture in the event of the employee’s termination of service to the Company under specified circumstances. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s restricted stock activity under the 2016 Plan:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,256</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,260</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(35,336</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,148</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,032</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(46,748</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s other restricted stock activity:</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,348</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,930</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(418</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated Other Comprehensive Loss</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The changes in accumulated other comprehensive loss by component for 2018 were as follows (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized Losses on Available-For-Sale Investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(386</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(413</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(831</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(837</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,217</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div> 5000000 0.001 50000000 0.001 The following tables summarize the Company’s cash dividend activity during <span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data):</span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Common Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 21, 2018 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,048</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 23, 2018</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 21, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,820</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 23, 2018</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 18, 2018 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,844</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 24, 2018</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 18, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,707</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 24, 2018</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 17, 2018 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,022</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 25, 2018</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 17, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,592</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 25, 2018</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 6, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,479</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 9, 2018</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.77</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,512</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Common Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 30, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,701</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 24, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,360</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">November 24, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 31, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 31, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">August 31, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 19, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">May 19, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,962</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 3, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,019</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">March 3, 2017</span></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.52</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,218</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><br/> 0.18 2048000 2018-11-23 0.16 1820000 2018-11-23 0.25 2844000 2018-08-24 0.15 1707000 2018-08-24 1.76 20022000 2018-05-25 0.14 1592000 2018-05-25 0.13 1479000 2018-03-09 2.77 31512000 0.15 1701000 2017-11-24 0.12 1360000 2017-11-24 0.25 2833000 2017-08-31 0.11 1246000 2017-08-31 0.35 3964000 2017-05-19 0.10 1133000 2017-05-19 0.35 3962000 2017-03-03 0.09 1019000 2017-03-03 1.52 17218000 15000000.0 70000000.0 0 32000000.0 70000000.0 0 35000 2500000 2359671 34202 554000 56260 1400000 The following table summarizes the Company’s restricted stock activity under the 2016 Plan:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,256</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,260</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(35,336</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,148</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,032</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(46,748</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div>The following table summarizes the Company’s other restricted stock activity:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,348</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21,930</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(418</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 38256 34.13 56260 25.44 35336 29.58 1148 28.55 58032 28.59 34202 16.19 46748 26.31 45486 21.61 22348 12.15 21930 12.15 418 12.28 0 0 The changes in accumulated other comprehensive loss by component for 2018 were as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized Losses on Available-For-Sale Investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(386</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(413</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(831</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(837</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,217</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div> -386000 -27000 -413000 -831000 -6000 -837000 -1217000 -33000 -1250000 INCOME TAXES<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of income before income taxes consist of the following (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,391</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,965</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,912</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,391</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,521</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of the income tax provision consist of the following (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,815</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,300</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,216</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,495</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>358</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax provision</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,848</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the reported income tax provision to the provision that would result from applying the domestic federal statutory tax rate to pretax income is as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax at federal statutory rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,249</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of permanent differences</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>346</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax Cut &amp; Jobs Act one-time transition tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(738</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,792</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Global Intangible Low Taxed Income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,964</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax Cut &amp; Jobs Act federal rate change</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>954</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign rate differential</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,541</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,002</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(786</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,738</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other reconciling items</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>226</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax provision</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,848</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before income taxes and the statutory tax rate for each country that materially contributed to the foreign rate differential presented above is as follows (in thousands): </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:54%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Statutory Tax Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cayman Islands</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,560</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,954</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,545</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes consist of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>270</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,062</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,374</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,447</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,842</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(183</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(192</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,264</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign earnings</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(241</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(267</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(271</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,021</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,379</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effective income tax rate for the year ended December 31, 2018 was impacted by recording the effect of the Tax Cuts and Jobs Act (the “Tax Act”), enacted on December 22, 2017 by the U.S. government. The Tax Act makes broad and complex changes to the Internal Revenue Code of 1986, as amended, which has affected the Company’s year ended December 31, 2018, including, but not limited to, requiring an annual tax on the earnings and profits of any greater than 10% owned foreign controlled corporation. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2017, the Securities and Exchange Commission staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provided a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740, </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:inherit;font-size:10pt;">. In accordance with the expiration of the SAB 118 measurement period, we completed the assessment of the income tax effect of the Tax Act by the fourth quarter of tax year 2018. All adjustments recorded to the provisional amounts have been included as an adjustment to income tax expense. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the Tax Act, the Company recorded additional income tax expense due to the Global Intangible Low Taxed Income inclusion on current earnings and profits of greater than 10% owned foreign controlled corporations (“GILTI”). To determine the amount of GILTI inclusion, the Company must determine, in addition to other factors, the current earnings of foreign controlled corporations, as well as the amount of foreign taxes paid by the foreign entities. The law provides that corporate taxpayers may benefit from a 50% reduction in the GILTI inclusion, which effectively reduces the 21% U.S. corporate tax rate on the foreign income to an effective rate of 10.5%. The GILTI inclusion further provides for a foreign tax credit in connection with the foreign taxes paid. The Company recorded a tax expense for GILTI of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> foreign tax credits. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2018, the Company does not have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2018, the Company has a valuation allowance against certain foreign deferred tax assets. The Company is recording a valuation allowance in foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2018, the Company has </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> U.S. federal net operating loss or credit carryforwards as any attributes generated are expected to be fully utilized to offset tax in the current year. At December 31, 2018, the Company has foreign net operating loss carryforwards of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in various jurisdictions with various expirations.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings is no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate. As of December 31, 2018, the Company has recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods. Due to the Tax Act, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to no impact on federal tax expense. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of December 31, 2018.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company and its subsidiaries file tax returns in the United States, California, New Jersey and Texas and various foreign jurisdictions. During the fourth quarter of 2018, the Company was notified that it was selected for audit of the 2016 tax year by the U.S. Internal Revenue Service. For purposes of this audit, fiscal years 2007 through 2016 are open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. No adjustments have been proposed at this time. The Company is no longer subject to state income tax examinations for years prior to 2014. The Taiwan Taxation Administration closed the audit for the 2016 tax year with immaterial tax adjustments that have been recorded in the foreign income tax provision. No other jurisdictions are currently examining any income tax returns of the Company. The components of income before income taxes consist of the following (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,391</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,965</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,912</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,391</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,521</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> -3391000 -2965000 37912000 46391000 34521000 43426000 The components of the income tax provision consist of the following (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,815</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,300</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,216</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,495</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>358</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax provision</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,848</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1815000 20277000 13000 2000 1300000 1216000 3128000 21495000 358000 -1647000 3486000 19848000 A reconciliation of the reported income tax provision to the provision that would result from applying the domestic federal statutory tax rate to pretax income is as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax at federal statutory rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,249</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of permanent differences</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>346</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax Cut &amp; Jobs Act one-time transition tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(738</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,792</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Global Intangible Low Taxed Income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,964</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax Cut &amp; Jobs Act federal rate change</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>954</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign rate differential</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,541</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,002</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign tax credits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(786</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,738</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other reconciling items</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>226</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax provision</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,848</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 7249000 15200000 346000 459000 -738000 20792000 3964000 0 -6000 954000 -9000 -43000 -6541000 -15002000 786000 2738000 7000 226000 3486000 19848000 Income before income taxes and the statutory tax rate for each country that materially contributed to the foreign rate differential presented above is as follows (in thousands): <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:54%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Statutory Tax Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cayman Islands</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,560</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,954</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,545</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 0 31560000 39954000 0.165 3545000 3315000 0.250 2725000 2584000 Deferred income taxes consist of the following (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>270</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,062</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,374</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,447</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,842</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(183</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(192</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,264</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign earnings</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(241</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(267</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(271</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,021</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,379</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 183000 192000 191000 270000 1062000 1374000 11000 6000 1447000 1842000 183000 192000 1264000 1650000 2000 4000 241000 267000 243000 271000 1021000 1379000 2900000 1000000.0 0 1200000 RELATED PARTY TRANSACTIONS<div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is a party to a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ReStor</span><span style="font-family:inherit;font-size:10pt;">™. George K. Broady, a director of the Company and beneficial owner of more than </span><span style="font-family:inherit;font-size:10pt;"><span>5%</span></span><span style="font-family:inherit;font-size:10pt;"> of its outstanding common stock, is owner of BHS. Under this agreement, the Company agreed to pay BHS a price per unit royalty in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States.  The Company recognized royalties of </span><span style="font-family:inherit;font-size:10pt;"><span>$327,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>$306,000</span></span><span style="font-family:inherit;font-size:10pt;"> during </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>120</span></span><span style="font-family:inherit;font-size:10pt;"> days’ notice or, under certain circumstances, with no notice. Otherwise, the agreement terminates March 31, 2020.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During each of 2018 and 2017, the Company procured in China and arranged for shipment to The Aberdeen Group, LLC (“Aberdeen”), </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> order of apparel products.  Aberdeen is owned </span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;"> by Sharng Holdings, which is wholly-owned by the Company’s president, Chris T. Sharng, and his wife, </span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;"> by Mr. Broady, and </span><span style="font-family:inherit;font-size:10pt;"><span>20%</span></span><span style="font-family:inherit;font-size:10pt;"> by an unrelated third party.  In each instance </span></div><span style="font-family:inherit;font-size:10pt;">Aberdeen promptly paid the Company for the product and shipping cost incurred. Such orders were in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$3,700</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3,800</span></span><span style="font-family:inherit;font-size:10pt;"> during 2018 and 2017, respectively.  Given the Company’s provision of such product sourcing services to Aberdeen, Aberdeen also paid the Company a market-based fee consistent with the provision of such services of </span><span style="font-family:inherit;font-size:10pt;"><span>$450</span></span>. The Company analyzed the nature of the transactions with Aberdeen to determine whether they could be construed a violation under the guidelines of Section 402 of the Sarbanes-Oxley Act of 2002. The Company, through advice from its legal counsel, concluded that there is not a reasonable possibility that the transactions with Aberdeen would be deemed a violation of Section 402. This relationship between the Company and Aberdeen ceased in early 2019. 0.05 327000 306000 P120D 1 0.40 0.40 0.20 3700 3800 450  EMPLOYEE BENEFIT PLANS<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><span style="font-family:inherit;font-size:10pt;">      The Company has a 401(k) defined contribution plan which permits participating employees in the United States to defer up to a maximum of </span><span style="font-family:inherit;font-size:10pt;"><span>90%</span></span><span style="font-family:inherit;font-size:10pt;"> of their compensation, subject to limitations established by the Internal Revenue Service. Employees age </span><span style="font-family:inherit;font-size:10pt;"><span>21</span></span><span style="font-family:inherit;font-size:10pt;"> and older are eligible to contribute to the plan starting the first day of the following month of employment.  Participating employees are eligible to receive discretionary matching contributions and profit sharing, subject to certain conditions, from the Company.  In </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company matched employee deferral contributions up to </span><span style="font-family:inherit;font-size:10pt;"><span>4.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of salary, which vested </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> immediately. No profit sharing has been paid under the plan. The Company recorded compensation expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$87,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$101,000</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span>, respectively, related to its matching contributions to the plan. Certain of the Company’s employees located outside the United States participate in employee benefit plans that are statutory in nature. 0.90 P21Y 0.045 1 87000 101000 SEGMENT INFORMATION<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to some consumers through an e-commerce platform, and the Russia and Kazakhstan market where the Company’s engagement of a third-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There is no separate segment manager who is held accountable by the Company’s chief operating decision-makers, or anyone else, for operations, operating results and planning for the China market or the Russia and Kazakhstan market on a stand-alone basis, and neither market is material for the periods presented. As such, the Company believes that all operating segments should be aggregated into a single reportable segment for disclosure purposes.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s net sales by geographic area are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales from external customers:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,637</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,348</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canada</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,710</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Peru</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,635</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>508</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>169,452</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>174,926</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,744</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taiwan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,591</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">South Korea</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>493</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Russia and Kazakhstan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>868</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,644</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,278</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other foreign countries</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>763</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>313</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>191,910</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197,563</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">_____________________________</sup> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s net sales by product and service are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales by product and service:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>181,865</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>187,591</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Freight and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,329</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,676</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: sales returns</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,284</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,704</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>191,910</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197,563</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due to system constraints, it is impracticable for the Company to separately disclose sales by product category for the years presented. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s long-lived assets by geographic area are as follows (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-lived assets:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>521</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>648</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other foreign countries</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-lived assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>934</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,149</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> The Company’s net sales by geographic area are as follows (in thousands):<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales from external customers:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,637</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,348</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canada</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,710</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Peru</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,635</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>508</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>169,452</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>174,926</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,744</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taiwan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,591</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">South Korea</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>493</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Russia and Kazakhstan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>868</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,644</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,278</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other foreign countries</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>763</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>313</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>191,910</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197,563</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">_____________________________</sup> </span></div><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></span><span style="font-family:inherit;font-size:10pt;"> </span>Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”. 3637000 3348000 1710000 1938000 1635000 508000 169452000 174926000 7744000 7282000 3964000 5591000 493000 466000 868000 913000 1644000 2278000 763000 313000 191910000 197563000 The Company’s net sales by product and service are as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales by product and service:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>181,865</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>187,591</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Freight and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,329</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,676</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: sales returns</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,284</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,704</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>191,910</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197,563</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 181865000 187591000 13329000 13676000 3284000 3704000 191910000 197563000 The Company’s long-lived assets by geographic area are as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-lived assets:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>521</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>648</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other foreign countries</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-lived assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>934</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,149</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 521000 648000 145000 78000 61000 112000 207000 311000 934000 1149000  SUBSEQUENT EVENTS<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">January 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Board of Directors declared a quarterly cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.16</span></span><span style="font-family:inherit;font-size:10pt;">, as well as a special cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.08</span></span><span style="font-family:inherit;font-size:10pt;"> on each share of common stock outstanding. The dividends were paid on </span><span style="font-family:inherit;font-size:10pt;">March 15, 2019</span><span style="font-family:inherit;font-size:10pt;"> to stockholders of record on </span><span style="font-family:inherit;font-size:10pt;">March 5, 2019</span><span style="font-family:inherit;font-size:10pt;">. Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">On February 1, 2019, the Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>22,603</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2018 performance incentives totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$377,000</span></span>. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances. 0.16 0.08 22603 377000 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.19.1
Document And Entity Information - USD ($)
12 Months Ended
Dec. 31, 2018
Apr. 22, 2019
Jun. 30, 2018
Document And Entity Information      
Entity Registrant Name NATURAL HEALTH TRENDS CORP.    
Entity Central Index Key 0000912061    
Current Fiscal Year End Date --12-31    
Entity Filer Category Accelerated Filer    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer No    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding (in shares)   11,398,695  
Entity Public Float     $ 182,584,301
Document Type 10-K    
Document Period End Date Dec. 31, 2018    
Document Fiscal Year Focus 2018    
Document Fiscal Period Focus FY    
Amendment Flag false    
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.19.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 132,653 $ 135,311
Inventories 12,165 8,398
Other current assets 5,369 7,534
Total current assets 150,187 151,243
Property and equipment, net 934 1,149
Goodwill 1,764 1,764
Restricted cash 2,998 3,167
Deferred tax asset 1,207 1,435
Other assets 831 796
Total assets 157,921 159,554
Current liabilities:    
Current assets: 1,631 1,751
Income taxes payable 287 309
Accrued commissions 12,502 11,170
Other accrued expenses 6,121 7,605
Deferred revenue 6,795 4,455
Amounts held in eWallets 14,611 15,152
Other current liabilities 1,137 1,479
Total current liabilities 43,084 41,921
Income taxes payable 16,982 19,052
Deferred tax liability 186 56
Long-term incentive 7,808 7,904
Total liabilities 68,060 68,933
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2018 and 2017 0 0
Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2018 and 2017 13 13
Additional paid-in capital 86,415 86,683
Retained earnings 44,431 44,908
Accumulated other comprehensive loss (1,250) (413)
Treasury stock, at cost; 1,603,322 and 1,637,524 shares at December 31, 2018 and 2017, respectively (39,748) (40,570)
Total stockholders’ equity 89,861 90,621
Total liabilities and stockholders’ equity $ 157,921 $ 159,554
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.19.1
CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares
Dec. 31, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 50,000,000 50,000,000
Common stock, shares issued (in shares) 12,979,414 12,979,414
Treasury stock, shares (in shares) 1,603,322 1,637,524
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.19.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Income Statement [Abstract]    
Net sales $ 191,910 $ 197,563
Cost of sales 39,367 38,645
Gross profit 152,543 158,918
Operating expenses:    
Commissions expense 87,502 83,638
Selling, general and administrative expenses 31,309 32,221
Total operating expenses 118,811 115,859
Income from operations 33,732 43,059
Other income, net 789 367
Income before income taxes 34,521 43,426
Income tax provision 3,486 19,848
Net income $ 31,035 $ 23,578
Net income per common share:    
Basic (in dollars per share) $ 2.75 $ 2.10
Diluted (in dollars per share) $ 2.74 $ 2.09
Weighted-average number of common shares outstanding:    
Basic (in shares) 11,304 11,251
Diluted (in shares) 11,318 11,267
Cash dividends declared per common share (in dollars per share) $ 2.77 $ 1.52
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.19.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Statement of Comprehensive Income [Abstract]    
Net income $ 31,035 $ 23,578
Other comprehensive income (loss), net of tax:    
Foreign currency translation adjustments (831) 677
Release of cumulative translation adjustment 0 (258)
Net change in foreign currency translation adjustment (831) 419
Unrealized losses on available-for-sale securities (6) (25)
Comprehensive income $ 30,198 $ 23,972
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.19.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Preferred Stock
Common Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive (Loss) Income
Treasury Stock
Preferred stock, beginning balance (in shares) at Dec. 31, 2016   0          
Common stock, beginning balance (in shares) at Dec. 31, 2016     12,979,414        
Treasury stock, beginning balance (in shares) at Dec. 31, 2016             (1,692,218)
Stockholders' equity, beginning balance at Dec. 31, 2016 $ 82,439 $ 0 $ 13 $ 86,574 $ 38,548 $ (807) $ (41,889)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 23,578       23,578    
Restricted stock forfeiture (38)     (5)     $ (33)
Restricted stock forfeiture (in shares)             (1,566)
Common stock issued 1,431     79     $ 1,352
Common stock issued (in shares)             56,260
Dividends declared (17,218)       (17,218)    
Elimination of CTA upon dissolution (258)         (258)  
Foreign currency translation adjustments 677         677  
Unrealized losses on available-for-sale securities (25)         (25)  
Stock-based compensation $ 35     35      
Preferred stock, ending balance (in shares) at Dec. 31, 2017 0 0          
Common stock, ending balance (in shares) at Dec. 31, 2017 12,979,414   12,979,414        
Treasury stock, beginning balance (in shares) at Dec. 31, 2017 (1,637,524)           (1,637,524)
Stockholders' equity, ending balance at Dec. 31, 2017 $ 90,621 $ 0 $ 13 86,683 44,908 (413) $ (40,570)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 31,035       31,035    
Common stock issued 554     (268)     $ 822
Common stock issued (in shares)             34,202
Dividends declared (31,512)       (31,512)    
Elimination of CTA upon dissolution 0            
Foreign currency translation adjustments (831)         (831)  
Unrealized losses on available-for-sale securities $ (6)         (6)  
Preferred stock, ending balance (in shares) at Dec. 31, 2018 0 0          
Common stock, ending balance (in shares) at Dec. 31, 2018 12,979,414   12,979,414        
Treasury stock, beginning balance (in shares) at Dec. 31, 2018 (1,603,322)           (1,603,322)
Stockholders' equity, ending balance at Dec. 31, 2018 $ 89,861 $ 0 $ 13 $ 86,415 $ 44,431 $ (1,250) $ (39,748)
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.19.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income $ 31,035 $ 23,578
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 424 536
Stock-based compensation 0 35
Cumulative translation adjustment realized in net income 0 (258)
Deferred income taxes 358 (1,644)
Changes in assets and liabilities:    
Inventories (3,879) 2,843
Other current assets 2,065 (3,399)
Other assets (55) (61)
Accounts payable (116) (392)
Income taxes payable (2,077) 18,676
Accrued commissions 1,410 (2,417)
Other accrued expenses (883) (6,033)
Deferred revenue 2,359 (481)
Amounts held in eWallets (509) (3,875)
Other current liabilities (326) (179)
Long-term incentive (96) (324)
Net cash provided by operating activities 29,710 26,605
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (214) (278)
Net cash used in investing activities (214) (278)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Dividends paid (31,512) (17,218)
Net cash used in financing activities (31,512) (17,218)
Effect of exchange rates on cash, cash equivalents and restricted cash (811) 485
Net (decrease) increase in cash, cash equivalents and restricted cash (2,827) 9,594
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period 138,478 128,884
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period 135,651 138,478
SUPPLEMENTAL CASH FLOW DISCLOSURE:    
Cash paid for income taxes, net 3,130 6,772
Issuance of treasury stock for employee awards, net $ 554 $ 1,393
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.19.1
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Nature of Operations
 
Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.
 
The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.

In January 2019, the Company relocated its corporate headquarters from Rolling Hills Estates, California to Hong Kong.

Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.
 
Reclassification

Certain prior year balances in the statement of operations have been reclassified to conform to current year presentation. Additionally, in accordance with the adoption of Accounting Standards Update (“ASU”) No. 2016-18, Statement of Cash Flows - Restricted Cash, the Company has included amounts classified as restricted cash or restricted cash equivalents with cash and cash equivalents when reconciling beginning-of-period and end-of-period total cash, cash equivalents and restricted cash amounts, as presented in its consolidated statements of cash flows.

Use of Estimates
 
The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.

The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.

Cash and Cash Equivalents
 
Cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes, bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at December 31, 2018 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive loss in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.

The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within two to five days.

The Company maintains certain cash balances at several institutions located in the United States, Hong Kong and Malaysia which at times may exceed insured limits.  The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.

Restricted Cash
 
In June 2015, the Company funded a bank deposit account in the amount of CNY 20 million ($2.9 million and $3.1 million at December 31, 2018 and 2017, respectively) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund.

The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely.
 
Inventories
 
Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.
 
Property and Equipment
 
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years for office equipment, office software and capitalized internal-use software development costs and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are included in the statement of operations as selling, general and administrative expenses. Such expense totaled $424,000 and $536,000 during 2018 and 2017, respectively.
 
The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value.
 
Goodwill
 
The Company assesses qualitative factors in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, through this qualitative assessment, the conclusion is made that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, a two-step impairment test is performed. The Company’s policy is to test for impairment annually during the fourth quarter. Considerable management judgment is necessary to measure fair value. The Company did not recognize any impairment charges for goodwill during the periods presented.
 
Income Taxes
 
The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than not recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are no uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided for state income tax purposes on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.

Amounts Held in eWallets
 
The Company requires commission payments of certain members in Hong Kong to be first recorded into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability.

Long-Term Incentive
 
Financial rewards earned under the 2014 Long-Term Incentive Plan (the “LTI Plan”) are recognized over the performance period as specified performance or other goals are achieved or exceeded. In accordance with the LTI Plan, fifty percent of any cash payment earned is payable in thirty-five equal consecutive monthly installments commencing in February of the calendar year immediately following the conclusion of the performance period and the remaining fifty percent of the payment earned is payable in thirty-five equal consecutive monthly installments commencing in February 2021 and ending in December 2023. As of December 31, 2018, unpaid installments for long-term incentive compensation total $9.0 million, of which $7.8 million is reflected on the balance sheet as a non-current liability and $1.2 million is reflected in other accrued expenses.

At the sole discretion of the Compensation Committee of the Company’s Board of Directors, distributions under the LTI Plan are made in cash, or alternatively awarded in the form of common stock or other common stock rights having an equivalent cash value under the terms of the Natural Health Trends Corp. 2016 Equity Incentive Plan. A determination of the form of distribution, if any, is made by the Compensation Committee subsequent to the end of each calendar year. As such, amounts earned are considered non-equity awards. See Note 7 for grant information of distributions settled in common stock.
 
Foreign Currency
 
The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into accumulated other comprehensive income.
 
Aggregate transaction gains or losses, including gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of certain inter-company balances, are included in the statement of operations as other income and expense. Loss on foreign exchange totaling $739,000 and $451,000 was recognized during 2018 and 2017, respectively.
 
Commissions
 
Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and as the related revenue is recognized and pays commissions on product sales generally two weeks following the end of the weekly sales period.
 
In some markets, the Company also pays certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.
 
From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. The Company also enters into performance-based agreements for business or market development, which may result in additional compensation to specific members.

Operating Leases

The Company leases its physical properties under operating leases. Certain lease agreements include rent holidays and incentives. The Company recognizes rent holiday periods on a straight-line basis over the lease term beginning when the Company has the right to the leased space.

Stock-Based Compensation
 
Stock-based compensation expense is determined based on the grant date fair value of each award, net of estimated forfeitures which are derived from historical experience, and is recognized on a straight-line basis over the requisite service period for the award.
 
Net Income Per Common Share
 
Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.

Certain Risks and Concentrations
 
A substantial portion of the Company’s sales are generated in Hong Kong (see Note 11). Substantially all of the Company’s Hong Kong revenues are derived from the sale of products that are delivered to members in China. In contrast to the Company’s operations in other parts of the world, the Company’s China subsidiary has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license, which the Company has applied for, and has also adopted anti-pyramid selling and multilevel marketing legislation. The Company operates an e-commerce direct selling model in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail model. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate separately or in both.

The Company continually evaluates its operations in China and Hong Kong for compliance with applicable laws and regulations, including seeking the input of outside professionals and certain Chinese authorities. This process can and has resulted in the identification of certain matters of potential noncompliance. The Company works on a continuing basis to satisfactorily address such matters, however there can be no assurance that adequate steps are taken or that applicable laws and regulations are properly interpreted. Should the government authorities determine that the Company’s activities violate applicable laws and regulations, including China’s direct selling, pyramid selling or multilevel marketing laws and regulations, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.
 
Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling, pyramid selling or multi-level marketing legislation, and subjective interpretations of laws and regulations. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.

No single market other than Hong Kong had net sales greater than 10% of total sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of its net sales. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.

The Company’s Premium Noni Juice and Enhanced Essential Probiotics® products each account for more than 10% of the Company’s total revenue. The Company currently sources each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected.

Fair Value of Financial Instruments
 
The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.
 
Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

Recently Issued and Adopted Accounting Pronouncements

In November 2016, the FASB issued ASU No. 2016-18 that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard was effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted the new standard effective January 1, 2018 using the retrospective transition method. Its adoption did not have a material impact on the Company’s consolidated financial statements.

In February 2016, the FASB established Topic 842, Leases, by issuing ASU No. 2016-02, which requires lessees to recognize the rights and obligations created by leases on the balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-11, Targeted Improvements, ASU No. 2018-10, Codification Improvements to Topic 842, and ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842. The new standard establishes a right-of-use model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations.

The new standard will be effective January 1, 2019. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. If an entity chooses the second option, the transition requirements for existing leases also apply to leases entered into between the date of initial application and the effective date. The entity must also recast its comparative period financial statements and provide the disclosures required by the new standard for the comparative periods. The Company expects to adopt the new standard on January 1, 2019 using the effective date as our date of initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019.

The new standard provides a number of optional practical expedients in transition. The Company expects to elect the “package of practical expedients”, which permits entities not to reassess under the new lease standard prior conclusions about lease identification, lease classification and initial direct costs. The Company does not expect to elect the use-of-hindsight or the practical expedient pertaining to land easements.

While the Company continues to assess all of the effects of adoption, it currently believes that most significant effects relate to the recognition of new ROU assets and lease liabilities on our balance sheet for office operating leases and providing significant new disclosures about our leasing activities. On adoption, the Company expects to recognize an operating lease liability of $4.6 million, with corresponding ROU assets of the same amount based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases.

The new standard also provides practical expedients for an entity’s ongoing accounting. The Company currently expects to elect the short-term leases recognition exemption for all leases that qualify. This means that the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets and lease liabilities for existing short-term leases of those assets in transition. The Company also currently expects to elect the practical expedient to not separate lease and nonlease components for its leases.

In May 2014, the FASB issued ASU No. 2014-09, Revenue From Contracts With Customers, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. In July 2015, the FASB approved the deferral of the effective date for annual reporting periods beginning after December 15, 2017, including interim reporting periods. The Company adopted the new standard effective January 1, 2018 using the modified retrospective transition method. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. See Note 2 for additional information.

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.19.1
REVENUE
12 Months Ended
Dec. 31, 2018
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE

Revenue Recognition

All revenue is recognized when the performance obligations under a contract are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.
 
Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 5% of sales. Sales returns were 2% of sales for both the years ended December 31, 2018 and 2017, respectively.  No material changes in estimates have been recognized during the periods presented. See Note 4 for additional information.
 
The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.
 
Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.
 
Deferred Revenue

The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are considered a contract liability and are recorded as deferred revenue. The increase in deferred revenue for the year ended December 31, 2018 is primarily due to $4.5 million of cash payments received for unshipped product primarily towards the end of the year offset by $2.4 million of revenue recognized during the year that was included in deferred revenue as of December 31, 2017. See Note 4 for additional information.

Disaggregation of Revenue

The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to some consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through the engagement of a third-party service provider. See Note 11 for additional information.

Arrangements with Multiple Performance Obligations

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.

Practical Expedients

The Company generally expenses sales commissions when incurred because the amortization period would be one year or less. These costs are recorded in commissions expense.

The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.19.1
NET INCOME PER COMMON SHARE
12 Months Ended
Dec. 31, 2018
Earnings Per Share [Abstract]  
NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE

The following table illustrates the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):
 
Year Ended December 31,
 
2018
 
2017
 
Income
 
Shares
 
Per Share
 
Income
 
Shares
 
Per Share
Basic net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
31,035

 
11,304

 
$
2.75

 
$
23,578

 
11,251

 
$
2.10

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 
14

 
 

 

 
16

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
31,035

 
11,318

 
$
2.74

 
$
23,578

 
11,267

 
$
2.09



Certain non-vested restricted stock is anti-dilutive upon applying the treasury stock method since the amount of compensation cost for future service results in the hypothetical repurchase of shares exceeding the actual number of shares to be vested. Non-vested restricted stock totaling 2,232 shares were not included for the year ended December 31, 2017 as their effect would have been anti-dilutive.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.19.1
BALANCE SHEET COMPONENTS
12 Months Ended
Dec. 31, 2018
Balance Sheet Components [Abstract]  
BALANCE SHEET COMPONENTS BALANCE SHEET COMPONENTS

The components of certain balance sheet amounts are as follows (in thousands):
 
December 31,
 
2018
 
2017
Cash and cash equivalents:
 
 
 
Cash
$
47,323

 
$
61,703

Cash equivalents
85,330

 
73,608

 
132,653

 
135,311

Restricted cash
2,998

 
3,167

 
$
135,651

 
$
138,478

 
 
 
 
Inventories:
 
 
 
Finished goods
$
11,171

 
$
7,779

Raw materials
1,145

 
799

Reserve for obsolescence
(151
)
 
(180
)
 
$
12,165

 
$
8,398

Property and equipment:
 
 
 
Office equipment
$
537

 
$
530

Office software
918

 
916

Machinery
29

 
30

Furniture and fixtures
319

 
276

Leasehold improvements
1,022

 
957

Construction in progress (including internal-use software development costs)
19

 
10

Property and equipment, at cost
2,844

 
2,719

Accumulated depreciation and amortization
(1,910
)
 
(1,570
)
 
$
934

 
$
1,149

Other accrued expenses:
 
 
 
Sales returns
$
801

 
$
614

Employee-related expense
4,051

 
5,568

Warehousing, inventory-related and other
1,269

 
1,423

 
$
6,121

 
$
7,605

Deferred revenue:
 

 
 

Unshipped product
$
4,574

 
$
2,411

Auto ship advances
1,876

 
1,665

Other
345

 
379

 
$
6,795

 
$
4,455


As of December 31, 2018, cash and cash equivalents include $11.1 million held in banks located within China subject to foreign currency controls.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.19.1
FAIR VALUE MEASUREMENTS
12 Months Ended
Dec. 31, 2018
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS

Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):
 
December 31, 2018
 
December 31, 2017
 
Adjusted Cost
 
Gross Unrealized Gains/Losses
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Gains/Losses
 
Fair Value
Municipal bonds and notes
$
12,149

 
$
(7
)
 
$
12,142

 
$
13,320

 
$
(1
)
 
$
13,319

Corporate debt securities
51,862

 
(26
)
 
51,836

 
49,432

 
(24
)
 
49,408

Financial institution instruments
21,352

 

 
21,352

 
10,881

 

 
10,881

Total available-for-sale investments
$
85,363

 
$
(33
)
 
$
85,330

 
$
73,633

 
$
(25
)
 
$
73,608


 
Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits.

FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs that are not corroborated by market data.

The tables below present the Company’s hierarchy for assets measured at fair value on a recurring basis as of December 31, 2018 and 2017.

 
December 31, 2018
 
Level 1
 
Level 2
 
Level 3
 
Total
Amounts included in cash and cash equivalents
$
85,330

 
$

 
$

 
$
85,330

Total assets measured at fair value on a recurring basis
$
85,330

 
$

 
$

 
$
85,330


 
December 31, 2017
 
Level 1
 
Level 2
 
Level 3
 
Total
Amounts included in cash and cash equivalents
$
73,608

 
$

 
$

 
$
73,608

Total assets measured at fair value on a recurring basis
$
73,608

 
$

 
$

 
$
73,608

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.19.1
COMMITMENTS AND CONTINGENCIES
12 Months Ended
Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND COMMITMENTS COMMITMENTS AND CONTINGENCIES
 
Operating Leases
 
The Company has entered into non-cancelable operating lease agreements for locations within the United States and for its international subsidiaries, with expirations through September 2025. Rent expense in connection with operating leases was $2.2 million and $2.0 million during 2018 and 2017, respectively.
 
Future minimum lease obligations as of December 31, 2018 are as follows (in thousands):
2019
$
1,796

2020
1,340

2021
452

2022
332

2023
208

Thereafter
327

Total minimum lease obligations
$
4,455



Purchase Commitment

In May 2013, the Company entered into an exclusive distribution agreement with one of its suppliers to purchase its product through July 2016 which automatically renews annually unless terminated 90 days prior to the termination date. To maintain exclusivity, the Company is required to purchase a minimum of $40,000 of product per month until the termination date. As of December 31, 2018, the Company was in compliance with the exclusivity provision.
 
Employment Agreements
 
The Company has employment agreements with certain members of its management team that can be terminated by either the employee or the Company upon four weeks’ notice.  The employment agreements entered into with the management team contain provisions that guarantee the payments of specified amounts in the event of a change in control, as defined, or if the employee is terminated without cause, as defined, or terminates employment for good reason, as defined.

Securities Class Actions

On January 8, 2019, the Company and its two executive officers were named in a putative securities class action filed in the United States District Court for the Central District of California, captioned Kauffman v. Natural Health Trends Corp., Case No. 2:19-cv-00163.  The complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between April 27, 2016 and January 5, 2019, inclusive, under (i) Section 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”) and Rule 10b-5 promulgated thereunder against the Company and Chris T. Sharng and Timothy S. Davidson (together, the “Individual Defendants”), and (ii) Section 20(a) of the Exchange Act against the Individual Defendants. The complaint alleges, in part, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multilevel marketing business.  The complaint seeks an indeterminate amount of damages, plus interest and costs.  Defendants believe that these claims are without merit and intend to vigorously defend against them.

In January 2016, two putative securities class action complaints were filed against the Company and its top executives in the United States District Court for the Central District of California. On March 29, 2016, the court consolidated these actions under the caption Ford v. Natural Health Trends Corp., Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class. On April 2, 2018, the court approved a class-wide settlement of the action in the amount of $1.75 million, which was fully funded by the Company’s insurers. On April 6, 2018, the court entered a Final Judgment and Order of Dismissal With Prejudice.

Shareholder Derivative Claims

In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: Zhou v. Sharng. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: Kleinfeldt v. Sharng. On November 10, 2017, the parties to both the Zhou and Kleinfeldt actions entered into a Memorandum of Understanding (“MOU”) to resolve both actions, subject to the negotiation of a written settlement agreement and approval by the federal court in the Kleinfeldt matter.  On July 16, 2018, the court granted final approval of the settlement and entered judgment in the Kleinfeldt matter.  In exchange for full releases, the settlement required the Company to implement certain corporate governance reforms and included an award of $250,000 in attorneys’ fees to plaintiffs’ counsel, all of which was fully funded by the Company’s insurers. On August 9, 2018, plaintiff filed a request to voluntarily dismiss the Zhou action, which was entered by the court on August 30, 2018.

Other Matters

The Company is currently involved in a legal matter with one of its vendors and an outside party. Per the royalty agreement with the vendor, the Company believes that it is fully indemnified in the event of an unfavorable outcome and any potential settlement costs related to the matter would be fully covered by the Company’s vendor.

Since August 2016, the SEC has been conducting a non-public investigation to determine whether there have been violations of the federal securities laws relating to the trading of the Company’s securities. The Company has fully cooperated with the SEC and has and continues to provide documents in response to subpoenas. The SEC has expressly stated that its document requests should not be construed as an indication that any violation of law has occurred, or as a reflection upon any person, entity, or security. The amount of time needed to resolve this matter is uncertain, and the Company cannot predict the outcome or whether it will face additional governmental inquiries or other actions.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.19.1
STOCKHOLDERS' EQUITY
12 Months Ended
Dec. 31, 2018
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
 
Authorized Shares
 
The Company is authorized to issue two classes of capital stock consisting of up to 5,000,000 shares of preferred stock, $0.001 par value, and 50,000,000 shares of common stock, $0.001 par value.
 
Dividends
 
The following tables summarize the Company’s cash dividend activity during 2018 and 2017 (in thousands, except per share data):
Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 21, 2018 (special)
 
$
0.18

 
$
2,048

 
November 23, 2018
October 21, 2018
 
0.16

 
1,820

 
November 23, 2018
July 18, 2018 (special)
 
0.25

 
2,844

 
August 24, 2018
July 18, 2018
 
0.15

 
1,707

 
August 24, 2018
April 17, 2018 (special)
 
1.76

 
20,022

 
May 25, 2018
April 17, 2018
 
0.14

 
1,592

 
May 25, 2018
February 6, 2018
 
0.13

 
1,479

 
March 9, 2018
 
 
$
2.77

 
$
31,512

 
 
Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 30, 2017 (special)
 
$
0.15

 
$
1,701

 
November 24, 2017
October 30, 2017
 
0.12

 
1,360

 
November 24, 2017
July 31, 2017 (special)
 
0.25

 
2,833

 
August 31, 2017
July 31, 2017
 
0.11

 
1,246

 
August 31, 2017
April 24, 2017 (special)
 
0.35

 
3,964

 
May 19, 2017
April 24, 2017
 
0.10

 
1,133

 
May 19, 2017
January 24, 2017 (special)
 
0.35

 
3,962

 
March 3, 2017
January 24, 2017
 
0.09

 
1,019

 
March 3, 2017
 
 
$
1.52

 
$
17,218

 
 


Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

Stock Repurchases

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. No shares of the Company’s common stock were repurchased by the Company during 2018 or 2017. As of December 31, 2018, $32.0 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

Restricted Stock

No stock-based compensation was recognized during 2018. Stock-based compensation expense totaled approximately $35,000 during 2017.

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. As of December 31, 2018, 2,359,671 shares remained available for issuance under the 2016 Plan.

On February 1, 2018, the Company granted 34,202 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2017 performance incentives totaling $554,000. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances.

On January 24, 2017, the Company granted 56,260 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2016 performance incentives totaling $1.4 million. The shares vest on a quarterly basis over three years and are subject to forfeiture in the event of the employee’s termination of service to the Company under specified circumstances.

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2016
38,256

 
$
34.13

Granted
56,260

 
25.44

Vested
(35,336
)
 
29.58

Forfeited
(1,148
)
 
28.55

Nonvested at December 31, 2017
58,032

 
28.59

Granted
34,202

 
16.19

Vested
(46,748
)
 
26.31

Nonvested at December 31, 2018
45,486

 
21.61



The following table summarizes the Company’s other restricted stock activity:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2016
22,348

 
$
12.15

Vested
(21,930
)
 
12.15

Forfeited
(418
)
 
12.28

Nonvested at December 31, 2017

 



Accumulated Other Comprehensive Loss

The changes in accumulated other comprehensive loss by component for 2018 were as follows (in thousands):
 
Foreign Currency Translation Adjustment
 
Unrealized Losses on Available-For-Sale Investments
 
Total
Balance, December 31, 2017
$
(386
)
 
$
(27
)
 
$
(413
)
Other comprehensive loss
(831
)
 
(6
)
 
(837
)
Balance, December 31, 2018
$
(1,217
)
 
$
(33
)
 
$
(1,250
)
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.19.1
INCOME TAXES
12 Months Ended
Dec. 31, 2018
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
 
The components of income before income taxes consist of the following (in thousands):
 
Year Ended December 31,
 
2018
 
2017
Domestic
$
(3,391
)
 
$
(2,965
)
Foreign
37,912

 
46,391

Income before income taxes
$
34,521

 
$
43,426


 
The components of the income tax provision consist of the following (in thousands):
 
Year Ended December 31,
 
2018
 
2017
Current:
 
 
 
Federal
$
1,815

 
$
20,277

State
13

 
2

Foreign
1,300

 
1,216

Total current taxes
3,128

 
21,495

Deferred taxes
358

 
(1,647
)
Income tax provision
$
3,486

 
$
19,848



A reconciliation of the reported income tax provision to the provision that would result from applying the domestic federal statutory tax rate to pretax income is as follows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
Income tax at federal statutory rate
$
7,249

 
$
15,200

Effect of permanent differences
346

 
459

Tax Cut & Jobs Act one-time transition tax
(738
)
 
20,792

Global Intangible Low Taxed Income
3,964

 

Tax Cut & Jobs Act federal rate change
(6
)
 
954

Change in valuation allowance
(9
)
 
(43
)
Foreign rate differential
(6,541
)
 
(15,002
)
Foreign tax credits
(786
)
 
(2,738
)
Other reconciling items
7

 
226

Income tax provision
$
3,486

 
$
19,848


 
Income before income taxes and the statutory tax rate for each country that materially contributed to the foreign rate differential presented above is as follows (in thousands):
 
 
 
Year Ended December 31,
 
Statutory Tax Rate
 
2018
 
2017
Cayman Islands
%
 
$
31,560

 
$
39,954

Hong Kong
16.5
%
 
3,545

 
3,315

China
25.0
%
 
2,725

 
2,584


Deferred income taxes consist of the following (in thousands):
 
December 31,
 
2018
 
2017
Deferred tax assets:
 
 
 
Net operating losses
$
183

 
$
192

Stock-based compensation
191

 
270

Accrued expenses
1,062

 
1,374

Other
11

 
6

Total deferred tax assets
1,447

 
1,842

Valuation allowance
(183
)
 
(192
)
Net deferred tax assets
1,264

 
1,650

Deferred tax liabilities:
 
 
 
Foreign earnings
(2
)
 
(4
)
Other
(241
)
 
(267
)
Total deferred tax liabilities
(243
)
 
(271
)
Net deferred tax assets
$
1,021

 
$
1,379


The effective income tax rate for the year ended December 31, 2018 was impacted by recording the effect of the Tax Cuts and Jobs Act (the “Tax Act”), enacted on December 22, 2017 by the U.S. government. The Tax Act makes broad and complex changes to the Internal Revenue Code of 1986, as amended, which has affected the Company’s year ended December 31, 2018, including, but not limited to, requiring an annual tax on the earnings and profits of any greater than 10% owned foreign controlled corporation.

On December 22, 2017, the Securities and Exchange Commission staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provided a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740,
Income Taxes. In accordance with the expiration of the SAB 118 measurement period, we completed the assessment of the income tax effect of the Tax Act by the fourth quarter of tax year 2018. All adjustments recorded to the provisional amounts have been included as an adjustment to income tax expense.

As a result of the Tax Act, the Company recorded additional income tax expense due to the Global Intangible Low Taxed Income inclusion on current earnings and profits of greater than 10% owned foreign controlled corporations (“GILTI”). To determine the amount of GILTI inclusion, the Company must determine, in addition to other factors, the current earnings of foreign controlled corporations, as well as the amount of foreign taxes paid by the foreign entities. The law provides that corporate taxpayers may benefit from a 50% reduction in the GILTI inclusion, which effectively reduces the 21% U.S. corporate tax rate on the foreign income to an effective rate of 10.5%. The GILTI inclusion further provides for a foreign tax credit in connection with the foreign taxes paid. The Company recorded a tax expense for GILTI of $2.9 million, net of $1.0 million foreign tax credits.

As of December 31, 2018, the Company does not have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets.

As of December 31, 2018, the Company has a valuation allowance against certain foreign deferred tax assets. The Company is recording a valuation allowance in foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

As of December 31, 2018, the Company has no U.S. federal net operating loss or credit carryforwards as any attributes generated are expected to be fully utilized to offset tax in the current year. At December 31, 2018, the Company has foreign net operating loss carryforwards of approximately $1.2 million in various jurisdictions with various expirations.

As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings is no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate. As of December 31, 2018, the Company has recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods. Due to the Tax Act, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to no impact on federal tax expense. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of December 31, 2018.

The Company and its subsidiaries file tax returns in the United States, California, New Jersey and Texas and various foreign jurisdictions. During the fourth quarter of 2018, the Company was notified that it was selected for audit of the 2016 tax year by the U.S. Internal Revenue Service. For purposes of this audit, fiscal years 2007 through 2016 are open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. No adjustments have been proposed at this time. The Company is no longer subject to state income tax examinations for years prior to 2014. The Taiwan Taxation Administration closed the audit for the 2016 tax year with immaterial tax adjustments that have been recorded in the foreign income tax provision. No other jurisdictions are currently examining any income tax returns of the Company.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.19.1
RELATED PARTY TRANSACTIONS
12 Months Ended
Dec. 31, 2018
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS
 
The Company is a party to a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called ReStor™. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. Under this agreement, the Company agreed to pay BHS a price per unit royalty in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States.  The Company recognized royalties of $327,000 and $306,000 during 2018 and 2017, respectively.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice or, under certain circumstances, with no notice. Otherwise, the agreement terminates March 31, 2020.

During each of 2018 and 2017, the Company procured in China and arranged for shipment to The Aberdeen Group, LLC (“Aberdeen”), one order of apparel products.  Aberdeen is owned 40% by Sharng Holdings, which is wholly-owned by the Company’s president, Chris T. Sharng, and his wife, 40% by Mr. Broady, and 20% by an unrelated third party.  In each instance
Aberdeen promptly paid the Company for the product and shipping cost incurred. Such orders were in the amount of $3,700 and $3,800 during 2018 and 2017, respectively.  Given the Company’s provision of such product sourcing services to Aberdeen, Aberdeen also paid the Company a market-based fee consistent with the provision of such services of $450. The Company analyzed the nature of the transactions with Aberdeen to determine whether they could be construed a violation under the guidelines of Section 402 of the Sarbanes-Oxley Act of 2002. The Company, through advice from its legal counsel, concluded that there is not a reasonable possibility that the transactions with Aberdeen would be deemed a violation of Section 402. This relationship between the Company and Aberdeen ceased in early 2019.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.19.1
EMPLOYEE BENEFIT PLANS
12 Months Ended
Dec. 31, 2018
Retirement Benefits [Abstract]  
EMPLOYEE BENEFIT PLANS  EMPLOYEE BENEFIT PLANS
 
     The Company has a 401(k) defined contribution plan which permits participating employees in the United States to defer up to a maximum of 90% of their compensation, subject to limitations established by the Internal Revenue Service. Employees age 21 and older are eligible to contribute to the plan starting the first day of the following month of employment.  Participating employees are eligible to receive discretionary matching contributions and profit sharing, subject to certain conditions, from the Company.  In 2018 and 2017, the Company matched employee deferral contributions up to 4.5% of salary, which vested 100% immediately. No profit sharing has been paid under the plan. The Company recorded compensation expense of $87,000 and $101,000 for 2018 and 2017, respectively, related to its matching contributions to the plan. Certain of the Company’s employees located outside the United States participate in employee benefit plans that are statutory in nature.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.19.1
SEGMENT INFORMATION
12 Months Ended
Dec. 31, 2018
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
 
The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to some consumers through an e-commerce platform, and the Russia and Kazakhstan market where the Company’s engagement of a third-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment.

There is no separate segment manager who is held accountable by the Company’s chief operating decision-makers, or anyone else, for operations, operating results and planning for the China market or the Russia and Kazakhstan market on a stand-alone basis, and neither market is material for the periods presented. As such, the Company believes that all operating segments should be aggregated into a single reportable segment for disclosure purposes.
 
The Company’s net sales by geographic area are as follows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
Net sales from external customers:
 
 
 
United States
$
3,637

 
$
3,348

Canada
1,710

 
1,938

Peru
1,635

 
508

Hong Kong1
169,452

 
174,926

China
7,744

 
7,282

Taiwan
3,964

 
5,591

South Korea
493

 
466

Russia and Kazakhstan
868

 
913

Europe
1,644

 
2,278

Other foreign countries
763

 
313

Total net sales
$
191,910

 
$
197,563


_____________________________ 
1 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.
 
The Company’s net sales by product and service are as follows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
Net sales by product and service:
 
 
 
Product sales
$
181,865

 
$
187,591

Freight and other
13,329

 
13,676

Less: sales returns
(3,284
)
 
(3,704
)
Total net sales
$
191,910

 
$
197,563


 
Due to system constraints, it is impracticable for the Company to separately disclose sales by product category for the years presented.

The Company’s long-lived assets by geographic area are as follows (in thousands):
 
December 31,
 
2018
 
2017
Long-lived assets:
 
 
 
United States
$
521

 
$
648

Hong Kong
145

 
78

China
61

 
112

Other foreign countries
207

 
311

Total long-lived assets
$
934

 
$
1,149

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.19.1
SUBSEQUENT EVENTS
12 Months Ended
Dec. 31, 2018
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS  SUBSEQUENT EVENTS

On January 27, 2019, the Board of Directors declared a quarterly cash dividend of $0.16, as well as a special cash dividend of $0.08 on each share of common stock outstanding. The dividends were paid on March 15, 2019 to stockholders of record on March 5, 2019. Declaration and payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

On February 1, 2019, the Company granted 22,603 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2018 performance incentives totaling $377,000. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of their termination of service to the Company under specified circumstances.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.19.1
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Principles of Consolidation Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.
Reclassification Reclassification

Certain prior year balances in the statement of operations have been reclassified to conform to current year presentation. Additionally, in accordance with the adoption of Accounting Standards Update (“ASU”) No. 2016-18, Statement of Cash Flows - Restricted Cash, the Company has included amounts classified as restricted cash or restricted cash equivalents with cash and cash equivalents when reconciling beginning-of-period and end-of-period total cash, cash equivalents and restricted cash amounts, as presented in its consolidated statements of cash flows.

Use of Estimates Use of Estimates
 
The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.

The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.
Cash and Cash Equivalents Cash and Cash Equivalents
 
Cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes, bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at December 31, 2018 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive loss in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.

The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within two to five days.

The Company maintains certain cash balances at several institutions located in the United States, Hong Kong and Malaysia which at times may exceed insured limits.  The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.
Restricted Cash Restricted Cash
 
In June 2015, the Company funded a bank deposit account in the amount of CNY 20 million ($2.9 million and $3.1 million at December 31, 2018 and 2017, respectively) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund.

The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely.
Inventories Inventories
 
Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.
Property and Equipment Property and Equipment
 
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years for office equipment, office software and capitalized internal-use software development costs and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are included in the statement of operations as selling, general and administrative expenses. Such expense totaled $424,000 and $536,000 during 2018 and 2017, respectively.
 
The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value.
Goodwill Goodwill
 
The Company assesses qualitative factors in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, through this qualitative assessment, the conclusion is made that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, a two-step impairment test is performed. The Company’s policy is to test for impairment annually during the fourth quarter. Considerable management judgment is necessary to measure fair value. The Company did not recognize any impairment charges for goodwill during the periods presented.
Income Taxes Income Taxes
 
The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than not recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are no uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided for state income tax purposes on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.

Amounts Held in eWallets Amounts Held in eWallets
 
The Company requires commission payments of certain members in Hong Kong to be first recorded into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability.
Long-Term Incentive Long-Term Incentive
 
Financial rewards earned under the 2014 Long-Term Incentive Plan (the “LTI Plan”) are recognized over the performance period as specified performance or other goals are achieved or exceeded. In accordance with the LTI Plan, fifty percent of any cash payment earned is payable in thirty-five equal consecutive monthly installments commencing in February of the calendar year immediately following the conclusion of the performance period and the remaining fifty percent of the payment earned is payable in thirty-five equal consecutive monthly installments commencing in February 2021 and ending in December 2023. As of December 31, 2018, unpaid installments for long-term incentive compensation total $9.0 million, of which $7.8 million is reflected on the balance sheet as a non-current liability and $1.2 million is reflected in other accrued expenses.

At the sole discretion of the Compensation Committee of the Company’s Board of Directors, distributions under the LTI Plan are made in cash, or alternatively awarded in the form of common stock or other common stock rights having an equivalent cash value under the terms of the Natural Health Trends Corp. 2016 Equity Incentive Plan. A determination of the form of distribution, if any, is made by the Compensation Committee subsequent to the end of each calendar year. As such, amounts earned are considered non-equity awards. See Note 7 for grant information of distributions settled in common stock.
Foreign Currency Foreign Currency
 
The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into accumulated other comprehensive income.
 
Aggregate transaction gains or losses, including gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of certain inter-company balances, are included in the statement of operations as other income and expense.
Commissions Commissions
 
Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and as the related revenue is recognized and pays commissions on product sales generally two weeks following the end of the weekly sales period.
 
In some markets, the Company also pays certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.
 
From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. The Company also enters into performance-based agreements for business or market development, which may result in additional compensation to specific members.
Operating Leases Operating Leases

The Company leases its physical properties under operating leases. Certain lease agreements include rent holidays and incentives. The Company recognizes rent holiday periods on a straight-line basis over the lease term beginning when the Company has the right to the leased space.
Stock-Based Compensation Stock-Based Compensation
 
Stock-based compensation expense is determined based on the grant date fair value of each award, net of estimated forfeitures which are derived from historical experience, and is recognized on a straight-line basis over the requisite service period for the award.
Net Income Per Common Share Net Income Per Common Share
 
Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.
Certain Risks and Concentrations Certain Risks and Concentrations
 
A substantial portion of the Company’s sales are generated in Hong Kong (see Note 11). Substantially all of the Company’s Hong Kong revenues are derived from the sale of products that are delivered to members in China. In contrast to the Company’s operations in other parts of the world, the Company’s China subsidiary has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license, which the Company has applied for, and has also adopted anti-pyramid selling and multilevel marketing legislation. The Company operates an e-commerce direct selling model in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail model. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate separately or in both.

The Company continually evaluates its operations in China and Hong Kong for compliance with applicable laws and regulations, including seeking the input of outside professionals and certain Chinese authorities. This process can and has resulted in the identification of certain matters of potential noncompliance. The Company works on a continuing basis to satisfactorily address such matters, however there can be no assurance that adequate steps are taken or that applicable laws and regulations are properly interpreted. Should the government authorities determine that the Company’s activities violate applicable laws and regulations, including China’s direct selling, pyramid selling or multilevel marketing laws and regulations, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.
 
Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling, pyramid selling or multi-level marketing legislation, and subjective interpretations of laws and regulations. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.

No single market other than Hong Kong had net sales greater than 10% of total sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of its net sales. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.

The Company’s Premium Noni Juice and Enhanced Essential Probiotics® products each account for more than 10% of the Company’s total revenue. The Company currently sources each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected.
Fair Value of Financial Instruments Fair Value of Financial Instruments
 
The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.
 
Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.
Recently Issued and Adopted Accounting Pronouncements Recently Issued and Adopted Accounting Pronouncements

In November 2016, the FASB issued ASU No. 2016-18 that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard was effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted the new standard effective January 1, 2018 using the retrospective transition method. Its adoption did not have a material impact on the Company’s consolidated financial statements.

In February 2016, the FASB established Topic 842, Leases, by issuing ASU No. 2016-02, which requires lessees to recognize the rights and obligations created by leases on the balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-11, Targeted Improvements, ASU No. 2018-10, Codification Improvements to Topic 842, and ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842. The new standard establishes a right-of-use model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations.

The new standard will be effective January 1, 2019. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. If an entity chooses the second option, the transition requirements for existing leases also apply to leases entered into between the date of initial application and the effective date. The entity must also recast its comparative period financial statements and provide the disclosures required by the new standard for the comparative periods. The Company expects to adopt the new standard on January 1, 2019 using the effective date as our date of initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019.

The new standard provides a number of optional practical expedients in transition. The Company expects to elect the “package of practical expedients”, which permits entities not to reassess under the new lease standard prior conclusions about lease identification, lease classification and initial direct costs. The Company does not expect to elect the use-of-hindsight or the practical expedient pertaining to land easements.

While the Company continues to assess all of the effects of adoption, it currently believes that most significant effects relate to the recognition of new ROU assets and lease liabilities on our balance sheet for office operating leases and providing significant new disclosures about our leasing activities. On adoption, the Company expects to recognize an operating lease liability of $4.6 million, with corresponding ROU assets of the same amount based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases.

The new standard also provides practical expedients for an entity’s ongoing accounting. The Company currently expects to elect the short-term leases recognition exemption for all leases that qualify. This means that the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets and lease liabilities for existing short-term leases of those assets in transition. The Company also currently expects to elect the practical expedient to not separate lease and nonlease components for its leases.

In May 2014, the FASB issued ASU No. 2014-09, Revenue From Contracts With Customers, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. In July 2015, the FASB approved the deferral of the effective date for annual reporting periods beginning after December 15, 2017, including interim reporting periods. The Company adopted the new standard effective January 1, 2018 using the modified retrospective transition method. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. See Note 2 for additional information.

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.
Revenue Recognition Revenue Recognition

All revenue is recognized when the performance obligations under a contract are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.
 
Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 5% of sales. Sales returns were 2% of sales for both the years ended December 31, 2018 and 2017, respectively.  No material changes in estimates have been recognized during the periods presented. See Note 4 for additional information.
 
The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.
 
Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.
 
Deferred Revenue

The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are considered a contract liability and are recorded as deferred revenue. The increase in deferred revenue for the year ended December 31, 2018 is primarily due to $4.5 million of cash payments received for unshipped product primarily towards the end of the year offset by $2.4 million of revenue recognized during the year that was included in deferred revenue as of December 31, 2017. See Note 4 for additional information.

Disaggregation of Revenue

The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to some consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through the engagement of a third-party service provider. See Note 11 for additional information.

Arrangements with Multiple Performance Obligations

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.

Practical Expedients

The Company generally expenses sales commissions when incurred because the amortization period would be one year or less. These costs are recorded in commissions expense.

The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.19.1
NET INCOME PER COMMON SHARE (Tables)
12 Months Ended
Dec. 31, 2018
Earnings Per Share [Abstract]  
Schedule of Computation of Basic and Diluted Income per Common Share The following table illustrates the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):
 
Year Ended December 31,
 
2018
 
2017
 
Income
 
Shares
 
Per Share
 
Income
 
Shares
 
Per Share
Basic net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
31,035

 
11,304

 
$
2.75

 
$
23,578

 
11,251

 
$
2.10

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 
14

 
 

 

 
16

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
31,035

 
11,318

 
$
2.74

 
$
23,578

 
11,267

 
$
2.09

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.19.1
BALANCE SHEET COMPONENTS (Tables)
12 Months Ended
Dec. 31, 2018
Balance Sheet Components [Abstract]  
Schedule of Additional Balance Sheet Components The components of certain balance sheet amounts are as follows (in thousands):
 
December 31,
 
2018
 
2017
Cash and cash equivalents:
 
 
 
Cash
$
47,323

 
$
61,703

Cash equivalents
85,330

 
73,608

 
132,653

 
135,311

Restricted cash
2,998

 
3,167

 
$
135,651

 
$
138,478

 
 
 
 
Inventories:
 
 
 
Finished goods
$
11,171

 
$
7,779

Raw materials
1,145

 
799

Reserve for obsolescence
(151
)
 
(180
)
 
$
12,165

 
$
8,398

Property and equipment:
 
 
 
Office equipment
$
537

 
$
530

Office software
918

 
916

Machinery
29

 
30

Furniture and fixtures
319

 
276

Leasehold improvements
1,022

 
957

Construction in progress (including internal-use software development costs)
19

 
10

Property and equipment, at cost
2,844

 
2,719

Accumulated depreciation and amortization
(1,910
)
 
(1,570
)
 
$
934

 
$
1,149

Other accrued expenses:
 
 
 
Sales returns
$
801

 
$
614

Employee-related expense
4,051

 
5,568

Warehousing, inventory-related and other
1,269

 
1,423

 
$
6,121

 
$
7,605

Deferred revenue:
 

 
 

Unshipped product
$
4,574

 
$
2,411

Auto ship advances
1,876

 
1,665

Other
345

 
379

 
$
6,795

 
$
4,455

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.19.1
FAIR VALUE MEASUREMENTS (Tables)
12 Months Ended
Dec. 31, 2018
Fair Value Disclosures [Abstract]  
Schedule of Available-for-sale Investments Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):
 
December 31, 2018
 
December 31, 2017
 
Adjusted Cost
 
Gross Unrealized Gains/Losses
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Gains/Losses
 
Fair Value
Municipal bonds and notes
$
12,149

 
$
(7
)
 
$
12,142

 
$
13,320

 
$
(1
)
 
$
13,319

Corporate debt securities
51,862

 
(26
)
 
51,836

 
49,432

 
(24
)
 
49,408

Financial institution instruments
21,352

 

 
21,352

 
10,881

 

 
10,881

Total available-for-sale investments
$
85,363

 
$
(33
)
 
$
85,330

 
$
73,633

 
$
(25
)
 
$
73,608

Schedule of Company's Hierarchy for Assets Measured on Recurring Basis The tables below present the Company’s hierarchy for assets measured at fair value on a recurring basis as of December 31, 2018 and 2017.

 
December 31, 2018
 
Level 1
 
Level 2
 
Level 3
 
Total
Amounts included in cash and cash equivalents
$
85,330

 
$

 
$

 
$
85,330

Total assets measured at fair value on a recurring basis
$
85,330

 
$

 
$

 
$
85,330


 
December 31, 2017
 
Level 1
 
Level 2
 
Level 3
 
Total
Amounts included in cash and cash equivalents
$
73,608

 
$

 
$

 
$
73,608

Total assets measured at fair value on a recurring basis
$
73,608

 
$

 
$

 
$
73,608

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.19.1
COMMITMENTS AND CONTINGENCIES (Tables)
12 Months Ended
Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Rental Payments for Operating Leases Future minimum lease obligations as of December 31, 2018 are as follows (in thousands):
2019
$
1,796

2020
1,340

2021
452

2022
332

2023
208

Thereafter
327

Total minimum lease obligations
$
4,455

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.19.1
STOCKHOLDERS' EQUITY (Tables)
12 Months Ended
Dec. 31, 2018
Stockholders' Equity Note [Abstract]  
Schedule of Dividends Payable The following tables summarize the Company’s cash dividend activity during 2018 and 2017 (in thousands, except per share data):
Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 21, 2018 (special)
 
$
0.18

 
$
2,048

 
November 23, 2018
October 21, 2018
 
0.16

 
1,820

 
November 23, 2018
July 18, 2018 (special)
 
0.25

 
2,844

 
August 24, 2018
July 18, 2018
 
0.15

 
1,707

 
August 24, 2018
April 17, 2018 (special)
 
1.76

 
20,022

 
May 25, 2018
April 17, 2018
 
0.14

 
1,592

 
May 25, 2018
February 6, 2018
 
0.13

 
1,479

 
March 9, 2018
 
 
$
2.77

 
$
31,512

 
 
Declaration Date
 
Per Common Share
 
Amount
 
Payment Date
October 30, 2017 (special)
 
$
0.15

 
$
1,701

 
November 24, 2017
October 30, 2017
 
0.12

 
1,360

 
November 24, 2017
July 31, 2017 (special)
 
0.25

 
2,833

 
August 31, 2017
July 31, 2017
 
0.11

 
1,246

 
August 31, 2017
April 24, 2017 (special)
 
0.35

 
3,964

 
May 19, 2017
April 24, 2017
 
0.10

 
1,133

 
May 19, 2017
January 24, 2017 (special)
 
0.35

 
3,962

 
March 3, 2017
January 24, 2017
 
0.09

 
1,019

 
March 3, 2017
 
 
$
1.52

 
$
17,218

 
 


Schedule of Restricted Stock Activity The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2016
38,256

 
$
34.13

Granted
56,260

 
25.44

Vested
(35,336
)
 
29.58

Forfeited
(1,148
)
 
28.55

Nonvested at December 31, 2017
58,032

 
28.59

Granted
34,202

 
16.19

Vested
(46,748
)
 
26.31

Nonvested at December 31, 2018
45,486

 
21.61

The following table summarizes the Company’s other restricted stock activity:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2016
22,348

 
$
12.15

Vested
(21,930
)
 
12.15

Forfeited
(418
)
 
12.28

Nonvested at December 31, 2017

 

Schedule of Changes in Accumulated Other Comprehensive Loss The changes in accumulated other comprehensive loss by component for 2018 were as follows (in thousands):
 
Foreign Currency Translation Adjustment
 
Unrealized Losses on Available-For-Sale Investments
 
Total
Balance, December 31, 2017
$
(386
)
 
$
(27
)
 
$
(413
)
Other comprehensive loss
(831
)
 
(6
)
 
(837
)
Balance, December 31, 2018
$
(1,217
)
 
$
(33
)
 
$
(1,250
)
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.19.1
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2018
Income Tax Disclosure [Abstract]  
Schedule of Income Before Income Taxes The components of income before income taxes consist of the following (in thousands):
 
Year Ended December 31,
 
2018
 
2017
Domestic
$
(3,391
)
 
$
(2,965
)
Foreign
37,912

 
46,391

Income before income taxes
$
34,521

 
$
43,426

Schedule of Components of Income Tax Provision The components of the income tax provision consist of the following (in thousands):
 
Year Ended December 31,
 
2018
 
2017
Current:
 
 
 
Federal
$
1,815

 
$
20,277

State
13

 
2

Foreign
1,300

 
1,216

Total current taxes
3,128

 
21,495

Deferred taxes
358

 
(1,647
)
Income tax provision
$
3,486

 
$
19,848

Schedule of Effective Income Tax Rate Reconciliation A reconciliation of the reported income tax provision to the provision that would result from applying the domestic federal statutory tax rate to pretax income is as follows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
Income tax at federal statutory rate
$
7,249

 
$
15,200

Effect of permanent differences
346

 
459

Tax Cut & Jobs Act one-time transition tax
(738
)
 
20,792

Global Intangible Low Taxed Income
3,964

 

Tax Cut & Jobs Act federal rate change
(6
)
 
954

Change in valuation allowance
(9
)
 
(43
)
Foreign rate differential
(6,541
)
 
(15,002
)
Foreign tax credits
(786
)
 
(2,738
)
Other reconciling items
7

 
226

Income tax provision
$
3,486

 
$
19,848

Schedule of Income Tax Foreign Rate Differential Income before income taxes and the statutory tax rate for each country that materially contributed to the foreign rate differential presented above is as follows (in thousands):
 
 
 
Year Ended December 31,
 
Statutory Tax Rate
 
2018
 
2017
Cayman Islands
%
 
$
31,560

 
$
39,954

Hong Kong
16.5
%
 
3,545

 
3,315

China
25.0
%
 
2,725

 
2,584

Schedule of Deferred Tax Assets and Liabilities Deferred income taxes consist of the following (in thousands):
 
December 31,
 
2018
 
2017
Deferred tax assets:
 
 
 
Net operating losses
$
183

 
$
192

Stock-based compensation
191

 
270

Accrued expenses
1,062

 
1,374

Other
11

 
6

Total deferred tax assets
1,447

 
1,842

Valuation allowance
(183
)
 
(192
)
Net deferred tax assets
1,264

 
1,650

Deferred tax liabilities:
 
 
 
Foreign earnings
(2
)
 
(4
)
Other
(241
)
 
(267
)
Total deferred tax liabilities
(243
)
 
(271
)
Net deferred tax assets
$
1,021

 
$
1,379

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.19.1
SEGMENT INFORMATION (Tables)
12 Months Ended
Dec. 31, 2018
Segment Reporting [Abstract]  
Schedule of Net Sales by Geographic Area The Company’s net sales by geographic area are as follows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
Net sales from external customers:
 
 
 
United States
$
3,637

 
$
3,348

Canada
1,710

 
1,938

Peru
1,635

 
508

Hong Kong1
169,452

 
174,926

China
7,744

 
7,282

Taiwan
3,964

 
5,591

South Korea
493

 
466

Russia and Kazakhstan
868

 
913

Europe
1,644

 
2,278

Other foreign countries
763

 
313

Total net sales
$
191,910

 
$
197,563


_____________________________ 
1 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.
Schedule of Net Sales by Product and Service The Company’s net sales by product and service are as follows (in thousands):
 
Year Ended December 31,
 
2018
 
2017
Net sales by product and service:
 
 
 
Product sales
$
181,865

 
$
187,591

Freight and other
13,329

 
13,676

Less: sales returns
(3,284
)
 
(3,704
)
Total net sales
$
191,910

 
$
197,563

Schedule of Long-lived Assets by Geographic Area The Company’s long-lived assets by geographic area are as follows (in thousands):
 
December 31,
 
2018
 
2017
Long-lived assets:
 
 
 
United States
$
521

 
$
648

Hong Kong
145

 
78

China
61

 
112

Other foreign countries
207

 
311

Total long-lived assets
$
934

 
$
1,149

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.19.1
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)
$ in Thousands, ¥ in Millions
12 Months Ended
Dec. 31, 2018
USD ($)
installment
Dec. 31, 2017
USD ($)
installment
Jan. 01, 2019
USD ($)
Jun. 30, 2015
CNY (¥)
Property, Plant and Equipment [Line Items]        
Depreciation and amortization expenses $ 424 $ 536    
Total long-term incentive compensation 9,000      
Non-current long-term incentive compensation 7,808 7,904    
Loss on foreign exchange 739 $ 451    
Subsequent Event | Scenario, Forecast | ASU 2016-02        
Property, Plant and Equipment [Line Items]        
Operating lease liability     $ 4,600  
Operating lease ROU assets     $ 4,600  
Non-current Liability        
Property, Plant and Equipment [Line Items]        
Non-current long-term incentive compensation 7,800      
Other Accrued Expenses        
Property, Plant and Equipment [Line Items]        
Current long-term incentive compensation $ 1,200      
Long-Term Incentive Plan, Payment Commencing in February of the Calendar Year Immediately Following the Conclusion of the Performance Period        
Property, Plant and Equipment [Line Items]        
Long-term incentive plan, percentage of award payable in cash 50.00%      
Long-term incentive plan, number of installments | installment 35      
Long-Term Incentive Plan, Payment Commencing in February 2021 and Ending in December 2023        
Property, Plant and Equipment [Line Items]        
Long-term incentive plan, percentage of award payable in cash 50.00%      
Long-term incentive plan, number of installments | installment   35    
Minimum        
Property, Plant and Equipment [Line Items]        
Period to receive cash proceeds from credit card processors 2 days      
Maximum        
Property, Plant and Equipment [Line Items]        
Period to receive cash proceeds from credit card processors 5 days      
Premium Noni Juice | Product Concentration Risk | Sales Revenue, Product Line        
Property, Plant and Equipment [Line Items]        
Concentration risk percentage (more than) 10.00%      
Enhanced Essential Probiotics | Product Concentration Risk | Sales Revenue, Product Line        
Property, Plant and Equipment [Line Items]        
Concentration risk percentage (more than) 10.00%      
Selling, General and Administrative Expenses        
Property, Plant and Equipment [Line Items]        
Depreciation and amortization expenses $ 424 $ 536    
Software | Minimum        
Property, Plant and Equipment [Line Items]        
Property, and equipment useful life 3 years      
Software | Maximum        
Property, Plant and Equipment [Line Items]        
Property, and equipment useful life 5 years      
Furniture and Fixtures | Minimum        
Property, Plant and Equipment [Line Items]        
Property, and equipment useful life 5 years      
Furniture and Fixtures | Maximum        
Property, Plant and Equipment [Line Items]        
Property, and equipment useful life 7 years      
China        
Property, Plant and Equipment [Line Items]        
Restricted cash $ 2,900 $ 3,100   ¥ 20
South Korea        
Property, Plant and Equipment [Line Items]        
Percentage of restricted cash required as collateral 100.00%      
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.19.1
REVENUE (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Disaggregation of Revenue [Line Items]    
Actual sales returns rate 2.00% 2.00%
Cash payments received toward unshipped products $ 4.5  
Revenue recognized that was included in deferred revenue in prior year $ 2.4  
Minimum    
Disaggregation of Revenue [Line Items]    
Sales return policy term 14 days  
Historical sales returns rate 1.00%  
Maximum    
Disaggregation of Revenue [Line Items]    
Sales return policy term 1 year  
Historical sales returns rate 5.00%  
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.19.1
NET INCOME PER COMMON SHARE (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Earnings Per Share, Basic [Abstract]    
Net income available to common stockholders $ 31,035 $ 23,578
Net income available to common stockholders, Shares (in shares) 11,304,000 11,251,000
Net income available to common stockholders, Per Share (in dollars per share) $ 2.75 $ 2.10
Effect of dilutive securities:    
Non-vested restricted stock (in shares) 14,000 16,000
Diluted net income per common share:    
Net income available to common stockholders plus assumed conversions $ 31,035 $ 23,578
Net income available to common stockholders plus assumed conversions, Shares (in shares) 11,318,000 11,267,000
Net income available to common stockholders plus assumed conversions, Per Share (in dollars per share) $ 2.74 $ 2.09
Antidilutive securities excluded from computation of earnings per share (in shares)   2,232
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.19.1
BALANCE SHEET COMPONENTS (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Cash and cash equivalents:      
Cash and cash equivalents $ 132,653 $ 135,311  
Restricted cash 2,998 3,167  
Cash, cash equivalents and restricted cash 135,651 138,478 $ 128,884
Inventories:      
Finished goods 11,171 7,779  
Raw materials 1,145 799  
Reserve for obsolescence (151) (180)  
Inventories, net 12,165 8,398  
Property and equipment:      
Office equipment 537 530  
Office software 918 916  
Machinery 29 30  
Furniture and fixtures 319 276  
Leasehold improvements 1,022 957  
Construction in progress (including internal-use software development costs) 19 10  
Property and equipment, at cost 2,844 2,719  
Accumulated depreciation and amortization (1,910) (1,570)  
Property and equipment, net 934 1,149  
Other accrued expenses:      
Sales returns 801 614  
Employee-related expense 4,051 5,568  
Warehousing, inventory-related and other 1,269 1,423  
Other accrued expenses 6,121 7,605  
Deferred revenue:      
Deferred revenue 6,795 4,455  
China      
Cash and cash equivalents:      
Cash and cash equivalents 11,100    
Unshipped product      
Deferred revenue:      
Deferred revenue 4,574 2,411  
Auto ship advances      
Deferred revenue:      
Deferred revenue 1,876 1,665  
Other      
Deferred revenue:      
Deferred revenue 345 379  
Cash      
Cash and cash equivalents:      
Cash and cash equivalents 47,323 61,703  
Cash equivalents      
Cash and cash equivalents:      
Cash and cash equivalents $ 85,330 $ 73,608  
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.19.1
FAIR VALUE MEASUREMENTS - Available-for-sale Investments Included in Cash Equivalents (Details) - Cash equivalents - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Adjusted Cost $ 85,363 $ 73,633
Gross Unrealized Gains/Losses (33) (25)
Fair Value 85,330 73,608
Municipal bonds and notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Adjusted Cost 12,149 13,320
Gross Unrealized Gains/Losses (7) (1)
Fair Value 12,142 13,319
Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Adjusted Cost 51,862 49,432
Gross Unrealized Gains/Losses (26) (24)
Fair Value 51,836 49,408
Financial institution instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Adjusted Cost 21,352 10,881
Gross Unrealized Gains/Losses 0 0
Fair Value $ 21,352 $ 10,881
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.19.1
FAIR VALUE MEASUREMENTS - Assets Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Cash equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amounts included in cash and cash equivalents $ 85,330 $ 73,608
Fair Value, Measurements, Recurring | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets measured at fair value on a recurring basis 85,330 73,608
Fair Value, Measurements, Recurring | Level 1 | Cash equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amounts included in cash and cash equivalents 85,330 73,608
Fair Value, Measurements, Recurring | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets measured at fair value on a recurring basis 0 0
Fair Value, Measurements, Recurring | Level 2 | Cash equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amounts included in cash and cash equivalents 0 0
Fair Value, Measurements, Recurring | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets measured at fair value on a recurring basis 0 0
Fair Value, Measurements, Recurring | Level 3 | Cash equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amounts included in cash and cash equivalents 0 0
Fair Value, Measurements, Recurring | Total    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets measured at fair value on a recurring basis 85,330 73,608
Fair Value, Measurements, Recurring | Total | Cash equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amounts included in cash and cash equivalents $ 85,330 $ 73,608
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.19.1
COMMITMENTS AND CONTINGENCIES - Narrative (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Jan. 08, 2019
defendant
Jul. 16, 2018
USD ($)
Apr. 02, 2018
USD ($)
Mar. 29, 2016
plaintiff
Jan. 31, 2016
claim
May 31, 2013
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Commitments and Contingencies Disclosure [Abstract]                
Rent expense for operating leases             $ 2,200 $ 2,000
Number of days to provide notification to terminate purchase commitment agreement           90 days    
Minimum monthly purchase amount           $ 40    
Employment Agreements                
Loss Contingencies [Line Items]                
Number of weeks (months) to provide notice of termination of agreement by either party             1 month  
Securities Class Actions                
Loss Contingencies [Line Items]                
Number of complaints filed | claim         2      
Number of lead plaintiffs named | plaintiff       2        
Litigation settlement amount     $ 1,750          
Securities Class Actions | Subsequent Event | Executive Officers                
Loss Contingencies [Line Items]                
Number of parties named in putative securities class action suit | defendant 2              
Shareholder Derivative Claims                
Loss Contingencies [Line Items]                
Litigation settlement amount   $ 250            
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.19.1
COMMITMENTS AND CONTINGENCIES - Future Minimum Lease Obligations (Details)
$ in Thousands
Dec. 31, 2018
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2019 $ 1,796
2020 1,340
2020 452
2022 332
2023 208
Thereafter 327
Total minimum lease obligations $ 4,455
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.19.1
STOCKHOLDERS' EQUITY - Narrative (Details)
6 Months Ended 12 Months Ended
Feb. 01, 2018
USD ($)
shares
Jan. 24, 2017
USD ($)
shares
Jun. 30, 2017
class
Dec. 31, 2018
USD ($)
$ / shares
shares
Dec. 31, 2017
USD ($)
$ / shares
shares
Apr. 07, 2016
shares
Jan. 12, 2016
USD ($)
Jul. 28, 2015
USD ($)
Class of Stock [Line Items]                
Number of classes of stock | class     2          
Preferred stock, shares authorized (in shares)       5,000,000 5,000,000      
Preferred stock, par value (in dollars per share) | $ / shares       $ 0.001 $ 0.001      
Common stock, shares authorized (in shares)       50,000,000 50,000,000      
Common stock, par value (in dollars per share) | $ / shares       $ 0.001 $ 0.001      
Authorized amount of shares to be repurchased | $             $ 70,000,000.0 $ 15,000,000.0
Repurchase of common stock (in shares)       0 0      
Remaining authorized repurchase amount | $       $ 32,000,000.0        
Restricted Stock                
Class of Stock [Line Items]                
Stock-based compensation expense recognized | $       $ 0 $ 35,000      
2016 Plan | Restricted Stock                
Class of Stock [Line Items]                
Number of shares granted (in shares) 34,202 56,260   34,202 56,260      
Shares vesting period 3 years 3 years            
Value of shares granted | $ $ 554,000 $ 1,400,000            
Common Stock | 2016 Plan                
Class of Stock [Line Items]                
Number of shares authorized (in shares)           2,500,000    
Number of shares available for issuance (in shares)       2,359,671        
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.19.1
STOCKHOLDERS' EQUITY - Dividend Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Nov. 23, 2018
Aug. 24, 2018
May 25, 2018
Mar. 09, 2018
Nov. 24, 2017
Aug. 31, 2017
May 19, 2017
Mar. 03, 2017
Dec. 31, 2018
Dec. 31, 2017
Stockholders' Equity Note [Abstract]                    
Special dividend per common share (in dollars per share) $ 0.18 $ 0.25 $ 1.76   $ 0.15 $ 0.25 $ 0.35 $ 0.35    
Special dividend amount $ 2,048 $ 2,844 $ 20,022   $ 1,701 $ 2,833 $ 3,964 $ 3,962    
Dividend per common share (in dollars per share) $ 0.16 $ 0.15 $ 0.14 $ 0.13 $ 0.12 $ 0.11 $ 0.10 $ 0.09 $ 2.77 $ 1.52
Dividend amount $ 1,820 $ 1,707 $ 1,592 $ 1,479 $ 1,360 $ 1,246 $ 1,133 $ 1,019 $ 31,512 $ 17,218
Payment Date Nov. 23, 2018 Aug. 24, 2018 May 25, 2018 Mar. 09, 2018 Nov. 24, 2017 Aug. 31, 2017 May 19, 2017 Mar. 03, 2017    
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.19.1
STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details) - 2016 Plan - $ / shares
12 Months Ended
Feb. 01, 2018
Jan. 24, 2017
Dec. 31, 2018
Dec. 31, 2017
Restricted Stock        
Shares        
Nonvested, beginning balance (in shares)     58,032 38,256
Granted (in shares) 34,202 56,260 34,202 56,260
Vested (in shares)     (46,748) (35,336)
Forfeited (in shares)       (1,148)
Nonvested, ending balance (in shares)     45,486 58,032
Wtd. Avg. Price at Date of Issuance        
Nonvested, beginning balance (in dollars per share)     $ 28.59 $ 34.13
Granted (in dollars per share)     16.19 25.44
Vested (in dollars per share)     26.31 29.58
Forfeited (in dollars per share)       28.55
Nonvested, ending balance (in dollars per share)     $ 21.61 $ 28.59
Other Restricted Stock        
Shares        
Nonvested, beginning balance (in shares)     0 22,348
Vested (in shares)       (21,930)
Forfeited (in shares)       (418)
Nonvested, ending balance (in shares)       0
Wtd. Avg. Price at Date of Issuance        
Nonvested, beginning balance (in dollars per share)     $ 0 $ 12.15
Vested (in dollars per share)       12.15
Forfeited (in dollars per share)       12.28
Nonvested, ending balance (in dollars per share)       $ 0
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.19.1
STOCKHOLDERS' EQUITY - Changes in Accumulated Other Comprehensive Loss (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2018
USD ($)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Balance, December 31, 2017 $ (413)
Other comprehensive loss (837)
Balance, December 31, 2018 (1,250)
Foreign Currency Translation Adjustment  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Balance, December 31, 2017 (386)
Other comprehensive loss (831)
Balance, December 31, 2018 (1,217)
Unrealized Losses on Available-For-Sale Investments  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Balance, December 31, 2017 (27)
Other comprehensive loss (6)
Balance, December 31, 2018 (33)
Total  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Balance, December 31, 2017 (413)
Balance, December 31, 2018 $ (1,250)
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.19.1
INCOME TAXES - Narrative (Details)
12 Months Ended
Dec. 31, 2018
USD ($)
Operating Loss Carryforwards [Line Items]  
Additional income tax expense due to GILTI $ 2,900,000
Foreign tax credits 1,000,000.0
Foreign net operating loss carryforwards 1,200,000
U.S. Federal  
Operating Loss Carryforwards [Line Items]  
Net operating loss carryforwards $ 0
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.19.1
INCOME TAXES - Components of Income Before Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]    
Domestic $ (3,391) $ (2,965)
Foreign 37,912 46,391
Income before income taxes $ 34,521 $ 43,426
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.19.1
INCOME TAXES - Components of Income Tax Provision (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Current:    
Federal $ 1,815 $ 20,277
State 13 2
Foreign 1,300 1,216
Total current taxes 3,128 21,495
Deferred taxes 358 (1,647)
Income tax provision $ 3,486 $ 19,848
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.19.1
INCOME TAXES - Reconciliation of Provision for Income Tax (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]    
Income tax at federal statutory rate $ 7,249 $ 15,200
Effect of permanent differences 346 459
Tax Cut & Jobs Act one-time transition tax (738) 20,792
Global Intangible Low Taxed Income 3,964 0
Tax Cut & Jobs Act federal rate change (6) 954
Change in valuation allowance (9) (43)
Foreign rate differential (6,541) (15,002)
Foreign tax credits (786) (2,738)
Other reconciling items 7 226
Income tax provision $ 3,486 $ 19,848
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.19.1
INCOME TAXES - Foreign Rate Differentials (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Income Tax Foreign Rate Differential [Line Items]    
Foreign income tax $ 37,912 $ 46,391
Cayman Islands    
Income Tax Foreign Rate Differential [Line Items]    
Statutory Tax Rate 0.00%  
Foreign income tax $ 31,560 39,954
Hong Kong    
Income Tax Foreign Rate Differential [Line Items]    
Statutory Tax Rate 16.50%  
Foreign income tax $ 3,545 3,315
China    
Income Tax Foreign Rate Differential [Line Items]    
Statutory Tax Rate 25.00%  
Foreign income tax $ 2,725 $ 2,584
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.19.1
INCOME TAXES - Deferred Income Taxes (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Deferred tax assets:    
Net operating losses $ 183 $ 192
Stock-based compensation 191 270
Accrued expenses 1,062 1,374
Other 11 6
Total deferred tax assets 1,447 1,842
Valuation allowance (183) (192)
Net deferred tax assets 1,264 1,650
Deferred tax liabilities:    
Foreign earnings (2) (4)
Other (241) (267)
Total deferred tax liabilities (243) (271)
Net deferred tax assets $ 1,021 $ 1,379
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.19.1
RELATED PARTY TRANSACTIONS (Details) - Affiliated Entity
12 Months Ended
Apr. 29, 2015
Dec. 31, 2018
USD ($)
order
Dec. 31, 2017
USD ($)
order
Feb. 28, 2013
Royalty Agreement and License | BHS | ReStor        
Related Party Transaction [Line Items]        
Royalty expense   $ 327,000 $ 306,000  
Number of days for termination notice 120 days      
Royalty Agreement and License | BHS | ReStor | Director        
Related Party Transaction [Line Items]        
Percentage of common stock outstanding (more than)       5.00%
Shipment of Apparel Products | Aberdeen        
Related Party Transaction [Line Items]        
Number of product orders | order   1 1  
Ownership interest by unrelated third party   20.00%    
Amount of product orders shipped   $ 3,700 $ 3,800  
Market-based fee paid be related party   $ 450    
Shipment of Apparel Products | Aberdeen | Sharng Holdings        
Related Party Transaction [Line Items]        
Ownership interest percentage by parent   40.00%    
Shipment of Apparel Products | Aberdeen | President and Wife        
Related Party Transaction [Line Items]        
Ownership interest percentage by parent   40.00%    
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.19.1
EMPLOYEE BENEFIT PLANS (Details) - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2017
Dec. 31, 2018
Dec. 31, 2017
Retirement Benefits [Abstract]      
Maximum compensation percentage   90.00%  
Age requirement for 401(k) contributions   21 years  
Employer matching contribution, percent of employees' gross pay   4.50%  
Employers matching contribution, immediate vesting percentage 100.00%    
Defined contribution plan, cost recognized   $ 87 $ 101
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.19.1
SEGMENT INFORMATION - Net Sales by Geographic Area (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Segment Reporting Information [Line Items]    
Total net sales $ 191,910 $ 197,563
United States    
Segment Reporting Information [Line Items]    
Total net sales 3,637 3,348
Canada    
Segment Reporting Information [Line Items]    
Total net sales 1,710 1,938
Peru    
Segment Reporting Information [Line Items]    
Total net sales 1,635 508
Hong Kong    
Segment Reporting Information [Line Items]    
Total net sales 169,452 174,926
China    
Segment Reporting Information [Line Items]    
Total net sales 7,744 7,282
Taiwan    
Segment Reporting Information [Line Items]    
Total net sales 3,964 5,591
South Korea    
Segment Reporting Information [Line Items]    
Total net sales 493 466
Russia and Kazakhstan    
Segment Reporting Information [Line Items]    
Total net sales 868 913
Europe    
Segment Reporting Information [Line Items]    
Total net sales 1,644 2,278
Other foreign countries    
Segment Reporting Information [Line Items]    
Total net sales $ 763 $ 313
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.19.1
SEGMENT INFORMATION - Net Sales by Product and Service (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Disaggregation of Revenue [Line Items]    
Total net sales $ 191,910 $ 197,563
Less: sales returns (3,284) (3,704)
Product sales    
Disaggregation of Revenue [Line Items]    
Total net sales 181,865 187,591
Freight and other    
Disaggregation of Revenue [Line Items]    
Total net sales $ 13,329 $ 13,676
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.19.1
SEGMENT INFORMATION - Long-live Assets by Geographic Area (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Segment Reporting Information [Line Items]    
Total long-lived assets $ 934 $ 1,149
United States    
Segment Reporting Information [Line Items]    
Total long-lived assets 521 648
Hong Kong    
Segment Reporting Information [Line Items]    
Total long-lived assets 145 78
China    
Segment Reporting Information [Line Items]    
Total long-lived assets 61 112
Other foreign countries    
Segment Reporting Information [Line Items]    
Total long-lived assets $ 207 $ 311
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.19.1
SUBSEQUENT EVENTS (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Mar. 15, 2019
Feb. 01, 2019
Jan. 27, 2019
Nov. 23, 2018
Aug. 24, 2018
May 25, 2018
Mar. 09, 2018
Feb. 01, 2018
Nov. 24, 2017
Aug. 31, 2017
May 19, 2017
Mar. 03, 2017
Jan. 24, 2017
Dec. 31, 2018
Dec. 31, 2017
Subsequent Event [Line Items]                              
Cash dividends declared per common stock outstanding (in dollars per share)                           $ 2.77 $ 1.52
Cash dividends paid per common stock outstanding (in dollars per share)       $ 0.16 $ 0.15 $ 0.14 $ 0.13   $ 0.12 $ 0.11 $ 0.10 $ 0.09   $ 2.77 $ 1.52
Special cash dividend paid per common stock outstanding (in dollars per share)       $ 0.18 $ 0.25 $ 1.76     $ 0.15 $ 0.25 $ 0.35 $ 0.35      
2016 Plan | Restricted Stock                              
Subsequent Event [Line Items]                              
Number of shares granted (in shares)               34,202         56,260 34,202 56,260
Shares vesting period               3 years         3 years    
Value of shares granted               $ 554         $ 1,400    
Subsequent Event                              
Subsequent Event [Line Items]                              
Cash dividends declared per common stock outstanding (in dollars per share)     $ 0.16                        
Special cash dividend declared per common stock outstanding (in dollars per share)     $ 0.08                        
Cash dividends paid per common stock outstanding (in dollars per share) $ 0.16                            
Special cash dividend paid per common stock outstanding (in dollars per share) $ 0.08                            
Subsequent Event | 2016 Plan | Restricted Stock                              
Subsequent Event [Line Items]                              
Number of shares granted (in shares)   22,603                          
Shares vesting period   3 years                          
Value of shares granted   $ 377                          
EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

[TC9, ME&2]08@D$:XW45A\FNC0G^AX0E]WIR9S])FL74H2-$M!%J '7P@FY=I"^R_- MS%5\J" *'IZV:)M78AJ:]%>R.(ALN+::CD9:(-EPK5S%CELM&;AO$TV5EG[< M'_3U?K(J;0]2)W%ZC_;4Z W^T^QB=GEZ!D?[#(X\G/./5Y?8S;9QG<0#;R@> M>&J#$NT\I.W1TEW&/,%)-:M!L-:VD%"B%4I*GPG :6\YXJT=HM[P3Z^BX20> M] ?P8=R+)]T!?^WB$$]&\6#0C2:#>-P%6AWTX_%H /_"UR#_KVM@QWX\G9Y$ M@[A'!(U7C>D,]P8G\1!HW6FN\ 9!PHQ^8]?\*SP)O0E>/HDGDVETG3P: [^, MX+?A*)I,I_A2XUCQNA0<]>!EK^&?DVZ$K ##"O<&>!-=U0KJ MPPVCP83^V]4?3=7\*:SM%/C'!ZPDN$$_6W\:P77O@O7Q83^F47\R;BN3#XRA MWX^FHPFA,JI"G$W4ZC*_IZ3 HYI7_/DZ_J\C>"GPS/!\8],!H1^?#(?PWPE< M/CNT$0*L;CSM=6F9@7WQ0D\'R,]PAZ;1514J9?>FY@^"/>GVB.R&T9GD+AUK M71^%B@WC+FSH*!Z-3Z)?8:I(\&1&F^X7YA9".-*;D9O"].,ADW7?P);VXC$0%T]W *0Y M )+%%TZF(WK(<#1J*UD8Q7N0OZK3ONKU;!N<.F-Y-SN_CGZ977PZBSZX+54.D>'K]RC4G5ITDM3%_*UAK,/)II MS0QTSD3O"_2A?[)]PMYC#;,?+KB F;,F5!X^OP\ZQZAO%!_YL]>-3TYZ5AWB/V\9-[Y_IU^11!CCV3H: M#&@Z(B)>D9 8T"_]$?TB4N/Y82K->]]Q$)_*"F'5>_)L+4./DLSII&RV(33- M!R7VX[4CI "G('NQ:9Z[S[9,'0("?(2ODZ[PD(&I!-K/4PW=*V J@J;=H;B2 M\OU<'PE4=&E3:%8[%A!11JG56GB!4M])3_IBRK)SA7"L#6PJD#1+_MMJG&JD MH/5P+Y+W@M)>>V^B_P@T=&/X M=OY=)F;& 2! T5/@>3XA:.YX?V09[6)RR5 MAV0RY']R%D7GJ"5%$**4W^6%(M2=1=.7#)!Q[WD$AY[V/ ;5KXH;TMV!\'PT M\*90X,WN,;D[>/:F5+G?II#Y,)F_(=]6C:PT0G\)ENDJZH3ET.J;LN# MLH'<(ZI'WOTD/\KQ?_GT#GM\DW-_WRD*KPF/07[\'5,\X/%U68H>@_-;D9^7 M;T']O[P]OWQ_=GEZ?M:0U%Q$UF(Y3K4Q,X4$K?#>([N;[S-_'Q3/WSO>_678 M* ;F KBI#C)J2VPSUW&*M1IR)B';I@;52]&35BW@K_:BLX)RM+W&K*/S!OMR M:S7I$>:3;2I;_XQ*'VPD,LTM9^L@3W1=O^H[19RI3FC?J1U]4''0=VQ9*V"2 MU\/%/[1RB_VZ$@'#40F?3,(,: M+Q?JT5<[/>;,#BM\::P5YT!S1V-!,UL&G6 W':1[K@3L[X$T.U2C5D;UB,?%"7I2-0L/(1V ML\*#E"9EJ+ #Z>)VW!9PT1%+C+9A9D]HXZ#;JYQS['6J-)4I> _='O=ILA;( M"E>T<38 I+2DQ- 8M:1%+5F:G%W8)8F+@&K?W@UFHFOJ1W"$'BF:I:B/32$K M#@Z%AGN_2[ 28II*KI/M4F$+YR9&9KF!9 RI"!PQDWIH^2J6\"!6$N3R'$M_ MUIE'FYKU36[VQKWF0F]SM'^39(Z[=W7<%M"GF$: F!B:[)5--SGA'(Q:E&0C MC68>L:&>5OIG9'RA+KEDS0([B=@%[KEK.6]!"F. 1K^RJ4H^SW^;L7<)WKTK MG( :U718V9]AA4\18IT7FRQ!TYJ0>BE&Q';+)6QP]*6SMUQ\C'ZOE+'";WK3 MX_F7XR[PD4''^.E6>.*YW8J4O$$M @8%<\G6%*6_2Q^2U9*V>Z4UG*GFL5/3 M3*N"/&;("^;"()"6O;*.FOXT U8$FM$D9K:&2Z][,]*]R3;"4&-!SAUEKW%W M:7%[W:.[UQK"=;;\3/&Q,UZ^'GIPM)FX^Z/MQP'OOMZML 7KW?$(3\=ZMV)( M"$XHU;)J:#=7#8(Y?2B GF\[%$H0\,AMMH:U>(IN0/U-OF0++&YP5.7WU(@N M=O-PSFUL"STXFT5BLV]>L^%TE#FS[G>/$C-K;ZKN^()/K>\XMDZYYZKH5#TM M;B+W"0[H5$A8)BL!L*^S$J3H0C(>-*<,8].%<8W#XQ--V/ JT 1*K+D(V6(G M8-J-C!'K*"'"YAYE>*@(ECZY/L622BECE>"-K5KD1@@6R3JA-: 0A]<)2?*+ M[/IIDHY9)DY3PB."^HNR,>IM)0E+6!&(+-P,S%/09R@BBL]S=VO- &4A?LFD M?LR?9R]FGL*:F-VTT2DQMGQK&5OY'3D3Y?=\0$LRZD]C)QU\3@_Q$,&\S%,US-9VIC9FK]T>CX]B\_'\_>??A*&:\([L3WP5J"7K_ 'AD9 MIIHM8;\_) \;.)LY,YX=D,BO";I?R2=L;T440@[6']/+8/5 ^U[9:"?SUU3RAVG!A =JKQ>[7@:9 MGO#5QX^8IJ65P@<9:P=.Y=V'OMP:>INM+W9D=^V4*H6L5&)=FDKHS% MG6.F=9&#[@#\=86.I?\73C>2I;!YR<\ABO\.X_L.9_!-]-=5FFV6Z6I1V8'2 M)IHZ(5AA@/&FK.D5FMMC\*HT38+@RY(3(=OYP!8HTI.+)P7]%PS M12_3!6$1F5)EB9T)<2%*6AJRK'H!^J;BX)+ L+)OT&1"9RA4I817QG8N;7WG M>2V%!T\D FS($H_K#[>6EL/.$=JO58"-73(W+G>N^$1648&HU[6I\L[>)I2K MC](PZ55_Q(8::K15!824/AF[8RF%-[:&<>HO<^9NL6:Y_AX&L[O'-/:I[H!Y MF?*"HX*SWK"IUC#1-B!EE\F7G!OMPE#FVD.&,*>FZJM# M=PQ:963!U,=/D?D>TA6&&SK=AA<%'>')T[1JX%< MVK@7KL<@]DF_&[B:.?Y)XS7=3G\DP 'A#_UA\!9X^@B=D=U)XT+6EGJ3QL-! M(4/7)6$BR)LX"M\!SQ["LT?3VF5&&1K;"P<(!9A,10L1!LH8K E#LT:]_N_< M#F&1D_IVC-@?"Y1H%W@HES;NA>O[Z+(==P-7T]J:P$ES.P8#PZY[P5O@Z3V$ M1@S'C0M%P1X&'CX818-X.A[2,O>FX1NZB,_KQ3T8@W>9,=;V/+DO^S)HNZ>+ MF+A>C+YM_TI8VI;?7D^-5Z?=?Z:][NLEBRRR5=H*7:JC13M# \P@XE:^F- M:^RD7#-\^8R.&+_^JC=R0AB81S#I.E]TO$D$FI2SJ6SE'Y7X==ID-ZI&FT;" M$L<[SC?'#R1GD2DSC]<]T-:3]>ZLJ%$Y!8H=X_^Y@N+&AP4T$_ 0,5"<%+:" MNE-[C3FTXA"7VP'4 ZCU1!Q>Y-7KB;W?.BU>CX1L>]H ?+Z;R! M&>*\[LL$BP22G<:. [-C[.QII1!3#$94Z+H&+2Y*VQUNW@!Q\H9)<>]R5VX9 M=;ELM,+"JC]PEJ0*S((+%)LC&)2[WK%,"1SN]8=P1^M*X[R0N'I[H.35P(W< MR0!\TF]=M?83)29$D2I:OW[DI60*'FP#*';PMF;?'+\NI]<(,LXT6+)-P#LN M"I/Y#JYL6\NG]H:&G>?[1!$,-UVXQ4UA^J\&I,XYSYI$IG=MHQ\ %PC0%G%( M1RZ,FKI6Y^I2F;B,,LCW]#ZO3L&WM8;U&E+395Y':N[T0]EC:+OTNZ#:M+28 MQ3-G'J#MP=5!P0VU8-Y?),_/Z^[J%4'0ITH3W:UP,PRNHT-Y1X7RS=>B_/+% MNPT%3^DSKHT!=+HE(9,DL+#$T2 55C*6P ^/RD2O%K;'L";P MZ!^()$],R8K%EZS,BSH+Z$2?R$SHQZ.&JO\LISAR7"6VA:J6(E)/0%;,=^N2 M#T30>3WHZV):SCB\A4>8U2A\+[5PY3CW3 MX=IE=.IS&0SC?K?O+(Q;>=9=C\!K*(E!5L)LIN^&9?#:%Y4@X9I$5 M-@@@EKA<;4C.G$JL9(,&,Q4]X4JOQ![D:;@">7JWDO^E/YIT&65<;_?5( MJN,J?*K.AC=R-([[X^[_E1LY?GXC>TZBZ,LV\W?LH5D+6UO^>VQIP'=@70=E MD#,U,EF,^R"PFV_4Y?)KA9SF"S7&H@K\8G'"R,^5>USF&\F6P5]K_&@<#4[B M_FB,)NX0K>#W/K'U1QTPX7_A^X\PFV. 6./^M#,Z0148UQ9_04S_"?YPTAF- M]K]R$HU.XB[BB^#:J7FAL*G>N ,VG+YP.(XG_-QQ9]#;_]R3:#B*AR?CJ-_K MC'O?L@A^$P/"$P-]H_^M\^[UX.L!<"?[:6>!A[X2_[I\\M[R* M-]1_W9P-]LV>>@7*J.4UQ7IM<8SG>H53"1K,HM?<).(EM O/@?6;K>2=5N8S M*X<=E+W@Z_%W@SJ'QQQCK@CE"BGJG*%IDH 5!]8&T>@G8P*='_49?@]+B_CT MJ[99'IT,*%L([X+/>%/K"TX(O!\#.?&C!?F.7XU@6^ON54D;O9W]SR;04](K M;Y.OAZ$ZW6<%TL;$#I#*'=8J2$OUNRI+M(>FOG//YXJ^Q6Z8%5A_./=X,.W) M2L?3,2+]=>L'DWC:ZT=PNO&2\_:A(5>*1Y29,QS$P_XX,+/JP;W)XK&^Y[R8 M5BL@7@F&HSQ'Q5]'CUX;PS86IQ/I[<(.[!888C M/YPZ*4?R&[!7H)KQ$ GI/#0[6!KB=J_0DW8"O&1FVP!XC5FY-IIG"CJ/$<'F M?&';HDJ/'.Z7XF:-+G2;-39HK0Q\>B%U5:D)UE=]+P/ M3&_%#*X^)=?T1B!/W(1@K+N;$*O2;CZ8Q# 8CD%N3.FXJ02+\);\K&?.T M28_9.^&4>8=+CR8#$DO=>#+M1^]7^1WU, $%@)M17.2/^$B8C0R;_:/*DEO> MII.BJ8@SA_C.=#2,3@TTT.9XD,E(\N9HBNQI.'!.&:<,:>/1D%,? MT1+O.Q?CI+@D"NS-A%@D'%N>Y97(1=MD@IMW3$",C0^DSCV'7$M4!(B(JF8Z MQ:F8.AT0%1F-" ZVCL5EZ_1M59KD+O_RK11Y8X:)NWB-;W$S:9\01WA>8IWC MTNSW'R6$,,;DA\$TQOVTO;5 YQG!)0/8''1W#X"O<*O,/KI<_XBIE^2^'YT, M+9_X-A;>QK<=[B-Y#YS5[J#;60;#AIX,:%O[[6Z@'G#U_J2+FH>7W8D>^C%% M+R9#H:I>+U+NN&@. H,RP *!UP[[E''5('L<#=+S%(GYDIK*AY[2'V,D:#SJ M^E-U$I.L8F(\ST=].E/F!!SU^?!@&O[KT*#=BKEP,8VL/^GM&=DK2NVEU.<8 M$T-1O-FBE ['-LIM.)%*[#O;"8ERLE^KS?+>T1GC_(I 7JOZ! Q[(1 ]E>! M!8[K %UJ4:)^_U-3!@5YZ7*I;JH;^L-I?O33#EX'GPCTU\/8JNSVS>PG_-ON MMI2LUP*5IIAIWBA=C(OAU&:O[(YW(GFL+>V?:%:5]M"F?D3(V[73*A6>)\CG M7?I$322T(HSI;*P$111)#S+59>?:NLHT'4TK*6AA1\V&]>SF-)H,NW%D%6ZX MC9LZUZ))'+;2E"&#>Y/)-6<$RY>:MTLK>JIG[\(.G3/>/)LX/85A(=[F07T@ M=!%<0"O"3GDLI6K=F*4MD%-7\9RF3[;RH04T<1TX:X=1[5,[1BVO,Y/:E:@A M^B/VO5>VS)E;_ZG^/"U.AG<>H$UEVOX "5&UZK8S^$WGKS1GXOWYQ>VYG@A* MZW&[&;M(4;K2CJT6Z<-@NKF3@.*Z(E17DR3,4OW?A+"JSPO=<_L'37SQ,45* M*&N#6UI%CPKA90M+62+WI#PYL^M5\FC/O=2.55 J&UD"BO7BA^84+]3UP=&>V 5?89MYY.IFV#LE* %8Y J$N%2E8X93EE M< >M!:D'>U= _>.ZWL\N1%8ZRE7XV<[C_@8RNUQHPV*&)VS(AXWKN&DHV_RN MT$,5]< GAKR 5-B #-7$2Z,S($?&-X8772$8(075OHM]<=RVVIQOD_?0.DX> MI :N0SZ(%VS@)F<:54.YN6I4+MJ4]BR>8/4Y,$=RC1JBL[VHO1K)'&S"51B. MN:NRE2(8I:@E>S0\!HU"F.+8!\Q J2$P*#\Z'G/R2DF+P"'A0-T92+& M-K^Y(; 5>RD5F]V>XAX+J9U?#^M"+;)D$4";TD1=1[@:V971YDF;N07B<]&_ ME*DC&R&W2VQ*A#/%CH9528%BVFTW6IY"ELHXKVC% M&&%N"#[BWMA-!7'C6*=24X28;L5F+[.VMF/74E @T#GB8G9[]C;Z.+N^_2VZ MO9Y=WLQ.;\^O+ALQC&N!(WVD$K$4Y]'TE_9 1OOC&PASS@#@LKS7@OZ?>

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
  •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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 174 282 1 false 69 0 false 12 false false R1.htm 0001000 - Document - Document And Entity Information Sheet http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1003000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 5 false false R6.htm 1004000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101100 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 2102100 - Disclosure - REVENUE Sheet http://www.naturalhealthtrendscorp.com/role/Revenue REVENUE Notes 9 false false R10.htm 2103100 - Disclosure - NET INCOME PER COMMON SHARE Sheet http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShare NET INCOME PER COMMON SHARE Notes 10 false false R11.htm 2104100 - Disclosure - BALANCE SHEET COMPONENTS Sheet http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponents BALANCE SHEET COMPONENTS Notes 11 false false R12.htm 2105100 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.naturalhealthtrendscorp.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS Notes 12 false false R13.htm 2106100 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 2107100 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 14 false false R15.htm 2108100 - Disclosure - INCOME TAXES Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxes INCOME TAXES Notes 15 false false R16.htm 2109100 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 16 false false R17.htm 2110100 - Disclosure - EMPLOYEE BENEFIT PLANS Sheet http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlans EMPLOYEE BENEFIT PLANS Notes 17 false false R18.htm 2111100 - Disclosure - SEGMENT INFORMATION Sheet http://www.naturalhealthtrendscorp.com/role/SegmentInformation SEGMENT INFORMATION Notes 18 false false R19.htm 2112100 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.naturalhealthtrendscorp.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 19 false false R20.htm 2201201 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 20 false false R21.htm 2303301 - Disclosure - NET INCOME PER COMMON SHARE (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareTables NET INCOME PER COMMON SHARE (Tables) Tables http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShare 21 false false R22.htm 2304301 - Disclosure - BALANCE SHEET COMPONENTS (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsTables BALANCE SHEET COMPONENTS (Tables) Tables http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponents 22 false false R23.htm 2305301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.naturalhealthtrendscorp.com/role/FairValueMeasurements 23 false false R24.htm 2306301 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies 24 false false R25.htm 2307301 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.naturalhealthtrendscorp.com/role/StockholdersEquity 25 false false R26.htm 2308301 - Disclosure - INCOME TAXES (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://www.naturalhealthtrendscorp.com/role/IncomeTaxes 26 false false R27.htm 2311301 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/SegmentInformationTables SEGMENT INFORMATION (Tables) Tables http://www.naturalhealthtrendscorp.com/role/SegmentInformation 27 false false R28.htm 2401402 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies 28 false false R29.htm 2402401 - Disclosure - REVENUE (Details) Sheet http://www.naturalhealthtrendscorp.com/role/RevenueDetails REVENUE (Details) Details http://www.naturalhealthtrendscorp.com/role/Revenue 29 false false R30.htm 2403402 - Disclosure - NET INCOME PER COMMON SHARE (Details) Sheet http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails NET INCOME PER COMMON SHARE (Details) Details http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareTables 30 false false R31.htm 2404402 - Disclosure - BALANCE SHEET COMPONENTS (Details) Sheet http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails BALANCE SHEET COMPONENTS (Details) Details http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsTables 31 false false R32.htm 2405402 - Disclosure - FAIR VALUE MEASUREMENTS - Available-for-sale Investments Included in Cash Equivalents (Details) Sheet http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails FAIR VALUE MEASUREMENTS - Available-for-sale Investments Included in Cash Equivalents (Details) Details 32 false false R33.htm 2405403 - Disclosure - FAIR VALUE MEASUREMENTS - Assets Measured at Fair Value on Recurring Basis (Details) Sheet http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails FAIR VALUE MEASUREMENTS - Assets Measured at Fair Value on Recurring Basis (Details) Details 33 false false R34.htm 2406402 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails COMMITMENTS AND CONTINGENCIES - Narrative (Details) Details 34 false false R35.htm 2406403 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Lease Obligations (Details) Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails COMMITMENTS AND CONTINGENCIES - Future Minimum Lease Obligations (Details) Details 35 false false R36.htm 2407402 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails STOCKHOLDERS' EQUITY - Narrative (Details) Details 36 false false R37.htm 2407403 - Disclosure - STOCKHOLDERS' EQUITY - Dividend Activity (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails STOCKHOLDERS' EQUITY - Dividend Activity (Details) Details 37 false false R38.htm 2407404 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details) Details 38 false false R39.htm 2407405 - Disclosure - STOCKHOLDERS' EQUITY - Changes in Accumulated Other Comprehensive Loss (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails STOCKHOLDERS' EQUITY - Changes in Accumulated Other Comprehensive Loss (Details) Details 39 false false R40.htm 2408402 - Disclosure - INCOME TAXES - Narrative (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails INCOME TAXES - Narrative (Details) Details 40 false false R41.htm 2408403 - Disclosure - INCOME TAXES - Components of Income Before Income Taxes (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails INCOME TAXES - Components of Income Before Income Taxes (Details) Details 41 false false R42.htm 2408404 - Disclosure - INCOME TAXES - Components of Income Tax Provision (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails INCOME TAXES - Components of Income Tax Provision (Details) Details 42 false false R43.htm 2408405 - Disclosure - INCOME TAXES - Reconciliation of Provision for Income Tax (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails INCOME TAXES - Reconciliation of Provision for Income Tax (Details) Details 43 false false R44.htm 2408406 - Disclosure - INCOME TAXES - Foreign Rate Differentials (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesForeignRateDifferentialsDetails INCOME TAXES - Foreign Rate Differentials (Details) Details 44 false false R45.htm 2408407 - Disclosure - INCOME TAXES - Deferred Income Taxes (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails INCOME TAXES - Deferred Income Taxes (Details) Details 45 false false R46.htm 2409401 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails RELATED PARTY TRANSACTIONS (Details) Details http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions 46 false false R47.htm 2410401 - Disclosure - EMPLOYEE BENEFIT PLANS (Details) Sheet http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetails EMPLOYEE BENEFIT PLANS (Details) Details http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlans 47 false false R48.htm 2411402 - Disclosure - SEGMENT INFORMATION - Net Sales by Geographic Area (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByGeographicAreaDetails SEGMENT INFORMATION - Net Sales by Geographic Area (Details) Details 48 false false R49.htm 2411403 - Disclosure - SEGMENT INFORMATION - Net Sales by Product and Service (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByProductAndServiceDetails SEGMENT INFORMATION - Net Sales by Product and Service (Details) Details 49 false false R50.htm 2411404 - Disclosure - SEGMENT INFORMATION - Long-live Assets by Geographic Area (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLiveAssetsByGeographicAreaDetails SEGMENT INFORMATION - Long-live Assets by Geographic Area (Details) Details 50 false false R51.htm 2412401 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails SUBSEQUENT EVENTS (Details) Details http://www.naturalhealthtrendscorp.com/role/SubsequentEvents 51 false false All Reports Book All Reports nhtc2018123110k.htm nhtc-20181231.xsd nhtc-20181231_cal.xml nhtc-20181231_def.xml nhtc-20181231_lab.xml nhtc-20181231_pre.xml q42018ex21-1.htm q42018ex31-1.htm q42018ex31-2.htm q42018ex32-1.htm http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2018-01-31 true true JSON 69 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nhtc2018123110k.htm": { "axisCustom": 1, "axisStandard": 26, "contextCount": 174, "dts": { "calculationLink": { "local": [ "nhtc-20181231_cal.xml" ] }, "definitionLink": { "local": [ "nhtc-20181231_def.xml" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml" ] }, "inline": { "local": [ "nhtc2018123110k.htm" ] }, "labelLink": { "local": [ "nhtc-20181231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-doc-2018-01-31.xml" ] }, "presentationLink": { "local": [ "nhtc-20181231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-ref-2018-01-31.xml" ] }, "schema": { "local": [ "nhtc-20181231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" ] } }, "elementCount": 481, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 26, "http://www.naturalhealthtrendscorp.com/20181231": 12, "http://xbrl.sec.gov/dei/2018-01-31": 12, "total": 50 }, "keyCustom": 34, "keyStandard": 248, "memberCustom": 25, "memberStandard": 44, "nsprefix": "nhtc", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document And Entity Information", "role": "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - NET INCOME PER COMMON SHARE", "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShare", "shortName": "NET INCOME PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - BALANCE SHEET COMPONENTS", "role": "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponents", "shortName": "BALANCE SHEET COMPONENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurements", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - INCOME TAXES", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - EMPLOYEE BENEFIT PLANS", "role": "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlans", "shortName": "EMPLOYEE BENEFIT PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - SEGMENT INFORMATION", "role": "http://www.naturalhealthtrendscorp.com/role/SegmentInformation", "shortName": "SEGMENT INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - SUBSEQUENT EVENTS", "role": "http://www.naturalhealthtrendscorp.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "lang": null, "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - NET INCOME PER COMMON SHARE (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareTables", "shortName": "NET INCOME PER COMMON SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - BALANCE SHEET COMPONENTS (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsTables", "shortName": "BALANCE SHEET COMPONENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDividendsPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDividendsPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - INCOME TAXES (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - SEGMENT INFORMATION (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/SegmentInformationTables", "shortName": "SEGMENT INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2018Q4", "decimals": "-5", "lang": null, "name": "us-gaap:DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "2", "first": true, "lang": null, "name": "nhtc:RevenueFromContractWithCustomersSalesReturnsPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - REVENUE (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/RevenueDetails", "shortName": "REVENUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "2", "first": true, "lang": null, "name": "nhtc:RevenueFromContractWithCustomersSalesReturnsPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2018Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - NET INCOME PER COMMON SHARE (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails", "shortName": "NET INCOME PER COMMON SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - BALANCE SHEET COMPONENTS (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "shortName": "BALANCE SHEET COMPONENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - FAIR VALUE MEASUREMENTS - Available-for-sale Investments Included in Cash Equivalents (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails", "shortName": "FAIR VALUE MEASUREMENTS - Available-for-sale Investments Included in Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2018Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - FAIR VALUE MEASUREMENTS - Assets Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "FAIR VALUE MEASUREMENTS - Assets Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Lease Obligations (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Future Minimum Lease Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2018Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "shortName": "STOCKHOLDERS' EQUITY - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "I2016Q1Jan12", "decimals": "INF", "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "D2018Q4SD11-23", "decimals": "INF", "first": true, "lang": null, "name": "nhtc:CommonStockSpecialDividendsPerShareCashPaid", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - STOCKHOLDERS' EQUITY - Dividend Activity (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails", "shortName": "STOCKHOLDERS' EQUITY - Dividend Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "D2018Q4SD11-23", "decimals": "-3", "lang": null, "name": "nhtc:SpecialDividendsCommonStockCash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails", "shortName": "STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407405 - Disclosure - STOCKHOLDERS' EQUITY - Changes in Accumulated Other Comprehensive Loss (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails", "shortName": "STOCKHOLDERS' EQUITY - Changes in Accumulated Other Comprehensive Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "nhtc:TaxCutsAndJobsActOf2017GlobalIntangibleLowtaxedIncomeGILTIIncomeTaxExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - INCOME TAXES - Narrative (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails", "shortName": "INCOME TAXES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "nhtc:TaxCutsAndJobsActOf2017GlobalIntangibleLowtaxedIncomeGILTIIncomeTaxExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - INCOME TAXES - Components of Income Before Income Taxes (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails", "shortName": "INCOME TAXES - Components of Income Before Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - INCOME TAXES - Components of Income Tax Provision (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails", "shortName": "INCOME TAXES - Components of Income Tax Provision (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408405 - Disclosure - INCOME TAXES - Reconciliation of Provision for Income Tax (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails", "shortName": "INCOME TAXES - Reconciliation of Provision for Income Tax (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408406 - Disclosure - INCOME TAXES - Foreign Rate Differentials (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesForeignRateDifferentialsDetails", "shortName": "INCOME TAXES - Foreign Rate Differentials (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_CaymanIslandsTaxInformationAuthorityMember", "decimals": "INF", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408407 - Disclosure - INCOME TAXES - Deferred Income Taxes (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails", "shortName": "INCOME TAXES - Deferred Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD_srt_CounterpartyNameAxis_nhtc_BroadyHealthSciencesMember_srt_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionAxis_nhtc_RoyaltyAgreementandLicenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RoyaltyExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409401 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD_srt_CounterpartyNameAxis_nhtc_BroadyHealthSciencesMember_srt_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionAxis_nhtc_RoyaltyAgreementandLicenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RoyaltyExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410401 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetails", "shortName": "EMPLOYEE BENEFIT PLANS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - SEGMENT INFORMATION - Net Sales by Geographic Area (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByGeographicAreaDetails", "shortName": "SEGMENT INFORMATION - Net Sales by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD_srt_StatementGeographicalAxis_country_US", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - SEGMENT INFORMATION - Net Sales by Product and Service (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByProductAndServiceDetails", "shortName": "SEGMENT INFORMATION - Net Sales by Product and Service (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "lang": null, "name": "nhtc:ContractwithCustomerRefundLiabilitySalesReturns", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - SEGMENT INFORMATION - Long-live Assets by Geographic Area (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLiveAssetsByGeographicAreaDetails", "shortName": "SEGMENT INFORMATION - Long-live Assets by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412401 - Disclosure - SUBSEQUENT EVENTS (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails", "shortName": "SUBSEQUENT EVENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "D2019Q1Jan27-Jan27_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies", "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - REVENUE", "role": "http://www.naturalhealthtrendscorp.com/role/Revenue", "shortName": "REVENUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nhtc2018123110k.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 69, "tag": { "country_CA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CANADA", "terseLabel": "Canada" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "country_CN": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CHINA", "terseLabel": "China" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLiveAssetsByGeographicAreaDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "country_HK": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "HONG KONG", "terseLabel": "Hong Kong" } } }, "localname": "HK", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLiveAssetsByGeographicAreaDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "country_KR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "KOREA, REPUBLIC OF", "terseLabel": "South Korea" } } }, "localname": "KR", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "country_PE": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "PERU", "terseLabel": "Peru" } } }, "localname": "PE", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "country_TW": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "TAIWAN, PROVINCE OF CHINA", "terseLabel": "Taiwan" } } }, "localname": "TW", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLiveAssetsByGeographicAreaDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "nhtc_AccruedSalesReturns": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Sales Returns", "label": "Accrued Sales Returns", "terseLabel": "Sales returns" } } }, "localname": "AccruedSalesReturns", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_AccruedWarehousingAndInventoryRelatedExpense": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Warehousing And Inventory Related Expense", "label": "Accrued Warehousing And Inventory Related Expense", "terseLabel": "Warehousing, inventory-related and other" } } }, "localname": "AccruedWarehousingAndInventoryRelatedExpense", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_AgeRequirementFor401KContributions": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents age requirement for 401K contributions.", "label": "Age Requirement For 401K Contributions", "terseLabel": "Age requirement for 401(k) contributions" } } }, "localname": "AgeRequirementFor401KContributions", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetails" ], "xbrltype": "durationItemType" }, "nhtc_AmountsHeldnDistributorEWalletsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the policy of amounts held in customer eWallets.", "label": "Amounts Held in Distributor eWallets [Policy Text Block]", "terseLabel": "Amounts Held in eWallets" } } }, "localname": "AmountsHeldnDistributorEWalletsPolicyTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nhtc_AutoShipAdvancesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Auto Ship advances.", "label": "Auto Ship Advances [Member]", "terseLabel": "Auto ship advances" } } }, "localname": "AutoShipAdvancesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "nhtc_BalanceSheetComponentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Balance Sheet Components [Abstract]", "label": "Balance Sheet Components [Abstract]" } } }, "localname": "BalanceSheetComponentsAbstract", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "xbrltype": "stringItemType" }, "nhtc_BroadyHealthSciencesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Broady Health Sciences.", "label": "Broady Health Sciences [Member]", "verboseLabel": "BHS" } } }, "localname": "BroadyHealthSciencesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "nhtc_CapitalizedContractCostsLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Capitalized Contract Costs, Liability, Current", "label": "Capitalized Contract Costs, Liability, Current", "terseLabel": "Amounts held in eWallets" } } }, "localname": "CapitalizedContractCostsLiabilityCurrent", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "nhtc_CashandCashEquivalentsPeriodtoReceiveCashProceedsFromCreditCardProcessors": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash and Cash Equivalents, Period to Receive Cash Proceeds From Credit Card Processors", "label": "Cash and Cash Equivalents, Period to Receive Cash Proceeds From Credit Card Processors", "terseLabel": "Period to receive cash proceeds from credit card processors" } } }, "localname": "CashandCashEquivalentsPeriodtoReceiveCashProceedsFromCreditCardProcessors", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "nhtc_CommonStockPercentageofBeneficialStockOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock, Percentage of Beneficial Stock Outstanding", "label": "Common Stock, Percentage of Beneficial Stock Outstanding", "terseLabel": "Percentage of common stock outstanding (more than)" } } }, "localname": "CommonStockPercentageofBeneficialStockOutstanding", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "nhtc_CommonStockSpecialDividendsPerShareCashPaid": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock, Special Dividends, Per Share, Cash Paid", "label": "Common Stock, Special Dividends, Per Share, Cash Paid", "terseLabel": "Special dividend per common share (in dollars per share)", "verboseLabel": "Special cash dividend paid per common stock outstanding (in dollars per share)" } } }, "localname": "CommonStockSpecialDividendsPerShareCashPaid", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "nhtc_CommonStockSpecialDividendsPerShareDeclared": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Special dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Special Dividends,Per Share, Declared", "terseLabel": "Special cash dividend declared per common stock outstanding (in dollars per share)" } } }, "localname": "CommonStockSpecialDividendsPerShareDeclared", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "nhtc_ContractWithCustomerLiabilityIncreaseFromCashReceipts": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Liability, Increase From Cash Receipts", "label": "Contract With Customer, Liability, Increase From Cash Receipts", "terseLabel": "Cash payments received toward unshipped products" } } }, "localname": "ContractWithCustomerLiabilityIncreaseFromCashReceipts", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_ContractwithCustomerArrangementTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract with Customer, Arrangement Type", "label": "Contract with Customer, Arrangement Type [Axis]", "terseLabel": "Contract with Customer, Arrangement Type [Axis]" } } }, "localname": "ContractwithCustomerArrangementTypeAxis", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "nhtc_ContractwithCustomerArrangementTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Contract with Customer, Arrangement Type", "label": "Contract with Customer, Arrangement Type [Domain]", "terseLabel": "Contract with Customer, Arrangement Type [Domain]" } } }, "localname": "ContractwithCustomerArrangementTypeDomain", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "nhtc_ContractwithCustomerRefundLiabilitySalesReturns": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contract with Customer, Refund Liability, Sales Returns", "label": "Contract with Customer, Refund Liability, Sales Returns", "negatedLabel": "Less: sales returns" } } }, "localname": "ContractwithCustomerRefundLiabilitySalesReturns", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByProductAndServiceDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents cumulative translation adjustment realized in net income.", "label": "Cumulative Translation Adjustment Realized In Net Income", "negatedLabel": "Cumulative translation adjustment realized in net income" } } }, "localname": "CumulativeTranslationAdjustmentRealizedInNetIncome", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nhtc_DeferredCompensationRewardPayableEqualConsecutiveMonthlyInstallments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of equal consecutive monthly installments of deferred compensation award payable.", "label": "nhtc_DeferredCompensationRewardPayableEqualConsecutiveMonthlyInstallments", "terseLabel": "Long-term incentive plan, number of installments" } } }, "localname": "DeferredCompensationRewardPayableEqualConsecutiveMonthlyInstallments", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "nhtc_DeferredCompensationRewardPaymentPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the percentage of deferred compensation award payable.", "label": "nhtc_DeferredCompensationRewardPaymentPercentage", "terseLabel": "Long-term incentive plan, percentage of award payable in cash" } } }, "localname": "DeferredCompensationRewardPaymentPercentage", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "nhtc_DeferredIncomeTaxExpenseBenefitExcludingEffectsofForeignExchange": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Income Tax Expense (Benefit), Excluding Effects of Foreign Exchange", "label": "Deferred Income Tax Expense (Benefit), Excluding Effects of Foreign Exchange", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefitExcludingEffectsofForeignExchange", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nhtc_DocumentAndEntityInformation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Document And Entity Information" } } }, "localname": "DocumentAndEntityInformation", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "xbrltype": "stringItemType" }, "nhtc_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActGlobalIntangibleLowtaxIncomeGILTIAmount": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Global Intangible Low-tax Income (GILTI), Amount", "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Global Intangible Low-tax Income (GILTI), Amount", "terseLabel": "Global Intangible Low Taxed Income" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActGlobalIntangibleLowtaxIncomeGILTIAmount", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActTransitionTaxonAccumulatedForeignEarningsAmount": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Transition Tax on Accumulated Foreign Earnings, Amount", "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Transition Tax on Accumulated Foreign Earnings, Amount", "terseLabel": "Tax Cut & Jobs Act one-time transition tax" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActTransitionTaxonAccumulatedForeignEarningsAmount", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_EmploymentAgreementNumberofWeeksToProvideTerminationNoticebyParties": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employment Agreement, Number of Weeks To Provide Termination Notice by Parties", "label": "Employment Agreement, Number of Weeks To Provide Termination Notice by Parties", "terseLabel": "Number of weeks (months) to provide notice of termination of agreement by either party" } } }, "localname": "EmploymentAgreementNumberofWeeksToProvideTerminationNoticebyParties", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "nhtc_EmploymentAgreementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employment Agreements", "label": "Employment Agreements [Member]", "terseLabel": "Employment Agreements" } } }, "localname": "EmploymentAgreementsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_EnhancedEssentialProbioticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Enhanced Essential Probiotics", "label": "Enhanced Essential Probiotics [Member]", "terseLabel": "Enhanced Essential Probiotics" } } }, "localname": "EnhancedEssentialProbioticsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "nhtc_EquityIncentive2016PlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Incentive 2016 Plan", "label": "Equity Incentive 2016 Plan [Member]", "verboseLabel": "2016 Plan" } } }, "localname": "EquityIncentive2016PlanMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "nhtc_FinancialInstitutionInstrumentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to financial institution instruments.", "label": "Financial Institution Instruments [Member]", "verboseLabel": "Financial institution instruments" } } }, "localname": "FinancialInstitutionInstrumentsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "nhtc_IncomeTaxForeignRateDifferentialLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Income Tax Foreign Rate Differential components", "label": "Income Tax Foreign Rate Differential [Line Items]", "terseLabel": "Income Tax Foreign Rate Differential [Line Items]" } } }, "localname": "IncomeTaxForeignRateDifferentialLineItems", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesForeignRateDifferentialsDetails" ], "xbrltype": "stringItemType" }, "nhtc_IncomeTaxForeignRateDifferentialTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Income Tax Foreign Rate Differential components", "label": "Income Tax Foreign Rate Differential [Table]", "terseLabel": "Income Tax Foreign Rate Differential [Table]" } } }, "localname": "IncomeTaxForeignRateDifferentialTable", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesForeignRateDifferentialsDetails" ], "xbrltype": "stringItemType" }, "nhtc_IncomeTaxForeignRateDifferentialTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Table Text Block] for Income Tax Foreign Rate Differential components", "label": "Income Tax Foreign Rate Differential [Table Text Block]", "terseLabel": "Schedule of Income Tax Foreign Rate Differential" } } }, "localname": "IncomeTaxForeignRateDifferentialTableTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "nhtc_IncomeTaxReconciliationEffectOfPermanentDifferences": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Effect of permanent differences.", "label": "Effect of permanent differences", "terseLabel": "Effect of permanent differences" } } }, "localname": "IncomeTaxReconciliationEffectOfPermanentDifferences", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_IncreaseDecreaseinCapitalizedContractCostLiability": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) in Capitalized Contract Cost Liability", "label": "Increase (Decrease) in Capitalized Contract Cost Liability", "terseLabel": "Amounts held in eWallets" } } }, "localname": "IncreaseDecreaseinCapitalizedContractCostLiability", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nhtc_LongTermIncentivePlanPaymentCommencingInFebruary2021AndEndingInDecember2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the Long-Term Incentive Plan (the \u201cLTI Plan\u201d), payments commencing in February 2021 and ending in December 2023.", "label": "Long-Term Incentive Plan, Payment Commencing in February 2021 and Ending in December 2023 [Member]", "terseLabel": "Long-Term Incentive Plan, Payment Commencing in February 2021 and Ending in December 2023" } } }, "localname": "LongTermIncentivePlanPaymentCommencingInFebruary2021AndEndingInDecember2023Member", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "nhtc_LongTermIncentivePlanPaymentCommencingInFebruaryOfTheCalendarYearImmediatelyFollowingTheConclusionOfThePerformancePeriodMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the Long-Term Incentive Plan (the \u201cLTI Plan\u201d), payments commencing in February of the calendar year immediately following the conclusion of the performance period.", "label": "Long-Term Incentive Plan, Payment Commencing in February of the Calendar Year Immediately Following the Conclusion of the Performance Period [Member]", "terseLabel": "Long-Term Incentive Plan, Payment Commencing in February of the Calendar Year Immediately Following the Conclusion of the Performance Period" } } }, "localname": "LongTermIncentivePlanPaymentCommencingInFebruaryOfTheCalendarYearImmediatelyFollowingTheConclusionOfThePerformancePeriodMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "nhtc_MunicipalBondsAndNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term and short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds and Notes [Member]", "verboseLabel": "Municipal bonds and notes" } } }, "localname": "MunicipalBondsAndNotesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "nhtc_NoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Noncurrent Liabilities", "label": "Noncurrent Liabilities [Member]", "terseLabel": "Non-current Liability" } } }, "localname": "NoncurrentLiabilitiesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "nhtc_NumberOfClassesOfStock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Classes Of Stock", "label": "Number Of Classes Of Stock", "terseLabel": "Number of classes of stock" } } }, "localname": "NumberOfClassesOfStock", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "integerItemType" }, "nhtc_NumberOfDaysTerminationNotice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents number of days termination notice.", "label": "Number Of Days Termination Notice", "terseLabel": "Number of days for termination notice" } } }, "localname": "NumberOfDaysTerminationNotice", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "durationItemType" }, "nhtc_NumberofProductOrders": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Product Orders", "label": "Number of Product Orders", "terseLabel": "Number of product orders" } } }, "localname": "NumberofProductOrders", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "integerItemType" }, "nhtc_OfficeEquipment": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents other equipment.", "label": "Office equipment", "terseLabel": "Office equipment" } } }, "localname": "OfficeEquipment", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_OtherAccruedExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents other accrued expenses abstract.", "label": "Other accrued expenses:", "terseLabel": "Other accrued expenses:" } } }, "localname": "OtherAccruedExpensesAbstract", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "nhtc_OtherAccruedExpensesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Accrued Expenses", "label": "Other Accrued Expenses [Member]", "terseLabel": "Other Accrued Expenses" } } }, "localname": "OtherAccruedExpensesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "nhtc_OtherForeignCountriesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents other foreign countries.", "label": "Other Foreign Countries [Member]", "terseLabel": "Other foreign countries" } } }, "localname": "OtherForeignCountriesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLiveAssetsByGeographicAreaDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "nhtc_OtherRestrictedStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Restricted Stock", "label": "Other Restricted Stock [Member]", "terseLabel": "Other Restricted Stock" } } }, "localname": "OtherRestrictedStockMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "nhtc_OtherRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Revenue", "label": "Other Revenue [Member]", "terseLabel": "Other" } } }, "localname": "OtherRevenueMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "nhtc_PremiumNoniJuiceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Premium Noni Juice", "label": "Premium Noni Juice [Member]", "terseLabel": "Premium Noni Juice" } } }, "localname": "PremiumNoniJuiceMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "nhtc_PresidentandHisWifeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "President and His Wife", "label": "President and His Wife [Member]", "terseLabel": "President and Wife" } } }, "localname": "PresidentandHisWifeMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "nhtc_PurchaseCommitmentAgreementPeriodtoProvideNoticeofTermination": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase Commitment Agreement, Period to Provide Notice of Termination", "label": "Purchase Commitment Agreement, Period to Provide Notice of Termination", "terseLabel": "Number of days to provide notification to terminate purchase commitment agreement" } } }, "localname": "PurchaseCommitmentAgreementPeriodtoProvideNoticeofTermination", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "nhtc_PurchaseCommitmentMonthlyAmountMinimum": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the monthly purchase minimum the Company is required to purchase until the termination date.", "label": "nhtc_PurchaseCommitmentMonthlyAmountMinimum", "terseLabel": "Minimum monthly purchase amount" } } }, "localname": "PurchaseCommitmentMonthlyAmountMinimum", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_ReStoreMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents a product called ReStore\u2122.", "label": "ReStore [Member]", "terseLabel": "ReStor" } } }, "localname": "ReStoreMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "nhtc_RestrictedCashCollateralRequirementPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted Cash, Collateral Requirement Percentage", "label": "Restricted Cash, Collateral Requirement Percentage", "terseLabel": "Percentage of restricted cash required as collateral" } } }, "localname": "RestrictedCashCollateralRequirementPercentage", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "nhtc_RevenueFromContractWithCustomerSalesReturnsPolicyTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue From Contract With Customer, Sales Returns Policy Term", "label": "Revenue From Contract With Customer, Sales Returns Policy Term", "terseLabel": "Sales return policy term" } } }, "localname": "RevenueFromContractWithCustomerSalesReturnsPolicyTerm", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueDetails" ], "xbrltype": "durationItemType" }, "nhtc_RevenueFromContractWithCustomersHistoricalSalesReturnsPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue From Contract With Customers, Historical Sales Returns Percentage", "label": "Revenue From Contract With Customers, Historical Sales Returns Percentage", "terseLabel": "Historical sales returns rate" } } }, "localname": "RevenueFromContractWithCustomersHistoricalSalesReturnsPercentage", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueDetails" ], "xbrltype": "percentItemType" }, "nhtc_RevenueFromContractWithCustomersSalesReturnsPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue From Contract With Customers, Sales Returns Percentage", "label": "Revenue From Contract With Customers, Sales Returns Percentage", "terseLabel": "Actual sales returns rate" } } }, "localname": "RevenueFromContractWithCustomersSalesReturnsPercentage", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueDetails" ], "xbrltype": "percentItemType" }, "nhtc_RoyaltyAgreementandLicenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Royalty Agreement and License", "label": "Royalty Agreement and License [Member]", "terseLabel": "Royalty Agreement and License" } } }, "localname": "RoyaltyAgreementandLicenseMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "nhtc_RussiaandKazakhstanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Russia and Kazakhstan [Domain]", "label": "Russia and Kazakhstan [Domain]", "terseLabel": "Russia and Kazakhstan" } } }, "localname": "RussiaandKazakhstanDomain", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Additional Balance Sheet Components [Table Text Block]", "label": "Schedule of Additional Balance Sheet Components [Table Text Block]", "terseLabel": "Schedule of Additional Balance Sheet Components" } } }, "localname": "ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "nhtc_SecuritiesClassActionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Securities Class Action [Member]", "label": "Securities Class Action [Member]", "terseLabel": "Securities Class Actions" } } }, "localname": "SecuritiesClassActionMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_ShareholderDerivativeClaimMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "shareholder derivative claim [Member]", "label": "Shareholder Derivative Claim [Member]", "terseLabel": "Shareholder Derivative Claims" } } }, "localname": "ShareholderDerivativeClaimMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_SharngHoldingsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sharng Holdings", "label": "Sharng Holdings [Member]", "terseLabel": "Sharng Holdings" } } }, "localname": "SharngHoldingsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "nhtc_ShipmentofApparelProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shipment of Apparel Products", "label": "Shipment of Apparel Products [Member]", "terseLabel": "Shipment of Apparel Products" } } }, "localname": "ShipmentofApparelProductsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "nhtc_SpecialDividendsCommonStockCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Special Dividends, Common Stock, Cash", "label": "Special Dividends, Common Stock, Cash", "terseLabel": "Special dividend amount" } } }, "localname": "SpecialDividendsCommonStockCash", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_TaxCutsAndJobsActOf2017GlobalIntangibleLowtaxedIncomeGILTIIncomeTaxExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts And Jobs Act Of 2017, Global Intangible Low-taxed Income (GILTI), Income Tax Expense", "label": "Tax Cuts And Jobs Act Of 2017, Global Intangible Low-taxed Income (GILTI), Income Tax Expense", "terseLabel": "Additional income tax expense due to GILTI" } } }, "localname": "TaxCutsAndJobsActOf2017GlobalIntangibleLowtaxedIncomeGILTIIncomeTaxExpense", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_TheAberdeenGroupLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The Aberdeen Group, LLC", "label": "The Aberdeen Group, LLC [Member]", "terseLabel": "Aberdeen" } } }, "localname": "TheAberdeenGroupLLCMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "nhtc_UnshippedProductMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents unshipped product.", "label": "Unshipped Product [Member]", "terseLabel": "Unshipped product" } } }, "localname": "UnshippedProductMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20181231", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r202", "r299", "r301", "r359" ], "lang": { "en-US": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_CondensedBalanceSheetStatementTable": { "auth_ref": [ "r104", "r256" ], "lang": { "en-US": { "role": { "label": "Condensed Balance Sheet Statement [Table]", "terseLabel": "Condensed Balance Sheet Statement [Table]" } } }, "localname": "CondensedBalanceSheetStatementTable", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "srt_CondensedBalanceSheetStatementsCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Balance Sheet Statements, Captions [Line Items]", "terseLabel": "Condensed Balance Sheet Statements, Captions [Line Items]" } } }, "localname": "CondensedBalanceSheetStatementsCaptionsLineItems", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r47", "r100" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.naturalhealthtrendscorp.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.naturalhealthtrendscorp.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r140", "r190", "r193", "r349" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByProductAndServiceDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByProductAndServiceDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.naturalhealthtrendscorp.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.naturalhealthtrendscorp.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLiveAssetsByGeographicAreaDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r143", "r190", "r194", "r355", "r358" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLiveAssetsByGeographicAreaDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r294" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "ASU 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Current assets:" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r9", "r10", "r35" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Employee-related expense" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r17", "r329", "r340" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "verboseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r18", "r329", "r340" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "Accrued Income Taxes, Noncurrent", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued commissions" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r31", "r157" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r52", "r53", "r54", "r58", "r62" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]", "terseLabel": "Unrealized Losses on Available-For-Sale Investments" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r56", "r57", "r58" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Balance, December 31, 2018", "periodStartLabel": "Balance, December 31, 2017", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r55", "r58", "r62", "r263" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income", "verboseLabel": "Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r50", "r58", "r62", "r263" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustment" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r23" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r107" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r206", "r208", "r224", "r225" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r208", "r221", "r223" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Stock-based compensation expense recognized" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r117" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r137", "r328", "r339" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r46" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r270" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured at fair value on a recurring basis" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "terseLabel": "Amounts included in cash and cash equivalents", "verboseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax", "verboseLabel": "Gross Unrealized Gains/Losses" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "totalLabel": "Adjusted Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Schedule of Available-for-sale Investments" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r209", "r222" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r267", "r268" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r1", "r106", "r134" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r360" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Capitalized Computer Software, Gross", "terseLabel": "Office software" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and cash equivalents:" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r28", "r86" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r13", "r87", "r94", "r145" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r13", "r87", "r94", "r145", "r327" ], "lang": { "en-US": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r81", "r86", "r92" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period", "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r81", "r284" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CaymanIslandsTaxInformationAuthorityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government of the Cayman Islands.", "label": "Cayman Islands Tax Information Authority [Member]", "terseLabel": "Cayman Islands" } } }, "localname": "CaymanIslandsTaxInformationAuthorityMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesForeignRateDifferentialsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommissionsPolicy": { "auth_ref": [ "r94", "r325", "r326" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fees earned by the broker dealer, acting as an agent in the buying and selling of securities and administrative efforts on behalf of customers and may include the timing of commission revenue recognition and presentation in the financial statements. Commissions earned are usually related to the broker dealer's customers' trading volume and the dollar amounts of the trades.", "label": "Commissions, Policy [Policy Text Block]", "terseLabel": "Commissions" } } }, "localname": "CommissionsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r37", "r161", "r332", "r345" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r160", "r169" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND COMMITMENTS" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r182" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Cash dividends paid per common stock outstanding (in dollars per share)", "verboseLabel": "Dividend per common share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r182" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash dividends declared per common share (in dollars per share)", "verboseLabel": "Cash dividends declared per common stock outstanding (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Common stock, ending balance (in shares)", "periodStartLabel": "Common stock, beginning balance (in shares)", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2018 and 2017" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r93", "r213" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Long-Term Incentive" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r65", "r67", "r68" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r129", "r130", "r279", "r280" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r129", "r130", "r279", "r280", "r350" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r129", "r130", "r279", "r280", "r350" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r125", "r337" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Certain Risks and Concentrations" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r129", "r130", "r279", "r280" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk percentage (more than)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r129", "r130", "r279", "r280" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r94", "r261", "r265", "r266" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r156" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 6.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Construction in progress (including internal-use software development costs)" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r186", "r187", "r191" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r192" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized that was included in deferred revenue in prior year" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r200", "r203" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "verboseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r74" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r98", "r248", "r252" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "verboseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r103", "r250" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "verboseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r98", "r248", "r252" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current taxes" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r98", "r248", "r252" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain": { "auth_ref": [ "r196", "r198" ], "lang": { "en-US": { "role": { "documentation": "Deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.", "label": "Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]", "terseLabel": "Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]" } } }, "localname": "DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.", "label": "Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage", "terseLabel": "Maximum compensation percentage" } } }, "localname": "DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis": { "auth_ref": [ "r196", "r198" ], "lang": { "en-US": { "role": { "documentation": "Information by type of deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.", "label": "Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]", "terseLabel": "Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationCashBasedArrangementsLiabilityCurrent": { "auth_ref": [ "r197", "r199" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for deferred compensation arrangements payable within one year (or the normal operating cycle, if longer). Represents currently earned compensation under cash arrangements (such as a profit-sharing plan, rabbi trust, and employee contract--excluding equity-based arrangements) that is not actually paid until a later date.", "label": "Deferred Compensation Cash-based Arrangements, Liability, Current", "terseLabel": "Current long-term incentive compensation" } } }, "localname": "DeferredCompensationCashBasedArrangementsLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for deferred compensation arrangements payable after one year (or the normal operating cycle, if longer). Represents currently earned compensation under cash arrangements (such as a profit-sharing plan, rabbi trust, and employee contract--excluding equity-based arrangements) that is not actually paid until a later date.", "label": "Deferred Compensation Cash-based Arrangements, Liability, Classified, Noncurrent", "terseLabel": "Non-current long-term incentive compensation", "verboseLabel": "Long-term incentive" } } }, "localname": "DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for deferred compensation arrangements. Represents currently earned compensation under cash arrangements (such as a profit-sharing plan, rabbi trust, and employee contract--excluding equity-based arrangements) that is not actually paid until a later date.", "label": "Deferred Compensation Cash-based Arrangements, Liability, Current and Noncurrent", "terseLabel": "Total long-term incentive compensation" } } }, "localname": "DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r242" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax asset" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r84", "r98", "r249", "r252" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r19", "r20", "r238", "r330", "r338" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r232", "r242" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Revenue [Abstract]", "terseLabel": "Deferred revenue:" } } }, "localname": "DeferredRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r239" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Assets, Gross [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r242" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r240" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r226", "r246", "r247" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating losses" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Foreign net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r227", "r246", "r247" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r226", "r246", "r247" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r226", "r246", "r247" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r241" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r227", "r246", "r247" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedTerseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "auth_ref": [ "r227", "r246", "r247" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiaries and other recognized entities not within the country of domicile of the entity.", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "negatedLabel": "Foreign earnings" } } }, "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r204" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Defined contribution plan, cost recognized" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Employer matching contribution, percent of employees' gross pay" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.", "label": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage", "terseLabel": "Employers matching contribution, immediate vesting percentage" } } }, "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r84", "r155" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization expenses" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DilutiveSecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "DilutiveSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DirectorMember": { "auth_ref": [ "r300" ], "lang": { "en-US": { "role": { "documentation": "Person serving on the board of directors (who collectively have responsibility for governing the entity).", "label": "Director [Member]", "terseLabel": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByProductAndServiceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RevenueDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByProductAndServiceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendPayableDateToBePaidDayMonthAndYear": { "auth_ref": [ "r89" ], "lang": { "en-US": { "role": { "documentation": "Date the declared dividend will be paid, in CCYY-MM-DD format.", "label": "Dividends Payable, Date to be Paid", "terseLabel": "Payment Date" } } }, "localname": "DividendPayableDateToBePaidDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails" ], "xbrltype": "dateItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r182", "r336" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedLabel": "Dividends declared" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCash": { "auth_ref": [ "r182", "r336" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.", "label": "Dividends, Cash", "terseLabel": "Dividend amount" } } }, "localname": "DividendsCash", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "U.S. Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r71", "r108", "r112", "r114", "r115", "r116", "r120", "r335", "r347" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Net income available to common stockholders, Per Share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Earnings Per Share, Basic [Abstract]" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Weighted-average number of common shares outstanding:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r71", "r108", "r112", "r114", "r115", "r116", "r120", "r335", "r347" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Net income available to common stockholders plus assumed conversions, Per Share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted net income per common share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r94", "r117", "r118", "r119" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income Per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r121" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET INCOME PER COMMON SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r284" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rates on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r233", "r234", "r251" ], "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory Tax Rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesForeignRateDifferentialsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r175" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExecutiveOfficerMember": { "auth_ref": [ "r300" ], "lang": { "en-US": { "role": { "documentation": "One of the ranking officers of the entity, appointed to the position by the board of directors.", "label": "Executive Officer [Member]", "terseLabel": "Executive Officers" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r269", "r270", "r271", "r272", "r274", "r275" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r269", "r270", "r271" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Company's Hierarchy for Assets Measured on Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r200", "r201", "r203", "r271", "r308" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r269" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel12And3Member": { "auth_ref": [ "r201" ], "lang": { "en-US": { "role": { "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3).", "label": "Fair Value, Inputs, Level 1, 2 and 3 [Member]", "terseLabel": "Total" } } }, "localname": "FairValueInputsLevel12And3Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r200", "r201", "r203", "r271", "r309" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r200", "r201", "r203", "r271", "r310" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r200", "r201", "r203", "r271", "r311" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [ "r269", "r273" ], "lang": { "en-US": { "role": { "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).", "label": "Fair Value, Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r269", "r273" ], "lang": { "en-US": { "role": { "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.", "label": "Fair Value, Measurements, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r94", "r276", "r278" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r85", "r281", "r282", "r283" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Unrealized", "negatedLabel": "Loss on foreign exchange" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r94", "r283", "r290" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r156" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures, Gross", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r152", "r153" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r94", "r154" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r73" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r102" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r69", "r108", "r324", "r333", "r348" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r102" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign", "verboseLabel": "Foreign income tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesForeignRateDifferentialsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesForeignRateDifferentialsDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesForeignRateDifferentialsDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r98", "r136", "r253" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision", "totalLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails", "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r94", "r230", "r231", "r236", "r237", "r243", "r254", "r357" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r229", "r233", "r234" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r228", "r233", "r234" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "terseLabel": "Tax Cut & Jobs Act federal rate change" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r96", "r233", "r234" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Foreign rate differential" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r97", "r233", "r234" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Income tax at federal statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "auth_ref": [ "r233", "r234" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount", "terseLabel": "Other reconciling items" } } }, "localname": "IncomeTaxReconciliationOtherReconcilingItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": { "auth_ref": [ "r233", "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount", "terseLabel": "Foreign tax credits" } } }, "localname": "IncomeTaxReconciliationTaxCreditsForeign", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsOther": { "auth_ref": [ "r233", "r234" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount", "negatedTerseLabel": "Foreign tax credits" } } }, "localname": "IncomeTaxReconciliationTaxCreditsOther", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesReconciliationOfProvisionForIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r88" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes, net" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued commissions" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Long-term incentive" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "terseLabel": "Other accrued expenses" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r113", "r118" ], "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Non-vested restricted stock (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InlandRevenueHongKongMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government of Hong Kong.", "label": "Inland Revenue, Hong Kong [Member]", "terseLabel": "Hong Kong" } } }, "localname": "InlandRevenueHongKongMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesForeignRateDifferentialsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventories:" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r41" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r43", "r148" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r12", "r44", "r94", "r122", "r149", "r150" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r42" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Inventory, Raw Materials and Supplies, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r43", "r105", "r148", "r151" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "negatedTerseLabel": "Reserve for obsolescence" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r351", "r352", "r353", "r354" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r351", "r352", "r353", "r354" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Rent expense for operating leases" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r7", "r156" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 5.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements, Gross", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r297" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Operating Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r34" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r331", "r343" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Litigation settlement amount" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r161", "r162", "r163", "r165", "r166", "r167", "r168", "r170", "r171" ], "lang": { "en-US": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r161", "r162", "r163", "r165", "r166", "r167", "r168", "r170", "r171" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r161", "r162", "r163", "r165", "r166", "r167", "r168", "r170", "r171" ], "lang": { "en-US": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Number of complaints filed" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyNumberOfDefendants": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of defendants named in a legal action.", "label": "Loss Contingency, Number of Defendants", "terseLabel": "Number of parties named in putative securities class action suit" } } }, "localname": "LossContingencyNumberOfDefendants", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.", "label": "Loss Contingency, Number of Plaintiffs", "terseLabel": "Number of lead plaintiffs named" } } }, "localname": "LossContingencyNumberOfPlaintiffs", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r7", "r156" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "terseLabel": "Machinery" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Ownership interest by unrelated third party" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Ownership interest percentage by parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r81" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r81" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r81", "r82", "r85" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r63", "r66", "r70", "r85", "r118", "r334", "r346" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r108", "r110" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net income available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r110", "r111" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net income available to common stockholders plus assumed conversions" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued and Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r142" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Total long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLiveAssetsByGeographicAreaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Schedule of Restricted Stock Activity" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r296" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease ROU assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r291", "r292" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total minimum lease obligations" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r291", "r292" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r291", "r292" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r291", "r292" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r291", "r292" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r291", "r292" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r291", "r292" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails": { "order": 6.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesFutureMinimumLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r244" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r9", "r10", "r11", "r35" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "totalLabel": "Other accrued expenses", "verboseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r51", "r56", "r285", "r286", "r289", "r290" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r49", "r287" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "totalLabel": "Net change in foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax": { "auth_ref": [ "r56", "r59", "r60", "r61", "r288" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax", "negatedLabel": "Elimination of CTA upon dissolution", "negatedTerseLabel": "Release of cumulative translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r64", "r67", "r259", "r260", "r262" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r52", "r56" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax", "terseLabel": "Unrealized losses on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r8", "r9", "r35" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "verboseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r77" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r80" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r79" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for pension and other postretirement benefits.", "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "EMPLOYEE BENEFIT PLANS" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/EmployeeBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r209", "r222" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred stock, ending balance (in shares)", "periodStartLabel": "Preferred stock, beginning balance (in shares)", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r21" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2018 and 2017" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.", "label": "Reclassification, Policy [Policy Text Block]", "terseLabel": "Reclassification" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]", "terseLabel": "Product Concentration Risk" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r193" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product sales" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByProductAndServiceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property and equipment:" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r31", "r158" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r30", "r156" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property and equipment, at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r14", "r15", "r158", "r344" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r29", "r94", "r158" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r14", "r156" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, and equipment useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r298", "r301", "r302" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Amount of product orders shipped" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r202", "r299", "r301" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.", "label": "Related Party Transaction, Other Revenues from Transactions with Related Party", "terseLabel": "Market-based fee paid be related party" } } }, "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r202", "r299", "r301", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r13", "r86", "r92", "r327", "r341" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsAvailableForSaleInvestmentsIncludedInCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r6", "r16", "r92", "r356" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r117" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r24", "r182", "r342" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r188", "r189", "r190" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales", "verboseLabel": "Total net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByGeographicAreaDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByProductAndServiceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r95", "r195" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r106", "r195" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesCommissionsAndFees": { "auth_ref": [ "r76" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).", "label": "Sales Commissions and Fees", "terseLabel": "Commissions expense" } } }, "localname": "SalesCommissionsAndFees", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueProductLineMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue during the period derived from a specified product line, after deducting returns, allowances and discounts, when it serves as a benchmark in a concentration of risk calculation.", "label": "Sales Revenue, Product Line [Member]", "terseLabel": "Sales Revenue, Product Line" } } }, "localname": "SalesRevenueProductLineMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The reporting scenario used to indicate financial results forecast for a future period.", "label": "Scenario, Forecast [Member]", "terseLabel": "Scenario, Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario, Unspecified [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r58" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Loss" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Provision" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDividendsPayableTextBlock": { "auth_ref": [ "r89" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all or some of the information related to dividends declared, but not paid, as of the financial reporting date.", "label": "Schedule of Dividends Payable [Table Text Block]", "terseLabel": "Schedule of Dividends Payable" } } }, "localname": "ScheduleOfDividendsPayableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Schedule of Computation of Basic and Diluted Income per Common Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.", "label": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]", "terseLabel": "Schedule of Long-lived Assets by Geographic Area" } } }, "localname": "ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r102" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Income Before Income Taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r31", "r158" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r99", "r299", "r301", "r302", "r303", "r304" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r72", "r141" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "terseLabel": "Schedule of Net Sales by Geographic Area" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r135", "r137", "r138", "r139", "r154" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLiveAssetsByGeographicAreaDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r135", "r137", "r138", "r139", "r154" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Net Sales by Product and Service" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r209", "r222" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r38", "r101", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "SEGMENT INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationLongLiveAssetsByGeographicAreaDetails", "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r76", "r147" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r78" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Shares vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r216" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "verboseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of shares granted (in shares)", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested, ending balance (in shares)", "periodStartLabel": "Nonvested, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested, ending balance (in dollars per share)", "periodStartLabel": "Nonvested, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Wtd. Avg. Price at Date of Issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r207", "r212" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r94", "r209", "r214" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShippingAndHandlingMember": { "auth_ref": [ "r193" ], "lang": { "en-US": { "role": { "documentation": "Packing and transport of product.", "label": "Shipping and Handling [Member]", "terseLabel": "Freight and other" } } }, "localname": "ShippingAndHandlingMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SegmentInformationNetSalesByProductAndServiceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAdministrationOfTaxationChinaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government of China.", "label": "State Administration of Taxation, China [Member]", "terseLabel": "China" } } }, "localname": "StateAdministrationOfTaxationChinaMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesForeignRateDifferentialsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r40", "r175" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveLossDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r89", "r90", "r91" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Issuance of treasury stock for employee awards, net" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r21", "r22", "r175", "r182" ], "lang": { "en-US": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "negatedTerseLabel": "Restricted stock forfeiture (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Shares, Share-based Compensation, Gross", "terseLabel": "Common stock issued (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": { "auth_ref": [ "r21", "r22", "r175", "r182" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures", "negatedTerseLabel": "Restricted stock forfeiture" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r21", "r22", "r175", "r182" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Value of shares granted" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gross value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Value, Share-based Compensation, Gross", "terseLabel": "Common stock issued" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Authorized amount of shares to be repurchased" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Remaining authorized repurchase amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r22", "r25", "r26", "r146" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r257", "r258", "r264" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Stockholders' equity, ending balance", "periodStartLabel": "Stockholders' equity, beginning balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r307" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r48" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "BALANCE SHEET COMPONENTS" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURE:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TitleOfIndividualAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Relationship to Entity [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r39", "r183" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r39", "r183" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "negatedPeriodEndLabel": "Treasury stock, beginning balance (in shares)", "negatedPeriodStartLabel": "Treasury stock, beginning balance (in shares)", "terseLabel": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r22", "r175", "r182" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Repurchase of common stock (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r39", "r183", "r184" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost; 1,603,322 and 1,637,524 shares at December 31, 2018 and 2017, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r123", "r124", "r126", "r127", "r131", "r132", "r133" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r111", "r116" ], "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Net income available to common stockholders plus assumed conversions, Shares (in shares)", "verboseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r109", "r116" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Net income available to common stockholders, Shares (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperations", "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 12 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1377-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1500-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e543-108305" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "305", "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14615-108349" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14394-108349" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14453-108349" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14472-108349" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349" }, "r169": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12053-110248" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=75028277&loc=d3e19793-108362" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32059-109318" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32123-109318" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5283-111683" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4590271-111686" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r277": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13279-108611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32022-110900" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32157-110900" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r305": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41256-110953" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41261-110953" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "305", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=84242212&loc=d3e2352-115587" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r361": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r48": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e689-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e709-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724391-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 70 0000912061-19-000029-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000912061-19-000029-xbrl.zip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�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

    WE'K@Z8'GI8$'-\<\*/'F$60RE':F M$*32"8< 9BH-1^[$(UPT>X%1*Q="RH5E*;"( 4&A(M()3+B@3%*F0?J(O"C/L1'8 3AQ?,2>EUWUX-2# M4P].#S8/42N@&QK_$5384,"HE4I;0['AC)%4I1H^XA3(R^\C=GK.B_;F86\> M]HCW.A#O/L!C#1T3'&NFI4R90Q2F+J2CXA02#$+H)WU: OH=8F"=GEK;7086 M=QC_/ \3M/S<=SO,S&BRR,I^=_&T5O?&HTE^?)Y'M(((_/'GZ_V-[T<3CU7S M<,??MX58F[8)DV[:=.]I._]Z,%X,\]7/BF*1#Y/I++G()MDW__+T*CF[Z59% M4BP&YTE6)!?327[EKY_]EL^3L\5DZ,7B_'5Z\ MW:W5L(,+])?\>SY.X-OD[XMIJ I0"4)&NU[/9]%T(5>Y_L6!-7E M\:(('_K/QJ/L=#2.VKHK5.BTA^AM\O'ZZCP^S<*JJE:>[\1BTEK!]8(,BSWS M*VXPG6E8I:EKN M8/SOUS6G8X#MB-HJRDX%W<./D\^![LX\?NFL&!5?_:WT>#KX[4VDV.'MEWR< M1WIY++ C0C*+"#+6*6LM@49IK0!0&"MQW'@=-'1IBDCJ4I,B21 QA/E+K9*4 M*$73DEI[ I+_,U?OGH@CA2Q2$YS#\<>2/+"#WI$ M:#.]\&-\%0. ^<]%2Z,$5*FPI +X8>*7:0ODO3;(O,ZIAB@Y#6,4Z(K7.FD^ MB'2^U%\8'B5A\,MW7M.4+X+)<%+S]&K*KJVG:V1VDW&'3QM.].8UDZA;*U6W M?K]BLP>^WNY">-]^P"387>,5ZS=R?'_+N,:203X>5]_^YQMO3X;WON&#^OT- M_?[J^6N1?,A_))^GGA1?;ZT'P&^C2=F\;#&?UA^4#I/XR8_1<'[NK_:=KXRU M@6<>V661OZU?K$W4FV5LYC+Z&;(WMX=NEL^@^(\_OUFS&ZOGW_Z5W.A7FWUU MV,^Z/^AV?WQUS<*E3XS;[]1O=ROH/+KSM1I):@VR[U'6#YIM_ *3_8BQZ&[Z M*T/H,!WQASK=J)_N0YINW$_W84QW/$!TL*GYU(5O>[,E$#Q\S?&/-1D[= "8$=4H):A1!A*922 M!,P7"D&$V-/R%NP:YJ,=Q/R=S+72XWV/][NY-GJ\WP#O25,2'G.N/-_C_8'A/6OPGG%CK98*$4N MVU"8DH+]PGN(? MV$?1[Q\[!YT=[=,!^?8-^1@@ M#?)I*E)+J&$8$JYAZ@R*?F@#+8=R/1_;RR'?87N1>]3K4:]'O:>@'L)-Q 6F MT@B$E/\*\50!I./N6TJQ@0:R'4*]732K>]3K4:]'O=>!>J1!/<:4%-1: 1&A M7&"H%8\^26D,T&2]!M0+6KF]1W'7X.^FU":=G'SLI(5K25;6/WEJ.^\_^IH* MQ;!)N25(40N)YAI0K00G--6,L'AVM8,3M->.P/;G1?OSHOOSK/Z\Z!Z?%^7[ MONO4'S'JSXL>^'3WYT4/:KK[\Z(',MW]>='^O.B.N.0.+[90T*;"G[ <<$%U MB@RW) 6(@=2H%%OJ_ZM3^N(Y@P\LWF7+^8U??5AA'T_>8WZ/^1M@/F_RQ%.( M"=/*AI\>2[AOF''>G3XWV/]SW>'R+>RR8E,;4.<98R M8I!-M4DY127'=T8A@-8CTE\SWN_B1G^/]SW>]WC?X_T6\5["5N&[E H#0(JQ ME8((YXRC >\=P9@;];0RP;N&]Z\ENJMW[/3G1?OSHGTD;8G6N$%K#G"**=4& M<:X,L3!%)J(UMX8CN5Y$^1&1M/S@SHL>4'W ]@8[Y%O[Y"/R"7R$1L*DUH! MK5626"=29"/R*48!)>M^Z)=#OL/V(O>HUZ->CWI/03TFEJCGF'84 F@ELPZR M5$'-(^JEBDKDGG1*OF/4VT6SND>]'O5ZU'L=J"<:U)..*HZ5E%@%>U+PE0@0%W*!2-2 M(6\368TYH9!*JYS2&()PT"U[EJ;&MS_*.YY.QT-_"W92XOGZWV2S4KUF>G$Q MFD=Q"=L*<2Z_>?$:Y44# '<6ZI728D*,8Y(1JKD4ECD- 6<08R! NU"O'T>@ M*#3> $64&R93Q*T&J340, ?4G95E[WW.6J%>\_']^W=?W]L/7[\DZD.:F(\? MOK[[\%_V@WEGOSRU3NY#FO.4WCRE3FX\$;PE[O"8-G4C ?'RMZ.YO_' W^/C MI5+0[:-C677'^?ELNOAVGGS)+^?E MJ5,$$#U)/H?:VO["?%+D\=C&=#(II:B\Q[4F^Z;Y/M8SL"'-^H];>1;$0.84 M->'\5MH0P\\ @HX"RW2:*F$I)()CS%)['7'CJO58&[J5C6W9KS>WX_6MI(4N M20N[D[2@$[3&6!(_"&/_XAIS>?1HQ=G>]E@W95>L306R0'@-DE(JG=8&*L&! M(Q1[NKM6=N6A8\V[&^OU;"*=C?5P$;S^B:7 MV;?\^'269[\=9V>^26^S\8_LJ@CL]WQ6]>9Q3

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end

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